0001193125-23-163282.txt : 20230608 0001193125-23-163282.hdr.sgml : 20230608 20230608130838 ACCESSION NUMBER: 0001193125-23-163282 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 90 CONFORMED PERIOD OF REPORT: 20230429 FILED AS OF DATE: 20230608 DATE AS OF CHANGE: 20230608 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AstroNova, Inc. CENTRAL INDEX KEY: 0000008146 STANDARD INDUSTRIAL CLASSIFICATION: COMPUTER PERIPHERAL EQUIPMENT, NEC [3577] IRS NUMBER: 050318215 STATE OF INCORPORATION: RI FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-13200 FILM NUMBER: 231001367 BUSINESS ADDRESS: STREET 1: 600 E GREENWICH AVENUE CITY: WEST WARWICK STATE: RI ZIP: 02893 BUSINESS PHONE: 4018284000 MAIL ADDRESS: STREET 1: 600 E GREENWICH AVENUE CITY: WEST WARWICK STATE: RI ZIP: 02893 FORMER COMPANY: FORMER CONFORMED NAME: ASTRO MED INC /NEW/ DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: ATLAN TOL INDUSTRIES INC DATE OF NAME CHANGE: 19850220 10-Q 1 d292174d10q.htm 10-Q 10-Q
Table of Contents
falseQ10000008146--01-31 0000008146 2023-02-01 2023-04-29 0000008146 2022-02-01 2022-04-30 0000008146 2023-04-29 0000008146 2023-01-31 0000008146 2022-08-04 0000008146 2022-08-04 2022-08-04 0000008146 2022-02-01 2023-01-31 0000008146 2023-06-02 0000008146 2022-01-31 0000008146 2022-04-30 0000008146 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-01-31 0000008146 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-01-31 0000008146 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-01-31 0000008146 alot:MiltopeCorporationMember us-gaap:CustomerContractsMember 2023-01-31 0000008146 us-gaap:CustomerContractsMember alot:RuggedInformationTechnologyEquipmentCorporationMember 2023-01-31 0000008146 alot:ExistingTechnologyMember alot:TrojanlabelApSMember 2023-01-31 0000008146 alot:DistributorRelationsMember alot:TrojanlabelApSMember 2023-01-31 0000008146 us-gaap:CustomerContractsMember alot:HoneywellAssetPurchaseAndLicenseAgreementMember 2023-01-31 0000008146 us-gaap:CustomerContractsMember alot:AgreementWithAstroMachineForAssetAcquisitionsMember 2023-01-31 0000008146 us-gaap:TrademarksMember alot:AgreementWithAstroMachineForAssetAcquisitionsMember 2023-01-31 0000008146 alot:TermLoanDueAugustFourthTwoThousandAndTwentySevenMember 2023-01-31 0000008146 alot:AerospaceCustomerMember 2023-01-31 0000008146 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-04-29 0000008146 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-04-29 0000008146 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-04-29 0000008146 us-gaap:CustomerContractsMember alot:MiltopeCorporationMember 2023-04-29 0000008146 us-gaap:CustomerContractsMember alot:RuggedInformationTechnologyEquipmentCorporationMember 2023-04-29 0000008146 alot:ExistingTechnologyMember alot:TrojanlabelApSMember 2023-04-29 0000008146 alot:TrojanlabelApSMember alot:DistributorRelationsMember 2023-04-29 0000008146 us-gaap:CustomerContractsMember alot:HoneywellAssetPurchaseAndLicenseAgreementMember 2023-04-29 0000008146 alot:AgreementWithAstroMachineForAssetAcquisitionsMember us-gaap:CustomerContractsMember 2023-04-29 0000008146 us-gaap:TrademarksMember alot:AgreementWithAstroMachineForAssetAcquisitionsMember 2023-04-29 0000008146 alot:TermLoanDueAugustFourthTwoThousandAndTwentySevenMember 2023-04-29 0000008146 alot:TwoThousandEighteenEquityIncentivePlanMember 2023-04-29 0000008146 alot:TwoThousandSevenEquityIncentivePlanMember 2023-04-29 0000008146 alot:TwoThousandFifteenEquityIncentivePlanMember us-gaap:RestrictedStockMember 2023-04-29 0000008146 alot:TermLoanMember 2023-04-29 0000008146 alot:RangeThreeMember 2023-04-29 0000008146 alot:RangeFourMember 2023-04-29 0000008146 alot:RangeFiveMember 2023-04-29 0000008146 us-gaap:RestrictedStockUnitsRSUMember alot:TwoThousandEighteenEquityIncentivePlanMember 2023-04-29 0000008146 alot:TwoThousandEighteenEquityIncentivePlanMember us-gaap:PerformanceSharesMember 2023-04-29 0000008146 alot:TwoThousandEighteenEquityIncentivePlanMember us-gaap:RestrictedStockMember 2023-04-29 0000008146 us-gaap:EmployeeStockOptionMember 2023-04-29 0000008146 us-gaap:RestrictedStockUnitsRSUMember 2023-04-29 0000008146 alot:TwoThousandAndTwentyTwoEmployeeStockPurchasePlanMember 2023-04-29 0000008146 alot:AerospaceCustomerMember 2023-04-29 0000008146 alot:HoneywellAssetPurchaseAndLicenseAgreementMember 2023-04-29 0000008146 alot:BankOfAmericaMember us-gaap:RevolvingCreditFacilityMember alot:SecondAmendmentCreditAgreementMember 2023-04-29 0000008146 us-gaap:RevolvingCreditFacilityMember alot:BankOfAmericaMember 2023-04-29 0000008146 alot:MeasurementInputRoyaltyRateMember 2023-04-29 0000008146 alot:MeasurementInputCustomerAttritionRateMember 2023-04-29 0000008146 us-gaap:MeasurementInputDiscountRateMember 2023-04-29 0000008146 alot:AgreementWithAstroMachineForAssetAcquisitionsMember 2023-04-29 0000008146 us-gaap:CustomerRelatedIntangibleAssetsMember 2023-04-29 0000008146 alot:NonCurrentLiabilityMember 2023-04-29 0000008146 alot:RoyaltyPaymentsDueInNextTwelveMonthsMember 2023-04-29 0000008146 alot:RoyaltyPaymentsDueYearTwoMember 2023-04-29 0000008146 alot:RoyaltyPaymentsDueYearFiveMember 2023-04-29 0000008146 alot:RoyaltyPaymentsDueYearFourMember 2023-04-29 0000008146 alot:RoyaltyPaymentsDueYearThreeMember 2023-04-29 0000008146 alot:RangeThreeMember 2023-02-01 2023-04-29 0000008146 alot:RangeFourMember 2023-02-01 2023-04-29 0000008146 alot:RangeFiveMember 2023-02-01 2023-04-29 0000008146 country:US 2023-02-01 2023-04-29 0000008146 srt:EuropeMember 2023-02-01 2023-04-29 0000008146 country:CA 2023-02-01 2023-04-29 0000008146 srt:AsiaMember 2023-02-01 2023-04-29 0000008146 alot:CentralAndSouthAmericaMember 2023-02-01 2023-04-29 0000008146 alot:OthersCountriesMember 2023-02-01 2023-04-29 0000008146 alot:HardwareProductsMember 2023-02-01 2023-04-29 0000008146 alot:SuppliesMember 2023-02-01 2023-04-29 0000008146 alot:ServiceAndOtherMember 2023-02-01 2023-04-29 0000008146 us-gaap:AccumulatedTranslationAdjustmentMember 2023-02-01 2023-04-29 0000008146 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-02-01 2023-04-29 0000008146 alot:RestrictedStockAwardPreferredStockUnitAndRestrictedStockUnitMember 2023-02-01 2023-04-29 0000008146 us-gaap:AdditionalPaidInCapitalMember 2023-02-01 2023-04-29 0000008146 us-gaap:CommonStockMember 2023-02-01 2023-04-29 0000008146 us-gaap:TreasuryStockMember 2023-02-01 2023-04-29 0000008146 us-gaap:RetainedEarningsMember 2023-02-01 2023-04-29 0000008146 us-gaap:RestrictedStockUnitsRSUMember 2023-02-01 2023-04-29 0000008146 alot:ProductIdentificationMember 2023-02-01 2023-04-29 0000008146 alot:TestAndMeasurementMember 2023-02-01 2023-04-29 0000008146 us-gaap:CorporateNonSegmentMember 2023-02-01 2023-04-29 0000008146 us-gaap:OperatingSegmentsMember alot:ProductIdentificationMember 2023-02-01 2023-04-29 0000008146 us-gaap:OperatingSegmentsMember alot:TestAndMeasurementMember 2023-02-01 2023-04-29 0000008146 us-gaap:OperatingSegmentsMember 2023-02-01 2023-04-29 0000008146 alot:TwoThousandAndTwentyTwoEmployeeStockPurchasePlanMember 2023-02-01 2023-04-29 0000008146 alot:RestrictedStockAwardMember 2023-02-01 2023-04-29 0000008146 alot:HoneywellAssetPurchaseAndLicenseAgreementMember 2023-02-01 2023-04-29 0000008146 us-gaap:GeneralAndAdministrativeExpenseMember 2023-02-01 2023-04-29 0000008146 us-gaap:RevolvingCreditFacilityMember us-gaap:OtherExpenseMember alot:BankOfAmericaMember 2023-02-01 2023-04-29 0000008146 us-gaap:RevolvingCreditFacilityMember srt:MinimumMember 2023-02-01 2023-04-29 0000008146 us-gaap:RevolvingCreditFacilityMember srt:MaximumMember 2023-02-01 2023-04-29 0000008146 us-gaap:RevolvingCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember srt:MinimumMember 2023-02-01 2023-04-29 0000008146 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2023-02-01 2023-04-29 0000008146 us-gaap:RevolvingCreditFacilityMember us-gaap:FederalFundsEffectiveSwapRateMember 2023-02-01 2023-04-29 0000008146 us-gaap:RevolvingCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2023-02-01 2023-04-29 0000008146 us-gaap:RevolvingCreditFacilityMember 2023-02-01 2023-04-29 0000008146 alot:AgreementWithAstroMachineForAssetAcquisitionsMember 2023-02-01 2023-04-29 0000008146 alot:BankOfAmericaMember us-gaap:RevolvingCreditFacilityMember 2023-02-01 2023-04-29 0000008146 alot:AerospaceCustomerMember 2023-02-01 2023-04-29 0000008146 us-gaap:CustomerRelatedIntangibleAssetsMember 2023-02-01 2023-04-29 0000008146 us-gaap:CustomerRelationshipsMember 2022-08-04 2022-08-04 0000008146 us-gaap:TrademarksAndTradeNamesMember 2022-08-04 2022-08-04 0000008146 alot:AgreementWithAstroMachineForAssetAcquisitionsMember 2022-08-04 2022-08-04 0000008146 alot:BankOfAmericaMember alot:SecondAmendmentCreditAgreementMember alot:TermLoanMember 2022-08-04 2022-08-04 0000008146 alot:BankOfAmericaMember us-gaap:RevolvingCreditFacilityMember alot:SecondAmendmentCreditAgreementMember 2022-08-04 2022-08-04 0000008146 alot:SecondAmendmentCreditAgreementMember alot:AdditionalTermLoanAvailedMember alot:TermLoanMember alot:BankOfAmericaMember 2022-08-04 0000008146 alot:BankOfAmericaMember alot:TermLoanMember alot:BeforeAmendmentToTheCreditAgreementMember 2022-08-04 0000008146 alot:AgreementWithAstroMachineForAssetAcquisitionsMember 2022-08-04 0000008146 alot:AerospaceCustomerMember 2022-12-31 0000008146 alot:BankOfAmericaMember alot:TermLoanMember 2022-10-31 2023-07-31 0000008146 alot:BankOfAmericaMember alot:TermLoanMember 2023-10-31 2027-04-30 0000008146 country:US 2022-02-01 2022-04-30 0000008146 srt:EuropeMember 2022-02-01 2022-04-30 0000008146 country:CA 2022-02-01 2022-04-30 0000008146 srt:AsiaMember 2022-02-01 2022-04-30 0000008146 alot:CentralAndSouthAmericaMember 2022-02-01 2022-04-30 0000008146 alot:OthersCountriesMember 2022-02-01 2022-04-30 0000008146 alot:HardwareProductsMember 2022-02-01 2022-04-30 0000008146 alot:SuppliesMember 2022-02-01 2022-04-30 0000008146 alot:ServiceAndOtherMember 2022-02-01 2022-04-30 0000008146 us-gaap:AdditionalPaidInCapitalMember 2022-02-01 2022-04-30 0000008146 us-gaap:CommonStockMember 2022-02-01 2022-04-30 0000008146 us-gaap:TreasuryStockMember 2022-02-01 2022-04-30 0000008146 us-gaap:RetainedEarningsMember 2022-02-01 2022-04-30 0000008146 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-02-01 2022-04-30 0000008146 alot:ProductIdentificationMember 2022-02-01 2022-04-30 0000008146 alot:TestAndMeasurementMember 2022-02-01 2022-04-30 0000008146 us-gaap:CorporateNonSegmentMember 2022-02-01 2022-04-30 0000008146 us-gaap:OperatingSegmentsMember alot:ProductIdentificationMember 2022-02-01 2022-04-30 0000008146 us-gaap:OperatingSegmentsMember alot:TestAndMeasurementMember 2022-02-01 2022-04-30 0000008146 us-gaap:OperatingSegmentsMember 2022-02-01 2022-04-30 0000008146 alot:PriorEmployeeStockPurchasePlanMember 2022-02-01 2022-04-30 0000008146 us-gaap:GeneralAndAdministrativeExpenseMember 2022-02-01 2022-04-30 0000008146 alot:BankOfAmericaMember us-gaap:OtherExpenseMember us-gaap:RevolvingCreditFacilityMember 2022-02-01 2022-04-30 0000008146 alot:BankOfAmericaMember us-gaap:RevolvingCreditFacilityMember 2022-02-01 2022-04-30 0000008146 alot:BankOfAmericaMember us-gaap:RevolvingCreditFacilityMember alot:BeforeAmendmentToTheCreditAgreementMember 2022-04-30 0000008146 alot:HoneywellAssetPurchaseAndLicenseAgreementMember 2018-01-31 0000008146 alot:HoneywellAssetPurchaseAndLicenseAgreementMember 2018-01-31 2018-01-31 0000008146 alot:EmployeeStockPurchasePlanMember 2022-02-01 2023-01-31 0000008146 alot:TwoThousandAndTwentyTwoEmployeeStockPurchasePlanMember 2022-02-01 2023-01-31 0000008146 us-gaap:GeneralAndAdministrativeExpenseMember alot:AgreementWithAstroMachineForAssetAcquisitionsMember 2022-02-01 2023-01-31 0000008146 alot:AerospaceCustomerMember 2022-02-01 2023-01-31 0000008146 alot:RestrictedStockAwardPreferredStockUnitAndRestrictedStockUnitMember 2023-01-31 0000008146 us-gaap:CommonStockMember 2023-01-31 0000008146 us-gaap:AdditionalPaidInCapitalMember 2023-01-31 0000008146 us-gaap:RetainedEarningsMember 2023-01-31 0000008146 us-gaap:TreasuryStockMember 2023-01-31 0000008146 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-31 0000008146 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-31 0000008146 alot:RestrictedStockAwardPreferredStockUnitAndRestrictedStockUnitMember 2023-04-29 0000008146 us-gaap:CommonStockMember 2023-04-29 0000008146 us-gaap:AdditionalPaidInCapitalMember 2023-04-29 0000008146 us-gaap:RetainedEarningsMember 2023-04-29 0000008146 us-gaap:TreasuryStockMember 2023-04-29 0000008146 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-29 0000008146 us-gaap:AccumulatedTranslationAdjustmentMember 2023-04-29 0000008146 us-gaap:CommonStockMember 2022-01-31 0000008146 us-gaap:AdditionalPaidInCapitalMember 2022-01-31 0000008146 us-gaap:RetainedEarningsMember 2022-01-31 0000008146 us-gaap:TreasuryStockMember 2022-01-31 0000008146 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-31 0000008146 us-gaap:CommonStockMember 2022-04-30 0000008146 us-gaap:AdditionalPaidInCapitalMember 2022-04-30 0000008146 us-gaap:RetainedEarningsMember 2022-04-30 0000008146 us-gaap:TreasuryStockMember 2022-04-30 0000008146 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-30 iso4217:USD xbrli:shares utr:Year xbrli:pure utr:sqft iso4217:USD xbrli:shares alot:Segment
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
 
FORM
10-Q
 
 
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended April 29, 2023
OR
 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from
    
        
    
    
to
    
        
    
    
Commission file number
0-13200
 
 
AstroNova, Inc.
(Exact name of registrant as specified in its charter)
 
 
 
Rhode Island
 
05-0318215
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)
   
600 East Greenwich Avenue, West Warwick, Rhode Island
 
02893
(Address of principal executive offices)
 
(Zip Code)
(401)
828-4000
(Registrant’s telephone number, including area code)
 
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading
Symbol
 
Name of each exchange
on which registered
Common Stock, $.05 Par Value
 
ALOT
 
NASDAQ Global Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes
  ☒    No  ☐.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T
(§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes
  ☒    No  ☐.
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule
12b-2
of the Exchange Act.
 
Large accelerated filer      Accelerated filer  
       
Non-accelerated
filer
       Smaller reporting company  
       
         Emerging growth company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule
12b-2
of the Exchange Act)    Yes  ☐    No  
.
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
The number of shares of the registrant’s common stock, $.05 par value per share, outstanding as of June 2, 2023 was 7,417,715.
 
 


Table of Contents

ASTRONOVA, INC.

INDEX

 

          Page No.  

Part I.

   Financial Information   

Item 1.

   Financial Statements   
   Unaudited Condensed Consolidated Balance Sheets – April 29, 2023 and January 31, 2023      1  
   Unaudited Condensed Consolidated Statements of Income – Three Months Ended April 29, 2023 and April 30, 2022      2  
   Unaudited Condensed Consolidated Statements of Comprehensive Income (Loss) – Three Months Ended April 29, 2023 and April 30, 2022      3  
   Unaudited Condensed Consolidated Statements of Changes in Shareholders’ Equity – Three Months Ended April 29, 2023 and April 30, 2022      4  
   Unaudited Condensed Consolidated Statements of Cash Flows – Three Months Ended April 29, 2023 and April 30, 2022      5  
   Notes to the Condensed Consolidated Financial Statements (unaudited)      6-18  

Item 2.

   Management’s Discussion and Analysis of Financial Condition and Results of Operations      19-25  

Item 3.

   Quantitative and Qualitative Disclosures about Market Risk      25  

Item 4.

   Controls and Procedures      25-26  

Part II.

   Other Information   

Item 1.

   Legal Proceedings      26  

Item 1A.

   Risk Factors      26  

Item 2.

   Unregistered Sales of Equity Securities and Use of Proceeds      27  

Item 6.

   Exhibits      27  

Signatures

     28  


Table of Contents
Part I. FINANCIAL INFORMATION
 
Item 1.
Financial Statements
ASTRONOVA, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In Thousands, Except Share Data)
 
 
  
April 29,

2023
 
 
January 31,

2023
 
 
  
 
 
 
 
 
 
  
(Unaudited)
 
 
 
 
ASSETS
  
 
CURRENT ASSETS
  
 
Cash and Cash Equivalents
   $ 5,413     $ 3,946  
Accounts Receivable, net
     19,285       21,598  
Inventories, net
     53,126       51,324  
Prepaid Expenses and Other Current Assets
     2,678       2,894  
    
 
 
   
 
 
 
Total Current Assets
     80,502       79,762  
Property, Plant and Equipment, net
     13,918       14,288  
Identifiable Intangibles, net
     20,630       21,232  
Goodwill
     14,760       14,658  
Deferred Tax Assets, net
     6,907       6,907  
Right of Use Asset
     858       794  
Other Assets
     1,621       1,566  
    
 
 
   
 
 
 
TOTAL ASSETS
   $ 139,196     $ 139,207  
    
 
 
   
 
 
 
LIABILITIES AND SHAREHOLDERS’ EQUITY
                
CURRENT LIABILITIES
                
Accounts Payable
   $ 8,000     $ 8,479  
Accrued Compensation
     3,267       2,750  
Other Accrued Expenses
     3,484       3,308  
Revolving Line of Credit
     15,900       15,900  
Current Portion of Long-Term Debt
     2,100       2,100  
Current Liability—Royalty Obligation
     1,600       1,725  
Current Liability—Excess Royalty Payment Due
     379       562  
Income Taxes Payable
     730       786  
Deferred Revenue
     1,971       1,888  
    
 
 
   
 
 
 
Total Current Liabilities
     37,431       37,498  
NON-CURRENT
LIABILITIES
                
Long-Term Debt, net of current portion
     11,678       12,040  
Royalty Obligation, net of current portion
     3,102       3,415  
Lease Liabilities, net of current portion
     581       555  
Income Taxes Payable
     491       491  
Deferred Revenue
     267       674  
Deferred Tax Liabilities
     172       167  
    
 
 
   
 
 
 
TOTAL LIABILITIES
     53,722       54,840  
SHAREHOLDERS’ EQUITY
                
Preferred Stock, $
10
Par Value, Authorized 100,000 shares, None Issued
                  
Common Stock, $0.05 Par Value, Authorized 13,000,000 shares; Issued 10,780,934 and 10,676,851 shares at April 29, 2023 and January 31, 2023, respectively
     538       534  
Additional
Paid-in
Capital
     61,526       61,131  
Retained Earnings
     60,023       59,175  
Treasury Stock, at Cost, 3,368,219 and 3,342,032
shares at April 29, 2023 and January 31, 2023, respectively
     (34,585     (34,235
Accumulated Other Comprehensive Loss, net of tax
     (2,028     (2,238
    
 
 
   
 
 
 
TOTAL SHAREHOLDERS’ EQUITY
     85,474       84,367  
    
 
 
   
 
 
 
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY
   $ 139,196     $ 139,207  
    
 
 
   
 
 
 
See Notes to condensed consolidated financial statements (unaudited).
 
1

ASTRONOVA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(In Thousands, Except Per Share Data)
(Unaudited)
 
 
  
Three Months Ended
 
 
  
April 29,

2023
 
 
April 30,

2022
 
 
  
 
 
 
 
 
Revenue
   $ 35,419     $ 31,010  
Cost of Revenue
     23,034       20,281  
    
 
 
   
 
 
 
Gross Profit
     12,385       10,729  
Operating Expenses:
                
Selling and Marketing
     6,010       5,883  
Research and Development
     1,788       1,522  
General and Administrative
     3,126       2,560  
    
 
 
   
 
 
 
Operating Expenses
     10,924       9,965  
    
 
 
   
 
 
 
Operating Income
     1,461       764  
Other Income (Expense)
                
Interest Expense
     (615     (175
Gain (Loss) on Foreign Currency Transaction
     186       (135 )
Other, net
     (5 )     31  
    
 
 
   
 
 
 

     (434 )     (279 )
    
 
 
   
 
 
 
Income Before Income Taxes
     1,027       485  
Income Tax Provision
     179       60  
    
 
 
   
 
 
 
Net Income
   $ 848     $ 425  
    
 
 
   
 
 
 
Net Income per Common Share—Basic:
   $ 0.12     $ 0.06  
    
 
 
   
 
 
 
Net Income per Common Share—Diluted:
   $ 0.11     $ 0.06  
    
 
 
   
 
 
 
Weighted Average Number of Common Shares Outstanding:
                
Basic
     7,370       7,263  
Diluted
     7,450       7,361  
See Notes to condensed consolidated financial statements (unaudited).
 
2

ASTRONOVA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(In Thousands)
(Unaudited)
 
 
  
Three Months Ended
 
 
  
April 29,

2023
 
  
April 30,

2022
 
 
  
 
 
  
 
 
Net Income
   $ 848      $ 425  
Other Comprehensive Income (Loss), Net of Taxes:
                 
Foreign Currency Translation Adjustments
     210        (933
Loss from Cash Flow Hedges Reclassified to Income Statement
               16  
    
 
 
    
 
 
 
Other Comprehensive Income (Loss)
     210        (917
    
 
 
    
 
 
 
Comprehensive Income (Loss)
   $ 1,058      $ (492
    
 
 
    
 
 
 
See Notes to condensed consolidated financial statements (unaudited).
 
3

ASTRONOVA, INC.
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
($ In Thousands, Except per Share Data)
(Unaudited)
 
 
  
Common Stock
 
  
Additional
Paid-in
 
 
Retained
 
  
Treasury
 
 
Accumulated
Other
Comprehensive
 
 
Total
Shareholders’
 
 
  
Shares
 
  
Amount
 
  
Capital
 
 
Earnings
 
  
Stock
 
 
Income (Loss)
 
 
Equity
 
 
  
 
 
  
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Balance January 31, 2022
     10,566,404      $ 528      $ 59,692     $ 56,514      $ (33,974   $ (1,748   $ 81,012  
Share-Based Compensation
     —          —          337       —          —         —         337  
Employee Option Exercises
     11,164        1        87       —                   —         88  
Restricted Stock Awards
     61,513        3        (3     —          (249     —         (249
Net Income
     —          —          —         425        —         —         425  
Other Comprehensive Loss
     —          —          —         —          —         (917     (917
    
 
 
    
 
 
    
 
 
   
 
 
    
 
 
   
 
 
   
 
 
 
Balance April 30, 2022
     10,639,081      $ 532      $ 60,113     $ 56,939      $ (34,223   $ (2,665   $ 80,696  
    
 
 
    
 
 
    
 
 
   
 
 
    
 
 
   
 
 
   
 
 
 
Balance January 31, 2023
     10,676,851      $ 534      $ 61,131     $ 59,175      $ (34,235   $ (2,238   $ 84,367  
Share-Based Compensation
     —          —          356       —          —         —         356  
Employee Option Exercises
     4,094                  43       —          —         —         43  
Restricted Stock Awards
     99,989        4        (4     —          (350     —         (350
Net Income
     —          —          —         848        —         —         848  
Other Comprehensive Income
     —          —          —         —          —         210       210  
    
 
 
    
 
 
    
 
 
   
 
 
    
 
 
   
 
 
   
 
 
 
Balance April 29, 2023
     10,780,934      $ 538      $ 61,526     $ 60,023      $ (34,585   $ (2,028   $ 85,474  
    
 
 
    
 
 
    
 
 
   
 
 
    
 
 
   
 
 
   
 
 
 
See Notes to condensed consolidated financial statements (unaudited).
 
4

ASTRONOVA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In Thousands)
(Unaudited)
 
 
  
Three Months Ended
 
 
  
April 29,

2023
 
 
April 30,

2022
 
Cash Flows from Operating Activities:
  
 
Net Income
   $ 848     $ 425  
Adjustments to Reconcile Net Income to Net Cash Provided (Used) by Operating Activities:
                
Depreciation and Amortization
     1,055       912  
Amortization of Debt Issuance Costs
     6       7  
Share-Based Compensation
     356       337  
Changes in Assets and Liabilities:
                
Accounts Receivable
     2,324       (1,489
Other Receivable – Employee Retention Credit Receivable
              3,135  
Inventories
     (1,756     (2,650
Income Taxes
     38       502  
Accounts Payable and Accrued Expenses
     8       (2,843
Other
     (237     50  
    
 
 
   
 
 
 
Net Cash Provided (Used) by Operating Activities
     2,642       (1,614
Cash Flows from Investing Activities:
                
Additions to Property, Plant and Equipment
     (48     (50
    
 
 
   
 
 
 
Net Cash Used for Investing Activities
     (48     (50
Cash Flows from Financing Activities:
                
Net Cash Proceeds from Employee Stock Option Plans
     18       69  
Net Cash Proceeds from Share Purchases under Employee Stock Purchase Plan
     25       19  
Net Cash Used for Payment of Taxes Related to Vested Restricted Stock
     (350     (249
Net Borrowings under Revolving Credit Facility
              3,000  
Payment of Minimum Guarantee Royalty Obligation
     (500     (500
Principal Payments on Long-Term Debt
     (375     (250
    
 
 
   
 
 
 
Net Cash Provided (Used) by Financing Activities
     (1,182     2,089  
    
 
 
   
 
 
 
Effect of Exchange Rate Changes on Cash and Cash Equivalents
     55       53  
    
 
 
   
 
 
 
Net Increase in Cash and Cash Equivalents
     1,467       478  
Cash and Cash Equivalents, Beginning of Period
     3,946       5,276  
    
 
 
   
 
 
 
Cash and Cash Equivalents, End of Period
   $ 5,413     $ 5,754  
    
 
 
   
 
 
 
Supplemental Disclosures of Cash Flow Information:
                
Cash Paid During the Period for Interest
   $ 538     $ 53  
Cash Paid (Received) During the Period for Income Taxes, Net of Refunds
   $ 235     $ (440
See Notes to condensed consolidated financial statements (unaudited).
 
5

ASTRONOVA, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
Note 1 – Business and Basis of Presentation
Overview
Headquartered in West Warwick, Rhode Island, AstroNova, Inc. leverages its expertise in data visualization technologies to design, develop, manufacture and distribute a broad range of specialty printers and data acquisition and analysis systems. Our products are employed around the world in a wide range of applications in the aerospace, apparel, automotive, avionics, chemical, computer peripherals, communications, distribution, food and beverage, general manufacturing, packaging and transportation industries.
Our business consists of two
segments, Product Identification (“PI”) and Test & Measurement (“T&M”). The PI segment includes specialty printing systems and related supplies sold under the QuickLabel
®
, TrojanLabel
®
and GetLabels
brand names. The T&M segment consists of our line of aerospace products, including flight deck printers, networking hardware, and related accessories as well as T&M data acquisition systems sold under the AstroNova
®
brand name.
On August 4, 2022, we acquired Astro Machine LLC (“Astro Machine”), an Illinois-based manufacturer of printing equipment, including label printers and related accessories, tabbers, conveyors, and envelope feeders. We reported Astro Machine as a part of our PI segment beginning in the third quarter of fiscal 2023.
PI products sold under the QuickLabel, TrojanLabel and GetLabels brands are used in brand owner and commercial applications to provide product packaging, marketing, tracking, branding, and labeling solutions to a wide array of industries. The PI segment offers a variety of digital color label tabletop printers and light commercial label printers,
direct-to-package
printers, high-volume presses, and specialty original equipment manufacturer (“OEM”) printing systems, as well as a wide range of label, tag and flexible packaging material substrates and other supplies, including ink and toner, allowing customers to mark, track, protect and enhance the appearance of their products. PI products sold under the Astro Machine brand also include a variety of label printers, envelope and packaging printing, and related processing and handling equipment.
In the T&M segment, we have a long history of using our technologies to provide networking systems and high-resolution flight deck and cabin printers for the aerospace market. In addition, the T&M segment includes data acquisition recorders, sold under the AstroNova brand, to enable our customers to acquire and record visual and electronic signal data from local and networked data streams and sensors. The recorded data is processed, analyzed, stored and presented in various visual output formats.
Our PI products are sold by direct field salespersons as well as independent dealers and representatives, while our T&M products are sold predominantly through direct sales and manufacturers’ representatives. In the United States, we have factory-trained direct field salespeople located throughout the country specializing in PI products. We also have direct field sales or service centers in Canada, China, Denmark, France, Germany, Malaysia, Mexico, Singapore, and the United Kingdom staffed by our own employees and dedicated third party contractors. Additionally, we utilize over 100 independent dealers and representatives selling and marketing our products in over 60 countries.
Unless otherwise indicated, references to “AstroNova”, “we,” “our,” and “us” in this Quarterly Report on
Form 10-Q
refer to AstroNova, Inc. and its consolidated subsidiaries.
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles and reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair presentation of the results of the interim periods included herein. These financial statements do not include all disclosures associated with annual financial statements and, accordingly, should be read in conjunction with our Annual Report on Form
10-K
for the fiscal year ended January 31, 2023.
The presentation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported and disclosed in the condensed consolidated financial statements and accompanying notes, including those that require consideration of forecasted financial information using information that is reasonably available to us at this time. Some of the more significant estimates relate to revenue recognition; the allowances for doubtful accounts; inventory valuation; income taxes; valuation of long-lived assets, intangible assets and goodwill; share-based compensation; and warranty reserves. Management’s estimates are based on the facts and circumstances available at the time estimates are made, historical experience, risk of loss, general economic conditions and trends, and management’s assessments of the probable future outcome of these matters, including our expectations at the time regarding the ongoing impact from the
COVID-19
pandemic. Consequently, actual results could differ from those estimates.
 
6

Results of operations for the interim periods presented herein are not necessarily indicative of the results that may be expected for the full year.
Certain amounts in the prior year’s financial statements have been reclassified to conform to the current year’s presentation.
Principles of Consolidation
The accompanying condensed consolidated financial statements include the accounts of AstroNova, Inc. and its wholly-owned subsidiaries. All significant intercompany accounts and transactions are eliminated in consolidation.
Note 2 – Summary of Significant Accounting Policies Update
The accounting policies used in preparing the condensed consolidated financial statements in this Form
10-Q
are the same as those used in preparing our consolidated financial statements included in our Annual Report on Form
10-K
for the fiscal year ended January 31, 2023.
Recently Adopted Accounting Pronouncements
No new accounting pronouncements, issued or effective during the first three months of the current year, have had or are expected to have a material impact on our consolidated financial statements.
Note 3 – Acquisitions
Astro Machine
On August 4, 2022, we acquired Astro Machine LLC (“Astro Machine”), an Illinois-based manufacturer of printing equipment, including label printers, tabbers, conveyors, and envelope feeders, for aggregate consideration of $17.1 million.
The acquisition was accomplished pursuant to an Equity Interest Purchase Agreement dated as of August 4, 2022 (the “Purchase Agreement”) by and among us, GSND Holding Corporation (“GSND”), the parent company of Astro Machine, and Astro Machine. Pursuant to the Purchase Agreement, we purchased 100% of the issued and outstanding equity interests of Astro Machine from GSND for a purchase price of $15.6 million. The acquisition was funded using borrowings under our credit facility. We obtained a representation and warranty insurance policy and placed $300,000 of the purchase price into an escrow account, which pursuant to the terms and conditions of the Purchase Agreement, are our sole recourse for breaches of representations and warranties by GSND. Upon the closing of the transaction, Astro Machine became a wholly owned subsidiary of AstroNova, Inc.
Concurrently with the signing of the Purchase Agreement, our newly acquired subsidiary, Astro Machine, entered into a Purchase and Sale Agreement with Selak Real Estate Limited Partnership (“SRE”), pursuant to which Astro Machine purchased certain real property assets of SRE for a purchase price, paid in cash, of $1.5 million. These real estate assets are comprised of a 34,460 square foot industrial manufacturing building (including offices) on 1.26 acres of land, which is Astro Machine’s principal place of business.
This transaction was a business combination and accounted for using the acquisition method of accounting prescribed by ASC 805, “Business Combinations” (“ASC 805”), whereby the results of operations, including the revenues and earnings of Astro Machine, are included in our financial statements from the date of acquisition. The purchase price of Astro Machine was allocated to the tangible and intangible assets acquired and liabilities assumed and recognized at their fair value based on widely accepted valuation techniques in accordance with ASC 820, “Fair Value Measurement,” as of the acquisition date. The process for estimating fair values requires the use of significant estimates, assumptions and judgments, including determining the timing and estimates of future cash flows and developing appropriate discount rates. The excess of the purchase price over the fair value of the net identified assets acquired and liabilities assumed was recorded as goodwill. ASC 805 establishes a measurement period to provide companies with a reasonable amount of time to obtain the information necessary to identify and measure various items in a business combination and cannot extend beyond one year from the acquisition date.
 
7

The following table sets forth the final purchase price allocation of the Astro Machine acquisition for the estimated fair value of the net assets acquired and liabilities assumed as of the date of acquisition:
 
(In thousands)       
Cash
   $ 91  
Accounts Receivable
     3,393  
Inventory
     5,715  
Property, Plant and Equipment
     4,200  
Identifiable Intangible Assets
     3,480  
Goodwill
     2,730  
Accounts Payable and Other Current Liabilities
     (2,484
    
 
 
 
Total Purchase Price
   $ 17,125  
    
 
 
 
The fair value of the intangible assets acquired was estimated by applying the income approach. This fair value measurement is based on significant inputs that are not observable in the market and therefore represents a Level 3 measurement as defined in ASC 820, “Fair Value Measurement.” Key assumptions in estimating the fair value of the intangibles include (1) remaining useful life of the tradename/trademarks and customer relations (2) royalty rate of
0.75%, (3) customer attrition rate of 18.0%, (4) discount rate of 19.0
% and (5) a range of revenue and net income projections for fiscal years 2023 through 2026.
The following table sets forth the fair value of the acquired identifiable intangible assets and related estimated useful lives:
 
(In thousands)   
Fair
Value
    
Useful Life
(years)
 
Customer Relations
   $ 3,060        5  
Trademarks/Tradenames
     420        5  
    
 
 
          
Total
   $ 3,480           
    
 
 
          
The Customer Relations intangible asset represents the relationships that will be maintained with certain historical customers of Astro Machine. The trademark/tradename intangible assets reflect the industry reputation of the Astro Machine name and the registered trademarks held by Astro Machine for the use of several marks and logos.
Goodwill of $2.73 
million, which is not deductible for tax purposes, represents the excess of the purchase price over the estimated fair value assigned to the tangible and identifiable intangible assets acquired and liabilities assumed from Astro Machine. The goodwill recognized under ASC 805 is attributable to synergies which are expected to enhance and expand our overall product portfolio, opportunities in new and existing markets, future technologies that have yet to be determined and Astro Machine’s assembled workforce. The carrying amount of the goodwill was allocated to the PI segment.
Total acquisition-related costs of $0.7 million were included in general and administrative expenses in our consolidated statement of income for the year ended January 31, 2023.
The amounts of revenue and earnings before taxes included in our consolidated statement of income for the quarter ended April 29, 2023:
 
(In thousands)
      
Revenue
   $ 4,229  
Earnings before Taxes
     689  
Astro Machine results are reported as part of the PI segment. Proforma results are not provided, as disclosure of such amounts was impractical to determine as the acquired business had insufficient financial records and no audit history prior to the transaction.
 
8

Honeywell Asset Purchase and License Agreement
On June 30, 2022, we entered into an Asset Purchase and License Agreement with Honeywell International Inc. (“New HW Agreement”) to acquire an exclusive, perpetual, world-wide license to manufacture Honeywell’s flight deck printers for the Boeing 787 aircraft. The New HW Agreement provides for royalty payments to Honeywell based on gross revenues from the sales of the printers, paper and repair services of the licensed products in perpetuity. The royalty rates vary based on the year in which they are paid or earned and as products are sold or as services are provided and range from single-digit to
mid-double-digit
percentages of gross revenue. The New HW Agreement includes a provision for guaranteed minimum royalty payments to be paid in the event that the royalties earned by Honeywell do not meet the minimum for the preceding calendar year as follows: $
100,000 in 2024, $200,000 in 2025, $233,000 in 2026 and 2027, and $234,000 in 2028.
This transaction was evaluated under ASC 805, “Business Combinations,” and was accounted for as an asset acquisition.
The purchase price was allocated to the customer relationship intangible, which was the only asset acquired as a result of this transaction. This asset will be amortized over the useful life of the intangible. The minimum royalty payment obligation and related customer relationships intangible were recorded at the present value of the minimum royalty payments.
The acquired identifiable intangible asset is as follows:
 
(In thousands)   
Fair
Value
    
Useful Life
(Years)
 
Customer Contract Relationships
   $ 530        20  
The minimum royalty payment due was discounted based on the payment schedule and applicable discount rate, resulting in an outstanding royalty obligation of $0.5 million as of January 31, 2023, including $0.1 million recorded as a current liability. As of April 29, 2023, the current outstanding royalty obligation remains $0.5 million, including $0.1 million recorded as a current liability in the accompanying balance sheet.
Additional royalties based on sales activity will be recorded in the period that the associated revenue is earned. During fiscal 2023, we incurred $0.1 
million in excess royalty expense, which was recorded as a current liability in our consolidated balance sheet at January 31, 2023 and was paid in the first quarter of the current fiscal year.
Note 4 – Revenue Recognition
We derive revenue from the sale of (i) hardware, including digital color label printers and specialty OEM printing systems, portable data acquisition systems and airborne printers and networking hardware used in the flight deck and cabin of military, commercial and business aircraft, (ii) related supplies required in the operation of the hardware, (iii) repairs and maintenance of hardware and (iv) service agreements.
Revenues disaggregated by primary geographic markets and major product types are as follows:
Primary geographical markets:
 
    
Three Months Ended
 
(In thousands)   
April 29,
2023
    
April 30,
2022
 
United States
   $ 22,834      $ 19,651  
Europe
     7,964        7,419  
Canada
     1,825        1,854  
Asia
     1,294        937  
Central and South America
     1,199        888  
Other
     303        261  
    
 
 
    
 
 
 
Total Revenue
   $ 35,419      $ 31,010  
    
 
 
    
 
 
 
 
9

Major product types:
 
    
Three Months Ended
 
(In thousands)   
April 29,
2023
    
April 30,
2022
 
Hardware
     11,667      $ 9,301  
Supplies
     19,070        17,944  
Service and Other
     4,682        3,765  
    
 
 
    
 
 
 
Total Revenue
   $ 35,419      $ 31,010  
    
 
 
    
 
 
 
In December 2022, we entered into an amended contract with one of our T&M customers that provided for a total payment of $3.25 
million to us as a result of our claims allowable under French law relating to additional component costs we have incurred and will continue to incur in order to supply aerospace printers under the contract for the period beginning in April 2022 and continuing through 2025. Revenue from this arrangement will be recognized in proportion to the total estimated shipments through the end of the contract period. As of January 31, 2023, we have recognized $
1.1 
million in revenue and the remainder $
2.15 
million balance was recorded as deferred revenue. During the first quarter of fiscal 2024, we recognized an additional $
0.4 
million in revenue which is included in the condensed consolidated statement of income for the quarter ended April 29, 2023. The remaining revenue to be recognized will be based on our shipments of the printers during the remainder of fiscal years 2024 and 2025.
Contract Assets and Liabilities
We normally do not have contract assets, which are primarily unbilled accounts receivable that are conditional on something other than the passage of time.
Our contract liabilities, which represent billings in excess of revenue recognized, are related to advanced billings for purchased service agreements and extended warranties. Contract liabilities were $443,000 and $412,000 at April 29, 2023 and January 31, 2023, respectively, and are recorded as deferred revenue in the accompanying condensed consolidated balance sheet. The increase in the deferred revenue balance during the three months ended April 29, 2023 is due to cash payments received in advance of satisfying performance obligations in the current period which was partially offset by $143,000 of revenue recognized during the period that was included in the deferred revenue balance at January 31, 2023.
Contract Costs
We recognize an asset for the incremental costs of obtaining a contract with a customer if we expect the benefit of those costs to be longer than one year. We have determined that certain costs related to obtaining sales contracts for our aerospace printer products meet the requirement to be capitalized. These costs are deferred and amortized over the remaining useful life of these contracts, which we currently estimate to be approximately 18 years as of April 29, 2023. The balance of these contract assets at January 31, 2023 was $1.4 million. We amortized $19,000 and $16,000 of direct costs during the three months ended April 29, 2023 and April 30, 2022, respectively. The balance of deferred incremental direct costs net of accumulated amortization at April 29, 2023 was $1.3 million, of which $0.1 million is reported in other current assets and $1.2 million is reported in other assets in the accompanying condensed consolidated balance sheet.
Note 5 – Net Income Per Common Share
Basic net income per share is calculated by dividing net income by the weighted average number of shares outstanding during the period. Diluted net income per share is calculated by dividing net income by the weighted average number of shares and, if dilutive, common equivalent shares, determined using the treasury stock method for stock options, restricted stock awards and restricted stock units outstanding during the period. A reconciliation of the shares used in calculating basic and diluted net income per share is as follows:
 
    
Three Months Ended
 
    
April 29,
2023
    
April 30,
2022
 
Weighted Average Common Shares Outstanding – Basic
     7,369,930        7,262,797  
Effect of Dilutive Options, Restricted Stock Awards and Restricted Stock Units
     80,122        97,713  
    
 
 
    
 
 
 
Weighted Average Common Shares Outstanding – Diluted
     7,450,052        7,360,510  
    
 
 
    
 
 
 
 
10

For the three months ended April 29, 2023 and April 30, 2022, the diluted per share amounts do not reflect common equivalent shares outstanding of 656,554 and 310,588, respectively, because of their anti-dilutive effect.
Note 6 – Intangible Assets
Intangible assets are as follows:
 
    
April 29, 2023
    
January 31, 2023
 
(In thousands)   
Gross
Carrying
Amount
    
Accumulated
Amortization
   
Currency
Translation
Adjustment
    
Net
Carrying
Amount
    
Gross
Carrying
Amount
    
Accumulated
Amortization
   
Currency
Translation
Adjustment
    
Net
Carrying
Amount
 
Miltope:
                                                                     
Customer Contract Relationships
   $ 3,100      $ (2,857   $ —        $ 243      $ 3,100      $ (2,777   $ —        $ 323  
RITEC:
                                                                     
Customer Contract Relationships
     2,830        (1,639     —          1,191        2,830        (1,623     —          1,207  
TrojanLabel:
                                                                     
Existing Technology
     2,327        (2,171     97        253        2,327        (2,087     94        334  
Distributor Relations
     937        (616     36        357        937        (588     27        376  
Honeywell:
                                                                     
Customer Contract Relationships
     27,773        (12,145     —          15,628        27,773        (11,913     —          15,860  
Astro Machine:
                                                                     
Customer Contract Relationships
     3,060        (459     —          2,601        3,060        (306     —          2,754  
Trademarks
     420        (63     —          357        420        (42     —          378  
    
 
 
    
 
 
   
 
 
    
 
 
    
 
 
    
 
 
   
 
 
    
 
 
 
Intangible Assets, net
   $ 40,447      $ (19,950   $ 133      $ 20,630      $ 40,447      $ (19,336   $ 121      $ 21,232  
    
 
 
    
 
 
   
 
 
    
 
 
    
 
 
    
 
 
   
 
 
    
 
 
 
There were no impairments to intangible assets during the periods ended April 29, 2023 and April 30, 2022.
With respect to the acquired intangibles included in the table above, amortization expense of $
0.6
 
million and $0.4 million has been included in the condensed consolidated statements of income for the three months ended April 29, 2023 and April 30, 2022, respectively.

Estimated amortization expense for the next five fiscal years is as follows:
 
(In thousands)
  
Remaining
2024
 
  
2025
 
  
2026
 
  
2027
 
  
2028
 
Estimated amortization expense
   $ 1,786      $ 1,723      $ 1,723      $ 1,723      $ 1,281  
Note 7 – Inventories
Inventories are stated at the lower of cost (standard and average methods) or net realizable value and include material, labor and manufacturing overhead. The components of inventories are as follows:
 
(In thousands)
  
April 29, 2023
 
  
January 31, 2023
 
Materials and Supplies
   $ 40,624      $ 38,387  
Work-In-Process
     1,485        1,146  
Finished Goods
     22,221        23,221  
    
 
 
    
 
 
 
       64,330        62,754  
Inventory Reserve
     (11,204      (11,430
    
 
 
    
 
 
 
     $ 53,126      $ 51,324  
    
 
 
    
 
 
 
 
11

Note 8 – Property, Plant and Equipment
Property, plant and equipment consist of the following:
 
 
  
April 29,

2023
 
  
January 31,

2023
 
(In thousands)
  
 
 
  
 
 
Land and Land Improvements
   $ 2,304      $ 2,304  
Buildings and Leasehold Improvements
     14,162        14,158  
Machinery and Equipment
     25,012        24,960  
Computer Equipment and Software
     13,996        13,972  
    
 
 
    
 
 
 
Gross Property, Plant and Equipment
     55,474        55,394  
Accumulated Depreciation
     (41,556      (41,106
    
 
 
    
 
 
 
Net Property Plant and Equipment
   $ 13,918      $ 14,288  
    
 
 
    
 
 
 
Depreciation expense on property, plant and equipment was $0.4 
million for the each of the quarters ended April 29, 2023 and April 30, 2022.
Note 9 – Credit Agreement and Long-Term Debt
In connection with the purchase of Astro Machine, on August 4, 2022, we entered into a Second Amendment to the Amended and Restated Credit Agreement (the “Second Amendment”) with Bank of America, N.A., as lender (the “Lender”). The Second Amendment amended the Amended and Restated Credit Agreement dated as of July 30, 2020, as amended by the First Amendment to Amended and Restated Credit Agreement, dated as of March 24, 2021, and the LIBOR Transition Amendment, dated as of December 24, 2021 (the “Existing Credit Agreement,” and the Existing Credit Agreement as amended by the Second Amendment, the “Amended Credit Agreement”), between us and the Lender.
The Amended Credit Agreement provides for (i) a new term loan in the principal amount of $6.0 million, which term loan was in addition to the existing term loan outstanding under the Existing Credit Agreement in the principal amount of $9.0 million as of the effective date of the Second Amendment, and (ii) an increase in the aggregate principal amount of the revolving credit facility available thereunder from $22.5 million to $25.0 million. At the closing of the Second Amendment, we borrowed the entire $6.0 million term loan and $12.4 million under the revolving credit facility, and the proceeds of such borrowings were used in part to pay the purchase price payable under the Purchase Agreement and certain related transaction costs. The revolving credit facility may otherwise be used for corporate purposes.

The Amended Credit Agreement requires that the term loan be paid in quarterly installments on the last day of each of our fiscal quarters over the term of the Amended Credit Agreement on the following repayment schedule: the principal amount of each quarterly installment required to be paid on the last day of each of our fiscal quarters ending on or about October 31, 2022 through July 31, 2023 is $
375,000; and the principal amount of each quarterly installment required to be paid on the last day of each of our fiscal quarters ending on or about October 31, 2023 through April 30, 2027 is $675,000. The entire remaining principal balance of the term loan is required to be paid on August 4, 2027. We may voluntarily prepay the term loan, in whole or in part, from time to time without premium or penalty (other than customary breakage costs, if applicable). We may repay borrowings under the revolving credit facility at any time without premium or penalty (other than customary breakage costs, if applicable), but in any event no later than August 4, 2027, and any outstanding revolving loans thereunder will be due and payable in full, and the revolving credit facility will terminate, on such date. We may reduce or terminate the revolving line of credit at any time, subject to certain thresholds and conditions, without premium or penalty.
The interest rates under the Amended Credit Agreement are as follows: the term loan and revolving credit loans bear interest at a rate per annum equal to, at our option, either (a) the BSBY Rate as defined in the Amended Credit Agreement (or, in the case of revolving credit loans denominated in a currency other than U.S. Dollars, the applicable quoted rate), plus a margin that varies within a range of 1.60% to 2.50% based on our consolidated leverage ratio, or (b) a fluctuating reference rate equal to the highest of (i) the federal fund rate plus 0.50%, (ii) Bank of America’s publicly announced prime rate, (iii) the BSBY Rate plus 1.00%, or (iv) 0.50%, plus a margin that varies within a range of 0.60% to 1.50% based on our consolidated leverage ratio. In addition to certain other fees and expenses that we are required to pay to the Lender, we are required to pay a commitment fee on the undrawn portion of the revolving credit facility that varies within a range of 0.15% and 0.35% based on our consolidated leverage ratio. The loans under the Amended Credit Agreement are subject to certain mandatory prepayments, subject to various exceptions, from (a) net cash proceeds from certain dispositions of property, (b) net cash proceeds from certain issuances of equity, (c) net cash proceeds from certain issuances of additional debt and (d) net cash proceeds from certain extraordinary receipts.
 
 
12

Amounts repaid under the revolving credit facility may be reborrowed, subject to our continued compliance with the Amended Credit Agreement. No amount of the term loan that is repaid may be reborrowed.
We must comply with various customary financial and
non-financial
covenants under the Amended Credit Agreement. The financial covenants under the Amended Credit Agreement consist of a maximum consolidated leverage ratio, a minimum consolidated fixed charge coverage ratio and a minimum consolidated asset coverage ratio. The primary
non-financial
covenants limit our and our subsidiaries’ ability to incur future indebtedness, to place liens on assets, to pay dividends or distributions on our or our subsidiaries’ capital stock, to repurchase or acquire our or our subsidiaries’ capital stock, to conduct mergers or acquisitions, to sell assets, to alter our or our subsidiaries’ capital structure, to make investments and loans, to change the nature of our or our subsidiaries’ business, and to prepay subordinated indebtedness, in each case subject to certain exceptions and thresholds as set forth in the Amended Credit Agreement, certain of which provisions were modified by the Second Amendment. As of April 29, 2023, we believe we are in compliance with all of the covenants in the Credit Agreement.
The Lender is entitled to accelerate repayment of the loans and to terminate its revolving credit commitment under the Amended Credit Agreement upon the occurrence of any of various customary events of default, which include, among other events, the following (which are subject, in some cases, to certain grace periods): failure to pay when due any principal, interest or other amounts in respect of the loans, breach of any of our covenants or representations under the loan documents, default under any other of our or our subsidiaries’ significant indebtedness agreements, a bankruptcy, insolvency or similar event with respect to us or any of our subsidiaries, a significant unsatisfied judgment against us or any of our subsidiaries, or a change of control.
Our obligations under the Amended Credit Agreement continue to be secured by substantially all of our personal property assets (including a pledge of the equity interests we hold in ANI ApS, AstroNova GmbH and AstroNova SAS), subject to certain exceptions, and by a mortgage on our owned real property in West Warwick, Rhode Island, and are guaranteed by, and secured by substantially all of the personal property assets of Astro Machine.
Summary of Outstanding Debt
At April 29, 2023, we ha
d
an outstanding balance of $15.9 million on our revolving line of credit. The balance outstanding under the revolving line of credit bore interest at a weighted average annual rate of 6.93% and 4.26% and we incurred $292,000 and $23,000 for interest on this obligation during the quarters ended April 29, 2023 and April 30, 2022, respectively. Additionally, during the quarters ended April 29, 2023 and April 30, 2022, we incurred $8,000 and $10,000, respectively, of commitment fees on the undrawn portion of our revolving credit facility. Both the interest expense and commitment fees are included as interest expense in the accompanying condensed consolidated income statement for the quarters ended April 29, 2023 and April 30, 2022. At April 29, 2023, there
wa
s $9.1 million remaining available for borrowing under the revolving line of credit.
 
13

Long-term debt in the accompanying condensed consolidated balance sheets is as follows:
 
(In thousands)
  
April 29,

2023
 
  
January 31,

2023
 
USD Term Loan (7.24% as of April 29, 2023 and 6.78% as of January 31, 2023); maturity date of August 4, 2027
   $ 13,875      $ 14,250  
    
 
 
    
 
 
 
       13,875        14,250  
Debt Issuance Costs, net of accumulated amortization
     (97      (110
Current Portion of Term Loan
     (2,100      (2,100
    
 
 
    
 
 
 
Long-Term Debt
   $ 11,678      $ 12,040  
    
 
 
    
 
 
 
During the three months ended April 29, 2023 and April 30, 2022, we recognized $248,000 and $53,000 of interest expense, respectively, which was included in other expense in the accompanying condensed consolidated income statement.
The schedule of required principal payments remaining during the next five years on long-term debt outstanding as of April 29, 2023 is as follows:
 
(In thousands)
      
Fiscal 2024, remainder
   $ 1,725  
Fiscal 2025
     2,700  
Fiscal 2026
     2,700  
Fiscal 2027
     2,700  
Fiscal 2028
     4,050  
    
 
 
 
     $ 13,875  
    
 
 
 
Note 10 –
Royalty Obligation
In fiscal 2018, we entered into an Asset Purchase and License Agreement with Honeywell International, Inc. (“Honeywell”) to acquire an exclusive, perpetual, world-wide license to manufacture Honeywell’s narrow-format flight deck printers for two aircraft families along with certain inventory used in the manufacturing of the licensed printers. The purchase price included a guaranteed minimum royalty payment of $15.0 million, to be paid over
ten years
, based on gross revenues from the sales of the printers, paper and repair services of the licensed products. The royalty rates vary based on the year in which they are paid or earned, and product sold or service provided, and range from single-digit to mid double-digit percentages of gross revenue.
The guaranteed minimum royalty payment obligation was recorded at the present value of the minimum annual royalty payments. As of April 29, 2023, we had paid an aggregate of $10.0 million of the guaranteed minimum royalty obligation. At April 29, 2023, the current portion of the outstanding guaranteed minimum royalty obligation of $1.5 million is to be paid over the next twelve months and is reported as a current liability and the remainder of $2.7 million is reported as a long-term liability on our condensed consolidated balance sheet. We incurred $0.4 million in excess royalty expense for the three-month period ended April 29, 2023, which is included in cost of revenue in our consolidated statements of income. A total of $0.4 million in excess royalties was paid in the first quarter of the current fiscal year
,
and there are $0.4 million in excess royalty payables due as a result of this agreement for the quarter ended April 29, 2023.
In fiscal 2023, AstroNova, Inc. entered into a second Asset Purchase and License Agreement with Honeywell International, Inc. as further discussed in Note 3 “Acquisitions”.
Note 11 – Leases
We enter into lease contracts for certain of our facilities at various locations worldwide. Our leases have remaining lease terms of one to six years.
Balance sheet and other information related to our leases is as follows:
 
Operating Leases
(In thousands)
  
Balance Sheet Classification
 
  
April 29,
2023
 
  
January 31,
2023
 
Lease Assets
  
 
Right of Use Assets
 
  
$
858
 
  
$
794
 
Lease Liabilities – Current
  
 
Other Liabilities and Accrued Expenses
 
  
 
312
 
  
$
275
 
Lease Liabilities – Long Term
  
 
Lease Liabilities
 
  
 
581
 
  
$
555
 
 
14

Lease cost information is as follows:
 
 
  
 
 
  
Three Months Ended
 
Operating Leases
(In thousands)
  
Statement of Income Classification
 
  
April 29,
2023
 
  
April 30,
2022
 
Operating Lease Costs
     General and Administrative Expense      $ 133      $ 113  
Maturities of operating lease liabilities are as follows:
 
(In thousands)
  
April 29,
2023
 
2024, remaining
   $ 263  
2025
     258  
2026
     199  
2027
     151  
2028
     93  
Thereafter
         
    
 
 
 
Total Lease Payments
     964  
Less: Imputed Interest
     (71
    
 
 
 
Total Lease Liabilities
   $ 893  
    
 
 
 
As of April 29, 2023, the weighted-average remaining lease term and weighted-average discount rate for our operating leases are 3.5 years and 4.37%, respectively. We calculated the weighted-average discount rate using incremental borrowing rates, which equal the rates of interest that we would pay to borrow funds on a fully collateralized basis over a similar term.
Supplemental cash flow information related to leases is as follows:
 
    
Three Months Ended
 
(In thousands)
  
April 29,
2023
    
April 30,
2022
 
Cash paid for amounts included in the measurement of lease liabilities:
                 
Operating cash flows for operating leases
   $ 93      $ 83  
Note 1
2
– Accumulated Other Comprehensive Loss
The changes in the balance of accumulated other comprehensive loss (“AOCL”) by component are as follows:
 
(In thousands)
  
Foreign Currency
Translation
Adjustments
    
Total
 
Balance at January 31, 2023
   $ (2,238    $ (2,238
Other Comprehensive Income before reclassification
     210        210  
    
 
 
    
 
 
 
Balance at April 29, 2023
   $ (2,028    $ (2,028
    
 
 
    
 
 
 
The amounts presented above in other comprehensive loss are net of taxes except for translation adjustments associated with our German and Danish subsidiaries.
Note 1
3
– Share-Based Compensation
We have one equity incentive plan from which we are authorized to grant equity awards, the AstroNova, Inc. 2018 Equity Incentive Plan (the “2018 Plan”). The 2018 Plan provides for, among other things, the issuance of awards, including incentive stock options,
non-qualified
stock options, stock appreciation rights, time-based restricted stock units (“RSUs”), or performance-based restricted stock units (“PSUs”) and restricted stock awards (“RSAs”). The 2018 Plan authorizes the issuance of up to 950,000
shares of common stock, plus an additional number of shares equal to the number of shares subject to awards granted under previous equity incentive plans that are forfeited, cancelled, satisfied without the issuance of stock, otherwise terminated (other than by exercise), or,
for shares of stock issued pursuant to any unvested award, that are reacquired by us at not more than the grantee’s purchase price (other than by exercise). Under the 2018 Plan, all awards to employees generally have a minimum vesting period of one year. Options granted under the 2018 Plan must be issued at an exercise price of not less than the fair market value of our common stock on the date of grant and expire after ten years. Under the 2018 Plan, there were
124,439 unvested RSUs; 188,633 unvested PSUs; 21,172 unvested RSAs and options to purchase an aggregate of 135,500 shares outstanding as of April 29,
2023.
 
15

In addition to the 2018 Plan, we previously granted equity awards under our 2015 Equity Incentive Plan (the “2015 Plan”) and our 2007 Equity Incentive Plan (the “2007 Plan”). No new awards may be issued under either the 2007 Plan or 2015 Plan, but outstanding awards will continue to be governed by those plans. As of April 29, 2023, options to purchase an aggregate of
270,649 shares were outstanding under the 2007 Plan and options to purchase an aggregate of 134,950 shares were outstanding under the 2015 Plan.
We also have a
Non-Employee
Director Annual Compensation Program (the “Program”), under which each of our
non-employee
directors automatically receives a grant of restricted stock on the date of their
re-election
to our board of directors. The number of whole shares granted is equal to the number calculated by dividing the stock component of the director compensation amount determined by the compensation committee for that year by the fair market value of our stock on that day. The value of the restricted stock award for fiscal 2024 is approximately $65,000. Shares of restricted stock granted under the Program become vested on the first anniversary of the date of grant, conditioned upon the recipient’s continued service on our board of directors through that date.
Share-based compensation expense was recognized as follows:
 
    
Three Months Ended
 
(In thousands)
  
April 29,
2023
    
April 30,
2022
 
Stock Options
   $         $ 6  
Restricted Stock Awards and Restricted Stock Units
     352        328  
Employee Stock Purchase Plan
     4        3  
    
 
 
    
 
 
 
Total
   $ 356      $ 337  
    
 
 
    
 
 
 
Stock Options
Aggregated information regarding stock option activity for the three months ended April 29, 2023 is summarized below:
 
    
Number of
Options
    
Weighted Average
Exercise Price
 
Outstanding at January 31, 2023
     547,199      $ 15.16  
Granted
                   
Exercised
     (1,700      10.50  
Forfeited
     (175      18.35  
Canceled
     (4,225      10.50  
    
 
 
    
 
 
 
Outstanding at April 29, 2023
     541,099      $ 15.21  
    
 
 
    
 
 
 
Set forth below is a summary of options outstanding at April 29, 2023:
 
Outstanding
 
  
Exercisable
 
Range of
Exercise prices
  
Number
of
Shares
 
  
Weighted-
Average
Exercise
Price
 
  
Weighted-
Average
Remaining
Contractual Life
 
  
Number
of
Shares
 
  
Weighted-
Average
Exercise
Price
 
  
Weighted
Average
Remaining
Contractual
Life
 
$5.00-10.00
             $           —                  $           —    
$10.01-15.00
     326,924      $ 13.74        2.7        326,924      $ 13.74        2.7  
$15.01-20.00
     214,175      $ 17.45        4.6        214,175      $ 17.45        4.6  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
       541,099      $ 15.21        3.5        541,099      $ 15.21        3.5  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
 
16

There were no
stock options granted in fiscal 2023 and fiscal 2022, or in the first quarter of fiscal 2024, and as of April 29, 2023, there was
no unrecognized compensation expense related to stock options.
Restricted Stock Units (RSUs), Performance-Based Stock Units (PSUs) and Restricted Stock Awards (RSAs)
Aggregated information regarding RSU and RSA activity for the three months ended April 29, 2023 is summarized below:
 
 
  
RSUs, PSUs & RSAs
 
  
Weighted Average
Grant Date Fair Value
 
Outstanding at January 31, 2023
     274,927      $ 12.82  
Granted
     142,811        12.48  
Vested
     (78,817      11.85  
Forfeited
     (4,677      12.49  
    
 
 
    
 
 
 
Outstanding at April 29, 2023
     334,244      $ 12.90  
    
 
 
    
 
 
 
As of April 29, 2023, there was approximately $2.5 million of unrecognized compensation expense related to RSUs, PSUs and RSAs, which is expected to be recognized over a weighted average period of 1.2 years.

Employee Stock Purchase Plan
On June 7, 2022, we adopted the AstroNova Inc. 2022 Employee Stock Purchase Plan (“2022 ESPP”) to replace our previous Employee Stock Purchase Plan (the “Prior ESPP”). The 2022 ESPP allows eligible employees to purchase shares of common stock at a 15% discount from fair value on the first or last day of an offering period, whichever is less. A total of 40,000
shares were reserved for issuance under the 2022 ESPP and
5,045 shares were purchased under the 2022 ES
P
P during the year ended January 31, 2023. During the three months ended April 29, 2023, there were 2,394 shares purchased under the 2022 ESPP. During the three months ended April 30, 2022, there were 1,550 shares purchased under the Prior ESPP, and no additional purchases may be made under the Prior ESPP. As of April 29, 2023, 32,560 shares remain available for purchase under the 2022 ESPP.
Note 1
4
– Income Taxes
Our effective tax rates are as follows:
 
    
First Quarter
Ended
 
Fiscal 2024
     17.4
Fiscal 2023
     12.4
We determine our estimated annual effective tax rate at the end of each interim period based on full-year forecasted
pre-tax
income and facts known at that time. The estimated annual effective tax rate is applied to the
year-to-date
pre-tax
income at the end of each interim period with the cumulative effect of any changes in the estimated annual effective tax rate being recorded in the fiscal quarter in which the change is determined. The tax effect of significant unusual items is reflected in the period in which they occur.
During the three months ended April 29, 2023, we recognized an income tax expense of approximately $179,000. The effective tax rate in this period was directly impacted by a $77,000 tax benefit related to the expiration of the statute of limitations on a previously uncertain tax position and a $29,000
tax benefit arising from windfall tax benefits related to our stock. During the three months ended April 30, 2022, we recognized an income tax expense of approximately $
60,000. The effective tax rate in this period was directly impacted by a $38,000 tax benefit related to the expiration of the statute of limitations on a previously uncertain tax position and a $30,000
tax benefit arising from windfall tax benefits related to our stock.
Note 1
5
– Segment Information
We report two segments: PI and T&M. We evaluate segment performance based on the segment profit before corporate expenses.
 
17

Summarized below are the Revenue and Segment Operating Profit for each reporting segment:
 
 
  
Three Months Ended
 
 
  
Revenue
 
  
Segment Operating Profit
 
(In thousands)
  
April 29,
2023
 
  
April 30,
2022
 
  
April 29,
2023
 
  
April 30,
2022
 
PI
   $ 25,095      $ 21,724      $ 2,515      $ 1,413  
T&M
     10,324        9,286        2,072        1,911  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total
   $ 35,419      $ 31,010        4,587        3,324  
    
 
 
    
 
 
                   
Corporate Expenses
              3,126        2,560  
             
 
 
    
 
 
 
Operating Income
              1,461        764  
Other Expense, Net
              434        279  
             
 
 
    
 
 
 
Income Before Income Taxes
              1,027        485  
Income Tax Provision
              179        60  
             
 
 
    
 
 
 
Net Income
            $ 848      $ 425  
             
 
 
    
 
 
 
Note 1
6
– Fair Value
Assets and Liabilities Not Recorded at Fair Value
Our long-term debt, including the current portion of long-term debt not reflected in the financial statements at fair value, is reflected in the table below:
 
    
April 29, 2023
 
    
Fair Value Measurement
        
(In thousands)
  
Level 1
    
Level 2
    
Level 3
    
Total
    
Carrying
Value
 
Long-Term debt and related current maturities
   $ —        $ —        $ 13,937      $ 13,937      $ 13,875  
 
    
January 31, 2023
 
    
Fair Value Measurement
        
(In thousands)
  
Level 1
    
Level 2
    
Level 3
    
Total
    
Carrying
Value
 
Long-Term debt and related current maturities
   $ —        $ —        $ 14,310      $ 14,310      $ 14,250  
The fair value of our long-term debt, including the current portion, is estimated by discounting the future cash flows using current interest rates at which similar loans with the same maturities would be made to borrowers with similar credit ratings and is classified as Level 3.
 
 
18


Table of Contents
Item 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Business Overview

This section should be read in conjunction with our condensed consolidated financial statements included elsewhere herein and our Annual Report on Form 10-K for the fiscal year ended January 31, 2023.

We are a multinational enterprise that leverages our proprietary data visualization technologies to design, develop, manufacture, distribute and service a broad range of products that acquire, store, analyze and present data in multiple formats. We organize our structure around a core set of competencies, including research and development, manufacturing, service, marketing and distribution. We market and sell our products and services through the following two segments:

 

   

Product Identification (“PI”) – offers color and monochromatic digital label printers, direct-to-package printers and custom OEM printers. PI also provides software to design, manage and print labeling and packaging images locally and across networked printing systems, as well as all related printing supplies such as pressure sensitive labels, tags, inks, toners and thermal transfer ribbons used by digital printers. PI also provides on-site and remote service, spare parts and various service contracts.

 

   

Test and Measurement (“T&M”) – offers a suite of products and services that acquire data from local and networked data streams and sensors as well as wired and wireless networks. The T&M segment includes a line of aerospace printers that are used to print hard copies of data required for the safe and efficient operation of aircraft including navigation maps, clearances, arrival and departure procedures, flight itineraries, weather maps, performance data, passenger data, and various air traffic control data. Aerospace products also include aircraft networking systems for high-speed onboard data transfer. T&M also provides repairs, service and spare parts.

On August 4, 2022, we completed the acquisition of Astro Machine, an Illinois-based manufacturer of printing equipment, including label printers, tabbers, conveyors, and envelope feeders, for aggregate consideration of $17.1 million. Astro Machine is reported as part of our PI segment beginning with the third quarter of fiscal 2023. Refer to Note 3, “Acquisitions,” in our condensed consolidated financial statements included elsewhere in this report for further details.

We market and sell our products and services globally through a diverse distribution structure of direct sales personnel, manufacturers’ representatives and authorized dealers that deliver a full complement of branded products and services to customers in our respective markets. Our growth strategy centers on organic growth through product innovation made possible by research and development initiatives, as well as strategic acquisitions that fit into or complement existing core businesses.

COVID-19 Update

All of our global operations were materially adversely affected by the worldwide COVID-19 pandemic and the related supply-chain disruptions. In the aftermath of the immediate severe impacts of COVID-19, the resulting changes in our customers’ purchasing behavior, the post-pandemic impact of inflation from macroeconomic factors, and the continued and lingering structural impacts on our global supply chain, particularly with respect to the availability and costs of electronic components, have made planning for customer demand and manufacturing production more difficult and have had an adverse impact on our operations and financial performance. Also, the post-pandemic impact has led to a rise in the cost of a number of classes of acquired goods for both the T&M and PI segments. We will continue to evaluate the impact of COVID-19 and its aftermath effects on our business, results of operations and cash flows throughout fiscal 2024, including the potential impacts on various estimates and assumptions inherent in the preparation of the consolidated financial statements.

Since the COVID-19 pandemic began we have experienced difficulties in obtaining raw materials and components for our products. Some of the structural dislocations in the global economy that were triggered by the pandemic are prolonging these difficulties. Particularly with respect to certain electronic components for legacy products in our T&M segment, availability has been curtailed and may not recover, and as a result, we have had to accelerate product redesign and quickly transition customers to products with more viable long-term product configurations. We expect to incur substantial costs in doing so but are unable to accurately estimate the financial impact due to the rapidly changing environment. We have also had to incur costs, related to higher shipping fees (i.e., air rather than ocean freight) and though these have abated to a degree, they have not returned to pre-pandemic levels. These factors negatively impacted our efficiency and delayed shipments for each of the fiscal quarters in fiscal 2023, and while those issues have somewhat abated in the first quarter of fiscal 2024, it is unclear whether this favorable trend will continue. We are addressing these issues through long-range planning and procuring higher inventory levels for the affected items to help mitigate potential shortages whenever practicable. For our T&M segment, we are also monitoring and reacting to extended lead times on electronic components, and utilizing a variety of strategies, including blanket orders, vendor-bonded inventories, extended commitments to our supply base, and seeking alternative suppliers. Additionally, we have taken actions to increase regular contact with our essential vendors and increased our forecasting horizon for our products to help us better manage our supply chain. In some cases, we are working with our vendors to help them procure components. Similarly, in our PI segment, we are increasing our inventory levels to ensure the adequacy of the supplies we sell to customers who use our printers. Our strategies to counteract these supply chain dislocations have significantly increased the amount of inventory we maintain to support our product sales. We have also experienced several situations where component shortages and scarcity have required us to pay significantly higher costs to obtain those components, particularly electronic components and circuit board assemblies in the T&M segment and inks and printer machine parts in the PI segment. We will continue to monitor our supply chain going forward and update our mitigation strategies as we determine appropriate. We are not able to predict how current supply chain difficulties will develop in the future, and if the steps we are taking are not effective, it could have a material adverse impact on our business and results of operations.

 

19


Table of Contents

Product Identification Update

The COVID-19 pandemic impacted our PI business by limiting our ability to meet with customers to demonstrate our products at trade shows and on-site in their facilities was curtailed. We partially countered this through a variety of virtual, on-line selling and digital marketing strategies, a number of which we continue to emphasize today. The degree to which post-pandemic selling practices will revert to traditional practices is unknow, and the ultimate mix of customer engagement methods of face-to-face selling versus digital selling methods are just starting to recover. For example, throughout fiscal 2023 we attended numerous trade shows, but demand generation through those selling methods has not fully recovered and digital marketing has, we believe, become a more permanent element of our go-to-market strategy. This has required us to shift resources to those technologies. Further, the reliability of timely delivery of acceptable quality printer components from one of our suppliers has deteriorated post-pandemic, which has caused us to incur additional direct procurement costs to carry higher inventories to assure adequate supplies to satisfy customers. We have also incurred additional warranty and technical service costs to offset the impacts of these quality issues and invested considerable time and resources with that supplier to improve their performance.

Test & Measurement Update

The aerospace industry, which we serve through our aerospace product line, was significantly disrupted by the COVID-19 pandemic, because of the severe decline in the demand for air travel, demand for aircraft, and a general curtailment of aircraft production rates. This had a material adverse impact on our financial results. Although air travel demand and aircraft production demand have improved and the direct and secondary impacts of the demand decline have somewhat abated, they have not recovered completely. As a result, demand for our products has not fully recovered to pre-pandemic levels. We believe that it will be at least another two or more years before we reach full revenue recovery due to the lingering impacts of the pandemic era on the economic structure of the airline industry. General economic conditions could also still become a negative factor impacting demand for new aircraft, which could potentially stall or reverse current favorable trends. If this were to happen individually or in combination, these factors would be difficult to respond to, which could have a material adverse impact on our business operations and financial results.

Results of Operations

Three Months Ended April 29, 2023 vs. Three Months Ended April 30, 2022

Revenue by segment and current quarter percentage change over the prior year for the three months ended April 29, 2023 and April 30, 2022 were:

 

(Dollars in thousands)

   April 29,
2023
     As a
% of
Revenue
    April 30,
2022
     As a
% of
Revenue
    % Change
Compared
to
Prior Year
 

PI

   $ 25,095        70.9   $ 21,724        70.1     15.5

T&M

     10,324        29.1     9,286        29.9     11.2
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

Total

   $ 35,419        100.0    $ 31,010        100.0      14.2
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

Revenue for the first quarter of the current year was $35.4 million, representing a 14.2% increase compared to the previous year first quarter revenue of $31.0 million. Revenue through domestic channels for the first quarter of the current year was $22.8 million, an increase of 16.2% from the prior year’s first quarter domestic revenue of $19.7 million. International revenue for the first quarter of the current year was $12.6 million, representing 35.5% of our first quarter revenue and reflecting a 10.8% increase from the previous year first quarter. Current year first quarter international revenue includes an unfavorable foreign exchange rate impact of $0.3 million.

Hardware revenue in the first quarter of current year was $11.7 million, a 25.4% increase compared to the prior year’s first quarter hardware revenue of $9.3 million. The current quarter increase is attributable to increased hardware sales in both the T&M and PI segments. Current quarter hardware sales in the PI segment were $5.1 million, an increase of 76.4% or $2.2 million compared to the previous year first quarter revenue of $2.9 million. This increase was the result of the $2.5 million of hardware sales from the newly acquired Astro Machine, slightly offset by a decline in sales of our QuickLabel and TrojanLabel printers. T&M hardware sales for the current quarter were $6.5 million, a 2.2% increase from the previous year’s first quarter revenue of $6.4 million, as the $1.1 million or 22.7% increase in sales in our aerospace printer product line was largely offset by the decline in sales of our data recorder product line.

 

20


Table of Contents

Supplies revenue in the first quarter of current year was $19.1 million, a 6.3% increase compared to the prior year’s first quarter supplies revenue of $17.9 million. Supplies revenue increased in both the PI and T&M segment in the current quarter, with the increase primarily due to the contribution of $1.3 million of supply sales from the newly acquired Astro Machine in the PI segment. Also contributing to the increase in the current quarter’s supply revenue was the increase in paper supply revenue for the aerospace printers in the T&M segment and increased supply sales in our TrojanLabel product line in the PI segment. The overall increase in supplies revenue for the current quarter was moderately offset by a decline in ink jet supplies sales in the PI segment.

Service and other revenues of $4.7 million in the current quarter increased 24.4% compared to first quarter revenue of $3.8 million in the prior year. The increase is due primarily to $0.4 million of Astro Machine parts revenues included since the acquisition in the PI segment and increased repair and parts revenue for aerospace printer products in the T&M segment due to the impact of increased flight hour usage and pricing increases. The current quarter increase was slightly offset by modest declines in aftermarket parts sales for Quick Label products in the PI segment.

The current year first quarter gross profit was $12.4 million, a 15.4% increase compared to the prior year’s first quarter gross profit of $10.7 million. Current quarter gross profit margin of 35.0% reflects a 0.4 percentage point increase from the prior year’s first quarter gross profit margin of 34.6%. The higher gross profit margin for the current quarter compared to the prior year’s first quarter is primarily attributable to a higher mix of profitable revenue in the T&M segment.

Operating expenses for the current quarter were $10.9 million, a 9.6% increase compared to the prior year’s first quarter operating expenses. Current quarter selling and marketing expenses were $6.0 million, a 2.2% increase compared to the first quarter of the prior year. The increase for the current quarter was primarily due to the increase in amortization expense related to the customer relationship and trademark intangibles acquired as part of the Astro Machine acquisition, as well an increase in employee benefits and bonuses. The increase in current quarter selling and marketing expenses was partially offset by decreases in commissions and maintenance contract fees. Current quarter general and administrative expenses were $3.1 million, a 22.1% increase compared to the first quarter of the prior year, primarily due to an increase in audit and accounting fees, employee wages and benefits, and outside services expenses. Research and development (“R&D”) expenses were $1.8 million in the current quarter, a 17.5% increase compared to $1.5 million in the first quarter of the prior year, primarily due to increases in supplies and repairs expenses and employee wage expenses. R&D spending as a percentage of revenue for the current quarter was 5.0% as compared to 4.9% for the same period in the prior year.

Other expense in the first quarter of the current year was $0.4 million compared to $0.3 million for the same period in the prior year. Current quarter other expense includes interest expense on term debt and our revolving line of credit of $0.6 million, offset by $0.2 million of net foreign exchange gain. Other expense for the first quarter of the prior year consisted of interest expense on our debt of $0.2 million and $0.1 million of net foreign exchange loss.

We recognized a federal, state and foreign income tax provision for the first quarter of the current year of $179,000, resulting in an effective tax rate of 17.4%. This rate was impacted by a $77,000 tax benefit related to the expiration of the statute of limitations on a previously uncertain tax position and a $29,000 tax benefit arising from windfall tax benefits related to our stock. During the three months ended April 30, 2022, we recognized an income tax expense of approximately $60,000. The effective tax rate in this period was directly impacted by a $38,000 tax benefit related to the expiration of the statute of limitations on a previously uncertain tax position and a $30,000 tax benefit arising from windfall tax benefits related to our stock.

We reported net income of $0.8 million or $0.11 per diluted share for the first quarter of the current year. On a comparable basis, net income for the prior year’s first quarter was $0.4 million or $0.06 per diluted share. Return on revenue was 2.4% for the first quarter of fiscal 2024 compared to 1.4% for the first quarter of fiscal 2023.

Segment Analysis

We report two segments: PI and T&M and evaluate segment performance based on the segment profit before corporate and financial administration expenses. Summarized below are the Revenue and Segment Operating Profit for each reporting segment:

 

     Three Months Ended  
     Revenue      Segment Operating Profit  

(In thousands)

   April 29,
2023
     April 30,
2022
     April 29,
2023
     April 30,
2022
 

PI

   $ 25,095      $ 21,724      $ 2,515      $ 1,413  

T&M

     10,324        9,286        2,072        1,911  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 35,419      $ 31,010        4,587        3,324  
  

 

 

    

 

 

       
                             

Corporate Expenses

        3,126        2,560  
     

 

 

    

 

 

 

Operating Income

        1,461        764  

Other Expense, Net

        434        279  
     

 

 

    

 

 

 

Income Before Income Taxes

        1,027        485  

Income Tax Provision

        179        60  
     

 

 

    

 

 

 

Net Income

      $ 848      $ 425  
     

 

 

    

 

 

 

 

21


Table of Contents

Product Identification-PI

Revenue from the PI segment increased $3.4 million or 15.5% in the first quarter of the current year, with revenue of $25.1 million compared to $21.7 million in the same period of the prior year. The current quarter increase is attributable to the contribution of the newly acquired Astro Machine, which provided revenue of $4.2 million for the first quarter of the current year. An increase in Trojan Label related product supply revenue due to the larger installed base of these printers also factored into the increase in the first quarter of fiscal 2024 revenue. The current quarter increase in PI revenue was offset by declines in the revenue from QuickLabel inkjet supply products and hardware sales, particularly in North America resulting from the continued adverse market reaction to quality problems caused by quality and reliability issues we faced from one supplier. Product Identification’s current quarter segment operating profit was $2.5 million, reflecting a profit margin of 10.0%. This compares to the prior year’s first quarter segment profit of $1.4 million and related profit margin of 6.5%. The increase in Product Identification current year first quarter segment operating profit and margin is primarily due to the inclusion of Astro Machine and a favorable product mix.

Test & Measurement—T&M

Revenue from the T&M segment was $10.3 million for the first quarter of the current fiscal year, representing an 11.2% increase compared to revenue of $9.3 million for the same period in the prior year. The increase in revenue for the current quarter is primarily attributable to strong hardware sales in our aerospace product lines as a result of increased aerospace printer product unit volume. Demand for printers, especially for narrow-body aircraft, has increased due to the post-pandemic recovery in air travel demand and new orders of airplanes and the corresponding increase in production rates. The sales of printers for wide-body aircraft have increased but at much slower rates compared with narrow-body demand. Also contributing to the current quarter increase were sales of ToughSwitch ethernet products and $0.4 million in revenue recognized in the first quarter as the result of successful claims for component cost increases for printer shipments to one customer throughout most of fiscal 2023 as described in Note 4, “Revenue Recognition,” in our consolidated financial statements included elsewhere in this report. Current quarter revenue increase was partially offset by a decline in hardware sales in the data recorder product line. T&M’s first quarter segment operating profit was $2.1 million, reflecting a profit margin of 20.1%, compared to the prior year first quarter segment operating profit of $1.9 million and related operating margin of 20.6%. The decrease in T&M’s current year first quarter segment operating profit margin is due to lower revenue of high margin product lines.

Liquidity and Capital Resources

Overview

Historically, our primary sources of liquidity have been cash generated from operating activities and borrowings under our revolving credit facility. These sources have also usually funded the majority of our capital expenditures and contractual contingent consideration obligations. We have funded acquisitions by borrowing under bank term loan facilities.

We believe cash flow generation from operations and available unused credit capacity under our credit facility will support our anticipated needs. In fiscal 2024 (after required debt amortization and payment of minimum guaranteed royalty payments to Honeywell), we plan to focus on inventory reduction and reduction of debt outstanding under our revolving credit facility, to the degree practicable and as constrained by supply chain management challenges. We also anticipate that we will have the capacity to spend $1.5 million to $2.0 million for capital investments to upgrade production machinery to support planned revenue growth and cost reduction objectives. Finally, if further acquisition opportunities develop that would require additional cash above our current available capacity, based on regular communication with our lender, we believe that our current operating performance and the reduction in leverage ratios as measured by the covenants within our credit facilities since the acquisition of Astro Machine would permit us to obtain sufficient additional debt financing, barring any unforeseen changes in the credit and capital markets.

 

22


Table of Contents

In connection with our purchase of Astro Machine on August 4, 2022, we entered into a Second Amendment to Amended and Restated Credit Agreement (the “Second Amendment”) with Bank of America, N.A., as lender (the “Lender”). The Second Amendment amended the Amended and Restated Credit Agreement dated as of July 30, 2020, as amended by the First Amendment to Amended and Restated Credit Agreement, dated as of March 24, 2021, and the LIBOR Transition Amendment, dated as of December 24, 2021 (the “Existing Credit Agreement,” and the Existing Credit Agreement as amended by the Second Amendment, the “Amended Credit Agreement”), between us and the Lender.

The Amended Credit Agreement provides for (i) a new term loan in the principal amount of $6.0 million, which term loan was in addition to the existing term loan outstanding under the Existing Credit Agreement in the principal amount of $9.0 million as of the effective date of the Second Amendment, and (ii) an increase in the aggregate principal amount of the revolving credit facility available thereunder from $22.5 million to $25.0 million. Under the Amended Credit Agreement, revolving credit loans may continue to be borrowed, at our option, in U.S. Dollars or, subject to certain conditions, Euros, British Pounds, Canadian Dollars or Danish Kroner.

In response to the COVID-19 pandemic and related economic dislocation, we have implemented and will continue to implement a variety of expense reduction and cash preservation initiatives. On April 27, 2020, our board of directors suspended our quarterly cash dividend beginning with the second quarter of our fiscal year 2021.

At April 29, 2023 our cash and cash equivalents were $5.4 million. We have borrowed $15.9 million on our revolving line of credit and have $9.1 million available for borrowing under that facility as of April 29, 2023.

Indebtedness

Term Loan

The Amended Credit Agreement requires that the term loan be paid in quarterly installments on the last day of each of our fiscal quarters over the term of the Amended Credit Agreement on the following repayment schedule: the principal amount of each quarterly installment required to be paid on the last day of each of our fiscal quarters ending on or about October 31, 2022 through July 31, 2023 is $375,000; and the principal amount of each quarterly installment required to be paid on the last day of each of our fiscal quarters ending on or about October 31, 2023 through April 30, 2027 is $675,000. The entire remaining principal balance of the term loan is required to be paid on August 4, 2027. We may voluntarily prepay the term loan, in whole or in part, from time to time without premium or penalty (other than customary breakage costs, if applicable). We may repay borrowings under the revolving credit facility at any time without premium or penalty (other than customary breakage costs, if applicable), but in any event no later than August 4, 2027, and any outstanding revolving loans thereunder will be due and payable in full, and the revolving credit facility will terminate, on such date. We may reduce or terminate the revolving line of credit at any time, subject to certain thresholds and conditions, without premium or penalty.

The loans under the Amended Credit Agreement are subject to certain mandatory prepayments, subject to various exceptions, from (a) net cash proceeds from certain dispositions of property, (b) net cash proceeds from certain issuances of equity, (c) net cash proceeds from certain issuances of additional debt and (d) net cash proceeds from certain extraordinary receipts.

Amounts repaid under the revolving credit facility may be reborrowed, subject to our continued compliance with the Amended Credit Agreement. No amount of the term loan that is repaid may be reborrowed.

The interest rates under the Amended Credit Agreement are as follows: the term loan and revolving credit loans bear interest at a rate per annum equal to, at our option, either (a) the BSBY Rate as defined in the Amended Credit Agreement (or, in the case of revolving credit loans denominated in a currency other than U.S. Dollars, the applicable quoted rate), plus a margin that varies within a range of 1.60% to 2.50% based on our consolidated leverage ratio, or (b) a fluctuating reference rate equal to the highest of (i) the federal fund rate plus 0.50%, (ii) Bank of America’s publicly announced prime rate, (iii) the BSBY Rate plus 1.00%, or (iv) 0.50%, plus a margin that varies within a range of 0.60% to 1.50% based on our consolidated leverage ratio. In addition to certain other fees and expenses that we are required to pay to the Lender, we are required to pay a commitment fee on the undrawn portion of the revolving credit facility that varies within a range of 0.15% and 0.35% based on our consolidated leverage ratio.

 

23


Table of Contents

We must comply with various customary financial and non-financial covenants under the Amended Credit Agreement. The financial covenants under the Amended Credit Agreement consist of a maximum consolidated leverage ratio, a minimum consolidated fixed charge coverage ratio and a minimum consolidated asset coverage ratio. The primary non-financial covenants limit our and our subsidiaries’ ability to incur future indebtedness, to place liens on assets, to pay dividends or distributions on our or our subsidiaries’ capital stock, to repurchase or acquire our or our subsidiaries’ capital stock, to conduct mergers or acquisitions, to sell assets, to alter our or our subsidiaries’ capital structure, to make investments and loans, to change the nature of our or our subsidiaries’ business, and to prepay subordinated indebtedness, in each case subject to certain exceptions and thresholds as set forth in the Amended Credit Agreement, certain of which provisions were modified by the Second Amendment. As of April 29, 2023, we believe we are in compliance with all of the covenants in the Credit Agreement.

The Lender is entitled to accelerate repayment of the loans and to terminate its revolving credit commitment under the Amended Credit Agreement upon the occurrence of any of various customary events of default, which include, among other events, the following (which are subject, in some cases, to certain grace periods): failure to pay when due any principal, interest or other amounts in respect of the loans, breach of any of our covenants or representations under the loan documents, default under any other of our or our subsidiaries’ significant indebtedness agreements, a bankruptcy, insolvency or similar event with respect to us or any of our subsidiaries, a significant unsatisfied judgment against us or any of our subsidiaries, or a change of control.

Our obligations under the Amended Credit Agreement continue to be secured by substantially all of our personal property assets (including a pledge of the equity interests we hold in ANI ApS, AstroNova GmbH and AstroNova SAS), subject to certain exceptions, and by a mortgage on our owned real property in West Warwick, Rhode Island, and are guaranteed by, and secured by substantially all of the personal property assets of Astro Machine.

Cash Flow

Our statements of cash flows for the three months ended April 29, 2023 and April 30, 2022 are included in Item 1 of this Quarterly Report on Form 10-Q. Net cash provided by operating activities was $2.6 million for the first three months of fiscal 2024 compared to cash used of $1.6 million for the same period of the previous year. The increase in net cash provided by operations for the first three months of the current year is primarily due to the increase in cash provided by working capital. The combination of changes in accounts receivable, inventory, income taxes payable, accounts payable and accrued expenses increased cash by $0.6 million for the first three months of fiscal 2024, compared to a decrease of $6.9 million for the same period in fiscal 2023. The cash used for operating activities for the first quarter of fiscal 2023 was partially offset by $3.1 million of cash received for the employee retention credit.

Our accounts receivable balance decreased to $19.3 million at the end of the first quarter of fiscal 2024 compared to $21.6 million at year end. Days sales outstanding for the first quarter of the current year remained at 49 days, consistent with prior year end. Our inventory balance was $53.1 million at the end of the first quarter of fiscal 2024, an increase compared to $51.3 million at year end. Inventory days on hand increased to 208 days at the end of the current quarter from 176 days at the prior year end. The increase in our inventory balance is primarily due to difficulties in the supply chain environment, including increased pricing and long lead times to obtain components and supplies, which has required us to increase our component and supply buffer stock to support the demands of our customers in our PI segment. We have also experienced increased inventory levels related to our T&M products to maintain our targeted inventory levels as a result of increased sales in that segment and parts shortage issues.

Our cash position at April 29, 2023, was $5.4 million compared to $3.9 million at year end. The increase in cash during the current quarter was primarily a result of cash provided from the working capital accounts, as discussed above. Cash outflows during the quarter included principal payments on our long-term debt and the guaranteed royalty obligation of $0.4 million and $0.5 million, respectively.

Contractual Obligations, Commitments and Contingencies

There have been no material changes to our contractual obligations as disclosed in our Annual Report on Form 10-K for the fiscal year ended January 31, 2023, other than those occurring in the ordinary course of business.

Critical Accounting Policies, Estimates and Certain Other Matters

The preparation of our condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and disclosure of commitments and contingencies at the date of the condensed consolidated financial statements and reported amounts of revenue and expenses during the reporting period. We base these estimates and judgments on factors we believe to be relevant, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.

 

24


Table of Contents

The process of determining significant estimates is fact-specific and takes into account factors such as historical experience, current and expected economic conditions, product mix, and in some cases, actuarial and appraisal techniques. We constantly re-evaluate these significant factors and make adjustments where facts and circumstances dictate.

While we believe that the factors considered provide a meaningful basis for the accounting policies applied in the preparation of the condensed consolidated financial statements, we cannot guarantee that our estimates and assumptions will be accurate. As the determination of these estimates requires the exercise of judgment, actual results may differ from those estimates, and such differences may be material to our condensed consolidated financial statements. There have been no material changes to the application of critical accounting policies as disclosed in our Annual Report on Form 10-K for the fiscal year ended January 31, 2023.

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact, but rather reflect our current expectations concerning future events and results. We generally use the words “believes,” “expects,” “intends,” “plans,” “anticipates,” “likely,” “continues,” “may,” “will,” and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. Factors which could cause actual results to differ materially from those anticipated include, but are not limited to (a) general economic, financial, industry and business conditions; (b) the continuing impact of the COVID-19 pandemic on us, our customers, our suppliers and the global economy; (c) declining demand in the test and measurement markets, especially defense and aerospace; (d) our ability to develop and introduce new products and achieve market acceptance of these products; (e) our dependance on contract manufacturers and/or single or limited source suppliers; (f) competition in the specialty printer or data acquisition industries; (g) our ability to obtain adequate pricing for our products and control our cost structure; (h) our ability to adequately enforce and protect our intellectual property, defend against assertions of infringement or loss of certain licenses; (i) the risk of incurring liabilities as a result of installed product failures due to design or manufacturing defects (j) the risk of a material security breach of our information technology system or cybersecurity attack impacting our business and our relationship with customers; (k) our ability to attract, develop and retain key employees and manage human capital resources; (l) economic, political and other risks associated with international sales and operations and the impact of changes in foreign currency exchange rates on the results of operations; (m) changes in tax rates or exposure to additional income tax liabilities; (n) our ability to comply with our current credit agreement or secure alternative financing and to otherwise manage our indebtedness; (o) our ability to successfully integrate and realize the expected benefits from Astro Machine and other acquisitions and realize benefits from divestitures; (p) our ability to maintain adequate self-insurance accruals or insurance coverage for employee health care benefits; (q) our compliance with customer or regulators certifications and our compliance with certain governmental laws and regulations; (r) our ability to achieve and maintain effective internal controls and procedures over financial reporting and (s) all other risks included under “Item 1A-Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended January 31, 2023. We assume no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

During the three months ended April 29, 2023, there were no material changes to our market risk disclosures as set forth in Part II, Item 7A “Quantitative and Qualitative Disclosures About Market Risk” in our Annual Report on Form 10-K for the year ended January 31, 2023.

 

Item 4.

Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)). Our disclosure controls and procedures are designed to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our senior leadership team, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosures. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

 

25


Table of Contents

Our management, under the supervision of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this quarterly report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were not effective as of April 29, 2023 as a result of the material weakness in our internal control over financial reporting described below.

Material Weakness in Internal Control Over Financial Reporting

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. As reported in Item 9A of our Annual Report on Form 10-K/A for the year ended January 31, 2023, our management concluded that our internal control over financial reporting was ineffective because of the following material weakness:

We did not maintain effective controls to properly identify and assess significant non-routine transactions.

Plan for Remediation of Material Weakness

Our management has discussed the identified material weakness with the Audit Committee of our Board of Directors. During the quarter ended April 29, 2023, we have begun to implement measures designed to improve internal control over financial reporting and to remediate our material weakness. Among other things, we have supplemented our controls regarding the review of contracts, hired additional qualified accounting and financial reporting personnel with appropriate expertise to perform specific functions and responsibilities. Additionally, we have engaged a national accounting firm to provide additional depth and expertise to assist with the identification, recording, and reporting of complex US GAAP technical accounting matters.

Management believes that when completed, the measures described above will be sufficient to remediate the identified material weakness and strengthen our overall internal control over financial reporting. As our management continues to evaluate and work to enhance our internal control over financial reporting, we may take additional measures to address control deficiencies or we may modify some of the remediation measures described above. The identified material weakness will not be considered remediated until the applicable remediated controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.

Changes in Internal Control over Financial Reporting

Except for the measures taken to remediate our identified material weakness noted above, there were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the fiscal quarter ended April 29, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

 

Item 1.

Legal Proceedings

There are no pending or threatened legal proceedings against us that we believe to be material to our financial position or results of operations.

 

Item 1A.

Risk Factors

In addition to the other information set forth in this Quarterly Report on Form 10-Q, one should carefully consider the factors discussed in Part I, Item 1A “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended January 31, 2023, which could materially affect our business, financial condition or future operating results. The risks described in our Annual Report on Form 10-K are not the only risks that could affect our business, as additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results as well as adversely affect the value of our common stock.

There have been no material updates to the risk factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended January 31, 2023.

 

26


Table of Contents
Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

During the first quarter of fiscal 2024, we made the following repurchases of our common stock:

 

     Total Number
of Shares
Repurchased
    Weighted
Average
Price paid
Per Share
    Total Number of
Shares Purchased as
Part of Publicly
Announced Plans or
Programs
     Maximum Number
of Shares That
May Be Purchased
Under the Plans
or Programs
 

February 1—February 28

     —       $ —       —          —    

March 1—March 31

     8,955  (a)    $ 11.94  (a)     —          —    

April 1—April 30

     17,232  (b)    $ 14.11  (b)      —          —    

 

(a)

Executives of the Company delivered 8,955 shares of the our common stock toward the satisfaction of taxes due with respect to vesting of restricted shares. The shares delivered were valued at an average market value of $11.94 per share and are included with treasury stock in the consolidated balance sheet. These transactions were not part of a publicly announced purchase plan or program.

(b)

Executives of the Company delivered 17,232 shares of the our common stock toward the satisfaction of taxes due with respect to vesting of restricted shares. The shares delivered were valued at a weighted-average market value of $14.11 per share and are included with treasury stock in the consolidated balance sheet. These transactions were not part of a publicly announced purchase plan or program.

 

Item 6.

Exhibits

 

3A    Restated Articles of Incorporation of the Company and all amendments thereto, filed as Exhibit 3A to the Company’s Quarterly Report on Form 10-Q for the quarter ended April 30, 2016 and incorporated by reference herein.
3B    By-laws of the Company as amended to date, filed as Exhibit 3B to the Company’s Annual Report on Form 10-K/A for the fiscal year ended January 31, 2008 (File no. 000-13200) and incorporated by reference herein.
31.1    Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2    Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1    Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2    Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS    XBRL Instance Document—the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
   101.SCH Inline XBRL Taxonomy Extension Schema Document
   101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document
   101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document
   101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document
   101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document
   104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

27


Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

   

ASTRONOVA, INC.

(Registrant)

Date: June 8, 2023     By  

/s/ Gregory A. Woods

      Gregory A. Woods,
      President and Chief Executive Officer
      (Principal Executive Officer)
    By  

/s/ David S. Smith

      David S. Smith,
      Vice President, Chief Financial Officer and Treasurer
      (Principal Accounting Officer and Principal Financial Officer)

 

28

EX-31.1 2 d292174dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION

Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Gregory A. Woods certify that:

 

1.

I have reviewed this Quarterly Report on Form 10-Q of AstroNova, Inc.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b)

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c)

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d)

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: June 8, 2023

/s/ Gregory A. Woods

Gregory A. Woods,
President and Chief Executive Officer
(Principal Executive Officer)
EX-31.2 3 d292174dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION

Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, David S. Smith, certify that:

 

1.

I have reviewed this Quarterly Report on Form 10-Q of AstroNova, Inc.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b)

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c)

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d)

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: June 8, 2023

/s/ David S. Smith

David S. Smith,
Vice President, Chief Financial Officer and Treasurer
(Principal Accounting Officer and Principal Financial Officer)
EX-32.1 4 d292174dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

ASTRONOVA, INC.

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of AstroNova, Inc. (the “Company”) on Form 10-Q for the period ended April 29, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Gregory A. Woods, President and Chief Executive Officer of the Company, certify, pursuant to Rule 13a-14(b) and 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

  (1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: June 8, 2023

/s/ Gregory A. Woods

Gregory A. Woods,
President and Chief Executive Officer
(Principal Executive Officer)

A signed original of this written statement required by Section 906 has been provided to AstroNova, Inc. and will be retained by AstroNova, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 d292174dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

ASTRONOVA, INC.

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of AstroNova, Inc. (the “Company”) on Form 10-Q for the period ended April 29, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David S. Smith, Vice President, Chief Financial Officer and Treasurer of the Company, certify, pursuant to Rule 13a-14(b) and 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

  (1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: June 8, 2023

/s/ David S. Smith

David S. Smith,
Vice President, Chief Financial Officer and Treasurer
(Principal Accounting Officer and Principal Financial Officer)

A signed original of this written statement required by Section 906 has been provided to AstroNova, Inc. and will be retained by AstroNova, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-101.SCH 6 alot-20230429.xsd XBRL TAXONOMY EXTENSION SCHEMA 1001 - Document - Cover Page link:presentationLink link:definitionLink link:calculationLink 1002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1004 - Statement - Condensed Consolidated Statements of Income link:presentationLink link:definitionLink link:calculationLink 1005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) link:presentationLink link:definitionLink link:calculationLink 1006 - Statement - Consolidated Statements of Changes in Shareholders' Equity link:presentationLink link:definitionLink link:calculationLink 1007 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 1008 - Disclosure - Business and Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 1009 - Disclosure - Summary of Significant Accounting Policies Update link:presentationLink link:definitionLink link:calculationLink 1010 - Disclosure - Acquisitions link:presentationLink link:definitionLink link:calculationLink 1011 - Disclosure - Revenue Recognition link:presentationLink link:definitionLink link:calculationLink 1012 - Disclosure - Net Income Per Common Share link:presentationLink link:definitionLink link:calculationLink 1013 - Disclosure - Intangible Assets link:presentationLink link:definitionLink link:calculationLink 1014 - Disclosure - Inventories link:presentationLink link:definitionLink link:calculationLink 1015 - Disclosure - Property, Plant and Equipment link:presentationLink link:definitionLink link:calculationLink 1016 - Disclosure - Credit Agreement and Long-Term Debt link:presentationLink link:definitionLink link:calculationLink 1017 - Disclosure - Royalty Obligation link:presentationLink link:definitionLink link:calculationLink 1018 - Disclosure - Leases link:presentationLink link:definitionLink link:calculationLink 1019 - Disclosure - Accumulated Other Comprehensive Loss link:presentationLink link:definitionLink link:calculationLink 1020 - Disclosure - Share-Based Compensation link:presentationLink link:definitionLink link:calculationLink 1021 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 1022 - Disclosure - Segment Information link:presentationLink link:definitionLink link:calculationLink 1023 - Disclosure - Fair Value link:presentationLink link:definitionLink link:calculationLink 1024 - Disclosure - Summary of Significant Accounting Policies Update (Policies) link:presentationLink link:definitionLink link:calculationLink 1025 - Disclosure - Acquisitions (Tables) link:presentationLink link:definitionLink link:calculationLink 1026 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:definitionLink link:calculationLink 1027 - Disclosure - Net Income Per Common Share (Tables) link:presentationLink link:definitionLink link:calculationLink 1028 - Disclosure - Intangible Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 1029 - Disclosure - Inventories (Tables) link:presentationLink link:definitionLink link:calculationLink 1030 - Disclosure - Property, Plant and Equipment (Tables) link:presentationLink link:definitionLink link:calculationLink 1031 - Disclosure - Credit Agreement and Long-Term Debt (Tables) link:presentationLink link:definitionLink link:calculationLink 1032 - Disclosure - Leases (Tables) link:presentationLink link:definitionLink link:calculationLink 1033 - Disclosure - Accumulated Other Comprehensive Loss (Tables) link:presentationLink link:definitionLink link:calculationLink 1034 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:definitionLink link:calculationLink 1035 - Disclosure - Income Taxes (Tables) link:presentationLink link:definitionLink link:calculationLink 1036 - Disclosure - Segment Information (Tables) link:presentationLink link:definitionLink link:calculationLink 1037 - Disclosure - Fair Value (Tables) link:presentationLink link:definitionLink link:calculationLink 1038 - Disclosure - Business and Basis of Presentation - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1039 - Disclosure - Acquisitions - Summary of Purchase Price of Acquisition Allocated on Basis of Fair Value (Detail) link:presentationLink link:definitionLink link:calculationLink 1040 - Disclosure - Acquisitions - Summary of Fair Value of the Acquired Identifiable Intangible Assets and Related Estimated Useful Lives (Detail) link:presentationLink link:definitionLink link:calculationLink 1041 - Disclosure - Acquisitions - Summary of Revenue and Earnings Before Taxes (Detail) link:presentationLink link:definitionLink link:calculationLink 1042 - Disclosure - Acquisitions - Summary of Acquired Identifiable Intangible Asset (Detail) link:presentationLink link:definitionLink link:calculationLink 1043 - Disclosure - Acquisitions - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1044 - Disclosure - Revenue Recognition - Summary of Revenues Disaggregated by Primary Geographic Markets (Detail) link:presentationLink link:definitionLink link:calculationLink 1045 - Disclosure - Revenue Recognition - Summary of Revenues Disaggregated by Primary Product Type (Detail) link:presentationLink link:definitionLink link:calculationLink 1046 - Disclosure - Revenue Recognition - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1047 - Disclosure - Net Income Per Common Share - Reconciliation of Shares Used in Calculating Basic and Diluted (Detail) link:presentationLink link:definitionLink link:calculationLink 1048 - Disclosure - Net Income Per Common Share - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1049 - Disclosure - Intangible Assets - Fair Value of Acquired Identifiable Intangible Assets and Related Estimated Useful Lives (Detail) link:presentationLink link:definitionLink link:calculationLink 1050 - Disclosure - Intangible Assets - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1051 - Disclosure - Intangible Assets - Summary of Estimated Amortization Expense (Detail) link:presentationLink link:definitionLink link:calculationLink 1052 - Disclosure - Inventories - Components of Inventories (Detail) link:presentationLink link:definitionLink link:calculationLink 1053 - Disclosure - Property, Plant and Equipment - Summary of Property, Plant and Equipment (Detail) link:presentationLink link:definitionLink link:calculationLink 1054 - Disclosure - Property, Plant and Equipment - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1055 - Disclosure - Credit Agreement and Long- Term Debt - Schedule of Long Term Debt in the Accompanying Condensed Consolidated Balance Sheets (Detail) link:presentationLink link:definitionLink link:calculationLink 1056 - Disclosure - Credit Agreement and Long- Term Debt - Schedule of Required Principal Payments Remaining on Long Term Debt Outstanding (Detail) link:presentationLink link:definitionLink link:calculationLink 1057 - Disclosure - Credit Agreement and Long- Term Debt - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1058 - Disclosure - Royalty Obligation - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1059 - Disclosure - Leases - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1060 - Disclosure - Leases - Schedule Of Balance Sheet And Other Information Related To Operating Leases (Detail) link:presentationLink link:definitionLink link:calculationLink 1061 - Disclosure - Leases - Lease Cost Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1062 - Disclosure - Leases - Maturities of lease liabilities (Detail) link:presentationLink link:definitionLink link:calculationLink 1063 - Disclosure - Leases - Supplemental cash flow information (Detail) link:presentationLink link:definitionLink link:calculationLink 1064 - Disclosure - Accumulated Other Comprehensive Loss - Changes in Balance of Accumulated Other Comprehensive Loss (Detail) link:presentationLink link:definitionLink link:calculationLink 1065 - Disclosure - Share-Based Compensation - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1066 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Detail) link:presentationLink link:definitionLink link:calculationLink 1067 - Disclosure - Share-Based Compensation - Aggregated Information Regarding Stock Option Activity (Detail) link:presentationLink link:definitionLink link:calculationLink 1068 - Disclosure - Share-Based Compensation - Summary of Options Outstanding (Detail) link:presentationLink link:definitionLink link:calculationLink 1069 - Disclosure - Share-Based Compensation - Aggregated Information Regarding RSU and RSA Activity (Detail) link:presentationLink link:definitionLink link:calculationLink 1070 - Disclosure - Income Taxes - Projected Effective Tax Rates (Detail) link:presentationLink link:definitionLink link:calculationLink 1071 - Disclosure - Income Taxes - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1072 - Disclosure - Segment Information - Net Sales and Segment Operating Profit (Loss) for Each Reporting Segment (Detail) link:presentationLink link:definitionLink link:calculationLink 1073 - Disclosure - Fair Value - Schedule of Company's Long-Term Debt Including the Current Portion Not Reflected in Financial Statements at Fair Value (Detail) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 alot-20230429_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 alot-20230429_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 alot-20230429_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 10 alot-20230429_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover Page - shares
3 Months Ended
Apr. 29, 2023
Jun. 02, 2023
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Apr. 29, 2023  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q1  
Entity Registrant Name AstroNova, Inc.  
Entity Central Index Key 0000008146  
Current Fiscal Year End Date --01-31  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Accelerated Filer  
Trading Symbol ALOT  
Entity Shell Company false  
Entity Small Business true  
Entity Emerging Growth Company false  
Title of 12(b) Security Common Stock  
Security Exchange Name NASDAQ  
Entity Incorporation, State or Country Code RI  
Entity File Number 0-13200  
Document Quarterly Report true  
Document Transition Report false  
Entity Tax Identification Number 05-0318215  
Entity Address, Address Line One 600 East Greenwich Avenue  
Entity Address, City or Town West Warwick  
Entity Address, Postal Zip Code 02893  
Entity Address, State or Province RI  
City Area Code 401  
Local Phone Number 828-4000  
Entity Common Stock, Shares Outstanding   7,417,715
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Apr. 29, 2023
Jan. 31, 2023
CURRENT ASSETS    
Cash and Cash Equivalents $ 5,413 $ 3,946
Accounts Receivable, net 19,285 21,598
Inventories, net 53,126 51,324
Prepaid Expenses and Other Current Assets 2,678 2,894
Total Current Assets 80,502 79,762
Property, Plant and Equipment, net 13,918 14,288
Identifiable Intangibles, net 20,630 21,232
Goodwill 14,760 14,658
Deferred Tax Assets, net 6,907 6,907
Right of Use Asset 858 794
Other Assets 1,621 1,566
TOTAL ASSETS 139,196 139,207
CURRENT LIABILITIES    
Accounts Payable 8,000 8,479
Accrued Compensation 3,267 2,750
Other Accrued Expenses 3,484 3,308
Revolving Line of Credit 15,900 15,900
Current Portion of Long-Term Debt 2,100 2,100
Current Liability—Royalty Obligation 1,600 1,725
Current Liability—Excess Royalty Payment Due 379 562
Income Taxes Payable 730 786
Deferred Revenue 1,971 1,888
Total Current Liabilities 37,431 37,498
NON-CURRENT LIABILITIES    
Long-Term Debt, net of current portion 11,678 12,040
Royalty Obligation, net of current portion 3,102 3,415
Lease Liabilities, net of current portion 581 555
Income Taxes Payable 491 491
Deferred Revenue 267 674
Deferred Tax Liabilities 172 167
TOTAL LIABILITIES 53,722 54,840
SHAREHOLDERS' EQUITY    
Preferred Stock 0 0
Common Stock 538 534
Additional Paid-in Capital 61,526 61,131
Retained Earnings 60,023 59,175
Treasury Stock, at Cost (34,585) (34,235)
Accumulated Other Comprehensive Loss, net of tax (2,028) (2,238)
TOTAL SHAREHOLDERS' EQUITY 85,474 84,367
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 139,196 $ 139,207
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Apr. 29, 2023
Jan. 31, 2023
Statement of Financial Position [Abstract]    
Preferred Stock, Par Value $ 10 $ 10
Preferred Stock, Shares Authorized 100,000 100,000
Preferred Stock, Shares Issued 0 0
Common Stock, Par Value $ 0.05 $ 0.05
Common Stock, Shares Authorized   13,000,000
Common Stock, Shares Issued 10,780,934 10,676,851
Treasury Stock, Shares 3,368,219 3,342,032
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Income - USD ($)
3 Months Ended
Apr. 29, 2023
Apr. 30, 2022
Income Statement [Abstract]    
Revenue $ 35,419,000 $ 31,010,000
Cost of Revenue 23,034,000 20,281,000
Gross Profit 12,385,000 10,729,000
Operating Expenses:    
Selling and Marketing 6,010,000 5,883,000
Research and Development 1,788,000 1,522,000
General and Administrative 3,126,000 2,560,000
Operating Expenses 10,924,000 9,965,000
Operating Income 1,461,000 764,000
Other Income (Expense)    
Interest Expense (615,000) (175,000)
Gain (Loss) on Foreign Currency Transaction 186,000 (135,000)
Other, net (5,000) 31,000
Other Expense, net (434,000) (279,000)
Income Before Income Taxes 1,027,000 485,000
Income Tax Provision 179,000 60,000
Net Income $ 848,000 $ 425,000
Net Income per Common Share—Basic $ 0.12 $ 0.06
Net Income per Common Share—Diluted $ 0.11 $ 0.06
Weighted Average Number of Common Shares Outstanding—Basic 7,369,930 7,262,797
Weighted Average Number of Common Shares Outstanding—Diluted 7,450,052 7,360,510
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($)
$ in Thousands
3 Months Ended
Apr. 29, 2023
Apr. 30, 2022
Statement of Comprehensive Income [Abstract]    
Net Income $ 848 $ 425
Other Comprehensive Income (Loss), Net of Taxes:    
Foreign Currency Translation Adjustments 210 (933)
Loss from Cash Flow Hedges Reclassified to Income Statement 0 16
Other Comprehensive Income (Loss) 210 (917)
Comprehensive Income (Loss) $ 1,058 $ (492)
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Changes in Shareholders' Equity - USD ($)
$ in Thousands
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Treasury Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Beginning Balance at Jan. 31, 2022 $ 81,012 $ 528 $ 59,692 $ 56,514 $ (33,974) $ (1,748)
Beginning Balance, Shares at Jan. 31, 2022   10,566,404        
Share-Based Compensation 337   337      
Employee Option Exercises 88 $ 1 87   0  
Employee Option Exercises, Shares   11,164        
Restricted Stock Awards (249) $ 3 (3)   (249)  
Restricted Stock Awards, Shares   61,513        
Net Income 425     425    
Other Comprehensive Income (Loss) (917)         (917)
Ending Balance at Apr. 30, 2022 80,696 $ 532 60,113 56,939 (34,223) (2,665)
Ending Balance, Shares at Apr. 30, 2022   10,639,081        
Beginning Balance at Jan. 31, 2023 84,367 $ 534 61,131 59,175 (34,235) (2,238)
Beginning Balance, Shares at Jan. 31, 2023   10,676,851        
Share-Based Compensation 356   356      
Employee Option Exercises $ 43 $ 0 43      
Employee Option Exercises, Shares 1,700 4,094        
Restricted Stock Awards $ (350) $ 4 (4)   (350)  
Restricted Stock Awards, Shares   99,989        
Net Income 848     848    
Other Comprehensive Income (Loss) 210         210
Ending Balance at Apr. 29, 2023 $ 85,474 $ 538 $ 61,526 $ 60,023 $ (34,585) $ (2,028)
Ending Balance, Shares at Apr. 29, 2023   10,780,934        
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Apr. 29, 2023
Apr. 30, 2022
Cash Flows from Operating Activities:    
Net Income $ 848 $ 425
Adjustments to Reconcile Net Income to Net Cash Provided (Used) by Operating Activities:    
Depreciation and Amortization 1,055 912
Amortization of Debt Issuance Costs 6 7
Share-Based Compensation 356 337
Changes in Assets and Liabilities:    
Accounts Receivable 2,324 (1,489)
Other Receivable – Employee Retention Credit Receivable 0 3,135
Inventories (1,756) (2,650)
Income Taxes 38 502
Accounts Payable and Accrued Expenses 8 (2,843)
Other (237) 50
Net Cash Provided (Used) by Operating Activities 2,642 (1,614)
Cash Flows from Investing Activities:    
Additions to Property, Plant and Equipment (48) (50)
Net Cash Used for Investing Activities (48) (50)
Cash Flows from Financing Activities:    
Net Cash Proceeds from Employee Stock Option Plans 18 69
Net Cash Proceeds from Share Purchases under Employee Stock Purchase Plan 25 19
Net Cash Used for Payment of Taxes Related to Vested Restricted Stock (350) (249)
Net Borrowings under Revolving Credit Facility 0 3,000
Payment of Minimum Guarantee Royalty Obligation (500) (500)
Principal Payments on Long-Term Debt (375) (250)
Net Cash Provided (Used) by Financing Activities (1,182) 2,089
Effect of Exchange Rate Changes on Cash and Cash Equivalents 55 53
Net Increase in Cash and Cash Equivalents 1,467 478
Cash and Cash Equivalents, Beginning of Period 3,946 5,276
Cash and Cash Equivalents, End of Period 5,413 5,754
Supplemental Disclosures of Cash Flow Information:    
Cash Paid During the Period for Interest 538 53
Cash Paid (Received) During the Period for Income Taxes, Net of Refunds $ 235 $ (440)
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.1
Business and Basis of Presentation
3 Months Ended
Apr. 29, 2023
Business and Basis Of Presentation [Abstract]  
Business and Basis of Presentation
Note 1 – Business and Basis of Presentation
Overview
Headquartered in West Warwick, Rhode Island, AstroNova, Inc. leverages its expertise in data visualization technologies to design, develop, manufacture and distribute a broad range of specialty printers and data acquisition and analysis systems. Our products are employed around the world in a wide range of applications in the aerospace, apparel, automotive, avionics, chemical, computer peripherals, communications, distribution, food and beverage, general manufacturing, packaging and transportation industries.
Our business consists of two
segments, Product Identification (“PI”) and Test & Measurement (“T&M”). The PI segment includes specialty printing systems and related supplies sold under the QuickLabel
®
, TrojanLabel
®
and GetLabels
brand names. The T&M segment consists of our line of aerospace products, including flight deck printers, networking hardware, and related accessories as well as T&M data acquisition systems sold under the AstroNova
®
brand name.
On August 4, 2022, we acquired Astro Machine LLC (“Astro Machine”), an Illinois-based manufacturer of printing equipment, including label printers and related accessories, tabbers, conveyors, and envelope feeders. We reported Astro Machine as a part of our PI segment beginning in the third quarter of fiscal 2023.
PI products sold under the QuickLabel, TrojanLabel and GetLabels brands are used in brand owner and commercial applications to provide product packaging, marketing, tracking, branding, and labeling solutions to a wide array of industries. The PI segment offers a variety of digital color label tabletop printers and light commercial label printers,
direct-to-package
printers, high-volume presses, and specialty original equipment manufacturer (“OEM”) printing systems, as well as a wide range of label, tag and flexible packaging material substrates and other supplies, including ink and toner, allowing customers to mark, track, protect and enhance the appearance of their products. PI products sold under the Astro Machine brand also include a variety of label printers, envelope and packaging printing, and related processing and handling equipment.
In the T&M segment, we have a long history of using our technologies to provide networking systems and high-resolution flight deck and cabin printers for the aerospace market. In addition, the T&M segment includes data acquisition recorders, sold under the AstroNova brand, to enable our customers to acquire and record visual and electronic signal data from local and networked data streams and sensors. The recorded data is processed, analyzed, stored and presented in various visual output formats.
Our PI products are sold by direct field salespersons as well as independent dealers and representatives, while our T&M products are sold predominantly through direct sales and manufacturers’ representatives. In the United States, we have factory-trained direct field salespeople located throughout the country specializing in PI products. We also have direct field sales or service centers in Canada, China, Denmark, France, Germany, Malaysia, Mexico, Singapore, and the United Kingdom staffed by our own employees and dedicated third party contractors. Additionally, we utilize over 100 independent dealers and representatives selling and marketing our products in over 60 countries.
Unless otherwise indicated, references to “AstroNova”, “we,” “our,” and “us” in this Quarterly Report on
Form 10-Q
refer to AstroNova, Inc. and its consolidated subsidiaries.
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles and reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair presentation of the results of the interim periods included herein. These financial statements do not include all disclosures associated with annual financial statements and, accordingly, should be read in conjunction with our Annual Report on Form
10-K
for the fiscal year ended January 31, 2023.
The presentation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported and disclosed in the condensed consolidated financial statements and accompanying notes, including those that require consideration of forecasted financial information using information that is reasonably available to us at this time. Some of the more significant estimates relate to revenue recognition; the allowances for doubtful accounts; inventory valuation; income taxes; valuation of long-lived assets, intangible assets and goodwill; share-based compensation; and warranty reserves. Management’s estimates are based on the facts and circumstances available at the time estimates are made, historical experience, risk of loss, general economic conditions and trends, and management’s assessments of the probable future outcome of these matters, including our expectations at the time regarding the ongoing impact from the
COVID-19
pandemic. Consequently, actual results could differ from those estimates.
Results of operations for the interim periods presented herein are not necessarily indicative of the results that may be expected for the full year.
Certain amounts in the prior year’s financial statements have been reclassified to conform to the current year’s presentation.
Principles of Consolidation
The accompanying condensed consolidated financial statements include the accounts of AstroNova, Inc. and its wholly-owned subsidiaries. All significant intercompany accounts and transactions are eliminated in consolidation.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies Update
3 Months Ended
Apr. 29, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Update
Note 2 – Summary of Significant Accounting Policies Update
The accounting policies used in preparing the condensed consolidated financial statements in this Form
10-Q
are the same as those used in preparing our consolidated financial statements included in our Annual Report on Form
10-K
for the fiscal year ended January 31, 2023.
Recently Adopted Accounting Pronouncements
No new accounting pronouncements, issued or effective during the first three months of the current year, have had or are expected to have a material impact on our consolidated financial statements.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions
3 Months Ended
Apr. 29, 2023
Business Combinations [Abstract]  
Acquisitions
Note 3 – Acquisitions
Astro Machine
On August 4, 2022, we acquired Astro Machine LLC (“Astro Machine”), an Illinois-based manufacturer of printing equipment, including label printers, tabbers, conveyors, and envelope feeders, for aggregate consideration of $17.1 million.
The acquisition was accomplished pursuant to an Equity Interest Purchase Agreement dated as of August 4, 2022 (the “Purchase Agreement”) by and among us, GSND Holding Corporation (“GSND”), the parent company of Astro Machine, and Astro Machine. Pursuant to the Purchase Agreement, we purchased 100% of the issued and outstanding equity interests of Astro Machine from GSND for a purchase price of $15.6 million. The acquisition was funded using borrowings under our credit facility. We obtained a representation and warranty insurance policy and placed $300,000 of the purchase price into an escrow account, which pursuant to the terms and conditions of the Purchase Agreement, are our sole recourse for breaches of representations and warranties by GSND. Upon the closing of the transaction, Astro Machine became a wholly owned subsidiary of AstroNova, Inc.
Concurrently with the signing of the Purchase Agreement, our newly acquired subsidiary, Astro Machine, entered into a Purchase and Sale Agreement with Selak Real Estate Limited Partnership (“SRE”), pursuant to which Astro Machine purchased certain real property assets of SRE for a purchase price, paid in cash, of $1.5 million. These real estate assets are comprised of a 34,460 square foot industrial manufacturing building (including offices) on 1.26 acres of land, which is Astro Machine’s principal place of business.
This transaction was a business combination and accounted for using the acquisition method of accounting prescribed by ASC 805, “Business Combinations” (“ASC 805”), whereby the results of operations, including the revenues and earnings of Astro Machine, are included in our financial statements from the date of acquisition. The purchase price of Astro Machine was allocated to the tangible and intangible assets acquired and liabilities assumed and recognized at their fair value based on widely accepted valuation techniques in accordance with ASC 820, “Fair Value Measurement,” as of the acquisition date. The process for estimating fair values requires the use of significant estimates, assumptions and judgments, including determining the timing and estimates of future cash flows and developing appropriate discount rates. The excess of the purchase price over the fair value of the net identified assets acquired and liabilities assumed was recorded as goodwill. ASC 805 establishes a measurement period to provide companies with a reasonable amount of time to obtain the information necessary to identify and measure various items in a business combination and cannot extend beyond one year from the acquisition date.
 
The following table sets forth the final purchase price allocation of the Astro Machine acquisition for the estimated fair value of the net assets acquired and liabilities assumed as of the date of acquisition:
 
(In thousands)       
Cash
   $ 91  
Accounts Receivable
     3,393  
Inventory
     5,715  
Property, Plant and Equipment
     4,200  
Identifiable Intangible Assets
     3,480  
Goodwill
     2,730  
Accounts Payable and Other Current Liabilities
     (2,484
    
 
 
 
Total Purchase Price
   $ 17,125  
    
 
 
 
The fair value of the intangible assets acquired was estimated by applying the income approach. This fair value measurement is based on significant inputs that are not observable in the market and therefore represents a Level 3 measurement as defined in ASC 820, “Fair Value Measurement.” Key assumptions in estimating the fair value of the intangibles include (1) remaining useful life of the tradename/trademarks and customer relations (2) royalty rate of
0.75%, (3) customer attrition rate of 18.0%, (4) discount rate of 19.0
% and (5) a range of revenue and net income projections for fiscal years 2023 through 2026.
The following table sets forth the fair value of the acquired identifiable intangible assets and related estimated useful lives:
 
(In thousands)   
Fair
Value
    
Useful Life
(years)
 
Customer Relations
   $ 3,060        5  
Trademarks/Tradenames
     420        5  
    
 
 
          
Total
   $ 3,480           
    
 
 
          
The Customer Relations intangible asset represents the relationships that will be maintained with certain historical customers of Astro Machine. The trademark/tradename intangible assets reflect the industry reputation of the Astro Machine name and the registered trademarks held by Astro Machine for the use of several marks and logos.
Goodwill of $2.73 
million, which is not deductible for tax purposes, represents the excess of the purchase price over the estimated fair value assigned to the tangible and identifiable intangible assets acquired and liabilities assumed from Astro Machine. The goodwill recognized under ASC 805 is attributable to synergies which are expected to enhance and expand our overall product portfolio, opportunities in new and existing markets, future technologies that have yet to be determined and Astro Machine’s assembled workforce. The carrying amount of the goodwill was allocated to the PI segment.
Total acquisition-related costs of $0.7 million were included in general and administrative expenses in our consolidated statement of income for the year ended January 31, 2023.
The amounts of revenue and earnings before taxes included in our consolidated statement of income for the quarter ended April 29, 2023:
 
(In thousands)
      
Revenue
   $ 4,229  
Earnings before Taxes
     689  
Astro Machine results are reported as part of the PI segment. Proforma results are not provided, as disclosure of such amounts was impractical to determine as the acquired business had insufficient financial records and no audit history prior to the transaction.
 
Honeywell Asset Purchase and License Agreement
On June 30, 2022, we entered into an Asset Purchase and License Agreement with Honeywell International Inc. (“New HW Agreement”) to acquire an exclusive, perpetual, world-wide license to manufacture Honeywell’s flight deck printers for the Boeing 787 aircraft. The New HW Agreement provides for royalty payments to Honeywell based on gross revenues from the sales of the printers, paper and repair services of the licensed products in perpetuity. The royalty rates vary based on the year in which they are paid or earned and as products are sold or as services are provided and range from single-digit to
mid-double-digit
percentages of gross revenue. The New HW Agreement includes a provision for guaranteed minimum royalty payments to be paid in the event that the royalties earned by Honeywell do not meet the minimum for the preceding calendar year as follows: $
100,000 in 2024, $200,000 in 2025, $233,000 in 2026 and 2027, and $234,000 in 2028.
This transaction was evaluated under ASC 805, “Business Combinations,” and was accounted for as an asset acquisition.
The purchase price was allocated to the customer relationship intangible, which was the only asset acquired as a result of this transaction. This asset will be amortized over the useful life of the intangible. The minimum royalty payment obligation and related customer relationships intangible were recorded at the present value of the minimum royalty payments.
The acquired identifiable intangible asset is as follows:
 
(In thousands)   
Fair
Value
    
Useful Life
(Years)
 
Customer Contract Relationships
   $ 530        20  
The minimum royalty payment due was discounted based on the payment schedule and applicable discount rate, resulting in an outstanding royalty obligation of $0.5 million as of January 31, 2023, including $0.1 million recorded as a current liability. As of April 29, 2023, the current outstanding royalty obligation remains $0.5 million, including $0.1 million recorded as a current liability in the accompanying balance sheet.
Additional royalties based on sales activity will be recorded in the period that the associated revenue is earned. During fiscal 2023, we incurred $0.1 
million in excess royalty expense, which was recorded as a current liability in our consolidated balance sheet at January 31, 2023 and was paid in the first quarter of the current fiscal year.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue Recognition
3 Months Ended
Apr. 29, 2023
Revenue from Contract with Customer [Abstract]  
Revenue Recognition
Note 4 – Revenue Recognition
We derive revenue from the sale of (i) hardware, including digital color label printers and specialty OEM printing systems, portable data acquisition systems and airborne printers and networking hardware used in the flight deck and cabin of military, commercial and business aircraft, (ii) related supplies required in the operation of the hardware, (iii) repairs and maintenance of hardware and (iv) service agreements.
Revenues disaggregated by primary geographic markets and major product types are as follows:
Primary geographical markets:
 
    
Three Months Ended
 
(In thousands)   
April 29,
2023
    
April 30,
2022
 
United States
   $ 22,834      $ 19,651  
Europe
     7,964        7,419  
Canada
     1,825        1,854  
Asia
     1,294        937  
Central and South America
     1,199        888  
Other
     303        261  
    
 
 
    
 
 
 
Total Revenue
   $ 35,419      $ 31,010  
    
 
 
    
 
 
 
 
Major product types:
 
    
Three Months Ended
 
(In thousands)   
April 29,
2023
    
April 30,
2022
 
Hardware
     11,667      $ 9,301  
Supplies
     19,070        17,944  
Service and Other
     4,682        3,765  
    
 
 
    
 
 
 
Total Revenue
   $ 35,419      $ 31,010  
    
 
 
    
 
 
 
In December 2022, we entered into an amended contract with one of our T&M customers that provided for a total payment of $3.25 
million to us as a result of our claims allowable under French law relating to additional component costs we have incurred and will continue to incur in order to supply aerospace printers under the contract for the period beginning in April 2022 and continuing through 2025. Revenue from this arrangement will be recognized in proportion to the total estimated shipments through the end of the contract period. As of January 31, 2023, we have recognized $
1.1 
million in revenue and the remainder $
2.15 
million balance was recorded as deferred revenue. During the first quarter of fiscal 2024, we recognized an additional $
0.4 
million in revenue which is included in the condensed consolidated statement of income for the quarter ended April 29, 2023. The remaining revenue to be recognized will be based on our shipments of the printers during the remainder of fiscal years 2024 and 2025.
Contract Assets and Liabilities
We normally do not have contract assets, which are primarily unbilled accounts receivable that are conditional on something other than the passage of time.
Our contract liabilities, which represent billings in excess of revenue recognized, are related to advanced billings for purchased service agreements and extended warranties. Contract liabilities were $443,000 and $412,000 at April 29, 2023 and January 31, 2023, respectively, and are recorded as deferred revenue in the accompanying condensed consolidated balance sheet. The increase in the deferred revenue balance during the three months ended April 29, 2023 is due to cash payments received in advance of satisfying performance obligations in the current period which was partially offset by $143,000 of revenue recognized during the period that was included in the deferred revenue balance at January 31, 2023.
Contract Costs
We recognize an asset for the incremental costs of obtaining a contract with a customer if we expect the benefit of those costs to be longer than one year. We have determined that certain costs related to obtaining sales contracts for our aerospace printer products meet the requirement to be capitalized. These costs are deferred and amortized over the remaining useful life of these contracts, which we currently estimate to be approximately 18 years as of April 29, 2023. The balance of these contract assets at January 31, 2023 was $1.4 million. We amortized $19,000 and $16,000 of direct costs during the three months ended April 29, 2023 and April 30, 2022, respectively. The balance of deferred incremental direct costs net of accumulated amortization at April 29, 2023 was $1.3 million, of which $0.1 million is reported in other current assets and $1.2 million is reported in other assets in the accompanying condensed consolidated balance sheet.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Net Income Per Common Share
3 Months Ended
Apr. 29, 2023
Earnings Per Share [Abstract]  
Net Income Per Common Share
Note 5 – Net Income Per Common Share
Basic net income per share is calculated by dividing net income by the weighted average number of shares outstanding during the period. Diluted net income per share is calculated by dividing net income by the weighted average number of shares and, if dilutive, common equivalent shares, determined using the treasury stock method for stock options, restricted stock awards and restricted stock units outstanding during the period. A reconciliation of the shares used in calculating basic and diluted net income per share is as follows:
 
    
Three Months Ended
 
    
April 29,
2023
    
April 30,
2022
 
Weighted Average Common Shares Outstanding – Basic
     7,369,930        7,262,797  
Effect of Dilutive Options, Restricted Stock Awards and Restricted Stock Units
     80,122        97,713  
    
 
 
    
 
 
 
Weighted Average Common Shares Outstanding – Diluted
     7,450,052        7,360,510  
    
 
 
    
 
 
 
 
For the three months ended April 29, 2023 and April 30, 2022, the diluted per share amounts do not reflect common equivalent shares outstanding of 656,554 and 310,588, respectively, because of their anti-dilutive effect.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.1
Intangible Assets
3 Months Ended
Apr. 29, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets
Note 6 – Intangible Assets
Intangible assets are as follows:
 
    
April 29, 2023
    
January 31, 2023
 
(In thousands)   
Gross
Carrying
Amount
    
Accumulated
Amortization
   
Currency
Translation
Adjustment
    
Net
Carrying
Amount
    
Gross
Carrying
Amount
    
Accumulated
Amortization
   
Currency
Translation
Adjustment
    
Net
Carrying
Amount
 
Miltope:
                                                                     
Customer Contract Relationships
   $ 3,100      $ (2,857   $ —        $ 243      $ 3,100      $ (2,777   $ —        $ 323  
RITEC:
                                                                     
Customer Contract Relationships
     2,830        (1,639     —          1,191        2,830        (1,623     —          1,207  
TrojanLabel:
                                                                     
Existing Technology
     2,327        (2,171     97        253        2,327        (2,087     94        334  
Distributor Relations
     937        (616     36        357        937        (588     27        376  
Honeywell:
                                                                     
Customer Contract Relationships
     27,773        (12,145     —          15,628        27,773        (11,913     —          15,860  
Astro Machine:
                                                                     
Customer Contract Relationships
     3,060        (459     —          2,601        3,060        (306     —          2,754  
Trademarks
     420        (63     —          357        420        (42     —          378  
    
 
 
    
 
 
   
 
 
    
 
 
    
 
 
    
 
 
   
 
 
    
 
 
 
Intangible Assets, net
   $ 40,447      $ (19,950   $ 133      $ 20,630      $ 40,447      $ (19,336   $ 121      $ 21,232  
    
 
 
    
 
 
   
 
 
    
 
 
    
 
 
    
 
 
   
 
 
    
 
 
 
There were no impairments to intangible assets during the periods ended April 29, 2023 and April 30, 2022.
With respect to the acquired intangibles included in the table above, amortization expense of $
0.6
 
million and $0.4 million has been included in the condensed consolidated statements of income for the three months ended April 29, 2023 and April 30, 2022, respectively.

Estimated amortization expense for the next five fiscal years is as follows:
 
(In thousands)
  
Remaining
2024
 
  
2025
 
  
2026
 
  
2027
 
  
2028
 
Estimated amortization expense
   $ 1,786      $ 1,723      $ 1,723      $ 1,723      $ 1,281  
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.1
Inventories
3 Months Ended
Apr. 29, 2023
Inventory Disclosure [Abstract]  
Inventories
Note 7 – Inventories
Inventories are stated at the lower of cost (standard and average methods) or net realizable value and include material, labor and manufacturing overhead. The components of inventories are as follows:
 
(In thousands)
  
April 29, 2023
 
  
January 31, 2023
 
Materials and Supplies
   $ 40,624      $ 38,387  
Work-In-Process
     1,485        1,146  
Finished Goods
     22,221        23,221  
    
 
 
    
 
 
 
       64,330        62,754  
Inventory Reserve
     (11,204      (11,430
    
 
 
    
 
 
 
     $ 53,126      $ 51,324  
    
 
 
    
 
 
 
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.1
Property, Plant and Equipment
3 Months Ended
Apr. 29, 2023
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment
Note 8 – Property, Plant and Equipment
Property, plant and equipment consist of the following:
 
 
  
April 29,

2023
 
  
January 31,

2023
 
(In thousands)
  
 
 
  
 
 
Land and Land Improvements
   $ 2,304      $ 2,304  
Buildings and Leasehold Improvements
     14,162        14,158  
Machinery and Equipment
     25,012        24,960  
Computer Equipment and Software
     13,996        13,972  
    
 
 
    
 
 
 
Gross Property, Plant and Equipment
     55,474        55,394  
Accumulated Depreciation
     (41,556      (41,106
    
 
 
    
 
 
 
Net Property Plant and Equipment
   $ 13,918      $ 14,288  
    
 
 
    
 
 
 
Depreciation expense on property, plant and equipment was $0.4 
million for the each of the quarters ended April 29, 2023 and April 30, 2022.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Credit Agreement and Long-Term Debt
3 Months Ended
Apr. 29, 2023
Debt Disclosure [Abstract]  
Credit Agreement and Long-Term Debt
Note 9 – Credit Agreement and Long-Term Debt
In connection with the purchase of Astro Machine, on August 4, 2022, we entered into a Second Amendment to the Amended and Restated Credit Agreement (the “Second Amendment”) with Bank of America, N.A., as lender (the “Lender”). The Second Amendment amended the Amended and Restated Credit Agreement dated as of July 30, 2020, as amended by the First Amendment to Amended and Restated Credit Agreement, dated as of March 24, 2021, and the LIBOR Transition Amendment, dated as of December 24, 2021 (the “Existing Credit Agreement,” and the Existing Credit Agreement as amended by the Second Amendment, the “Amended Credit Agreement”), between us and the Lender.
The Amended Credit Agreement provides for (i) a new term loan in the principal amount of $6.0 million, which term loan was in addition to the existing term loan outstanding under the Existing Credit Agreement in the principal amount of $9.0 million as of the effective date of the Second Amendment, and (ii) an increase in the aggregate principal amount of the revolving credit facility available thereunder from $22.5 million to $25.0 million. At the closing of the Second Amendment, we borrowed the entire $6.0 million term loan and $12.4 million under the revolving credit facility, and the proceeds of such borrowings were used in part to pay the purchase price payable under the Purchase Agreement and certain related transaction costs. The revolving credit facility may otherwise be used for corporate purposes.

The Amended Credit Agreement requires that the term loan be paid in quarterly installments on the last day of each of our fiscal quarters over the term of the Amended Credit Agreement on the following repayment schedule: the principal amount of each quarterly installment required to be paid on the last day of each of our fiscal quarters ending on or about October 31, 2022 through July 31, 2023 is $
375,000; and the principal amount of each quarterly installment required to be paid on the last day of each of our fiscal quarters ending on or about October 31, 2023 through April 30, 2027 is $675,000. The entire remaining principal balance of the term loan is required to be paid on August 4, 2027. We may voluntarily prepay the term loan, in whole or in part, from time to time without premium or penalty (other than customary breakage costs, if applicable). We may repay borrowings under the revolving credit facility at any time without premium or penalty (other than customary breakage costs, if applicable), but in any event no later than August 4, 2027, and any outstanding revolving loans thereunder will be due and payable in full, and the revolving credit facility will terminate, on such date. We may reduce or terminate the revolving line of credit at any time, subject to certain thresholds and conditions, without premium or penalty.
The interest rates under the Amended Credit Agreement are as follows: the term loan and revolving credit loans bear interest at a rate per annum equal to, at our option, either (a) the BSBY Rate as defined in the Amended Credit Agreement (or, in the case of revolving credit loans denominated in a currency other than U.S. Dollars, the applicable quoted rate), plus a margin that varies within a range of 1.60% to 2.50% based on our consolidated leverage ratio, or (b) a fluctuating reference rate equal to the highest of (i) the federal fund rate plus 0.50%, (ii) Bank of America’s publicly announced prime rate, (iii) the BSBY Rate plus 1.00%, or (iv) 0.50%, plus a margin that varies within a range of 0.60% to 1.50% based on our consolidated leverage ratio. In addition to certain other fees and expenses that we are required to pay to the Lender, we are required to pay a commitment fee on the undrawn portion of the revolving credit facility that varies within a range of 0.15% and 0.35% based on our consolidated leverage ratio. The loans under the Amended Credit Agreement are subject to certain mandatory prepayments, subject to various exceptions, from (a) net cash proceeds from certain dispositions of property, (b) net cash proceeds from certain issuances of equity, (c) net cash proceeds from certain issuances of additional debt and (d) net cash proceeds from certain extraordinary receipts.
 
 
Amounts repaid under the revolving credit facility may be reborrowed, subject to our continued compliance with the Amended Credit Agreement. No amount of the term loan that is repaid may be reborrowed.
We must comply with various customary financial and
non-financial
covenants under the Amended Credit Agreement. The financial covenants under the Amended Credit Agreement consist of a maximum consolidated leverage ratio, a minimum consolidated fixed charge coverage ratio and a minimum consolidated asset coverage ratio. The primary
non-financial
covenants limit our and our subsidiaries’ ability to incur future indebtedness, to place liens on assets, to pay dividends or distributions on our or our subsidiaries’ capital stock, to repurchase or acquire our or our subsidiaries’ capital stock, to conduct mergers or acquisitions, to sell assets, to alter our or our subsidiaries’ capital structure, to make investments and loans, to change the nature of our or our subsidiaries’ business, and to prepay subordinated indebtedness, in each case subject to certain exceptions and thresholds as set forth in the Amended Credit Agreement, certain of which provisions were modified by the Second Amendment. As of April 29, 2023, we believe we are in compliance with all of the covenants in the Credit Agreement.
The Lender is entitled to accelerate repayment of the loans and to terminate its revolving credit commitment under the Amended Credit Agreement upon the occurrence of any of various customary events of default, which include, among other events, the following (which are subject, in some cases, to certain grace periods): failure to pay when due any principal, interest or other amounts in respect of the loans, breach of any of our covenants or representations under the loan documents, default under any other of our or our subsidiaries’ significant indebtedness agreements, a bankruptcy, insolvency or similar event with respect to us or any of our subsidiaries, a significant unsatisfied judgment against us or any of our subsidiaries, or a change of control.
Our obligations under the Amended Credit Agreement continue to be secured by substantially all of our personal property assets (including a pledge of the equity interests we hold in ANI ApS, AstroNova GmbH and AstroNova SAS), subject to certain exceptions, and by a mortgage on our owned real property in West Warwick, Rhode Island, and are guaranteed by, and secured by substantially all of the personal property assets of Astro Machine.
Summary of Outstanding Debt
At April 29, 2023, we ha
d
an outstanding balance of $15.9 million on our revolving line of credit. The balance outstanding under the revolving line of credit bore interest at a weighted average annual rate of 6.93% and 4.26% and we incurred $292,000 and $23,000 for interest on this obligation during the quarters ended April 29, 2023 and April 30, 2022, respectively. Additionally, during the quarters ended April 29, 2023 and April 30, 2022, we incurred $8,000 and $10,000, respectively, of commitment fees on the undrawn portion of our revolving credit facility. Both the interest expense and commitment fees are included as interest expense in the accompanying condensed consolidated income statement for the quarters ended April 29, 2023 and April 30, 2022. At April 29, 2023, there
wa
s $9.1 million remaining available for borrowing under the revolving line of credit.
 
Long-term debt in the accompanying condensed consolidated balance sheets is as follows:
 
(In thousands)
  
April 29,

2023
 
  
January 31,

2023
 
USD Term Loan (7.24% as of April 29, 2023 and 6.78% as of January 31, 2023); maturity date of August 4, 2027
   $ 13,875      $ 14,250  
    
 
 
    
 
 
 
       13,875        14,250  
Debt Issuance Costs, net of accumulated amortization
     (97      (110
Current Portion of Term Loan
     (2,100      (2,100
    
 
 
    
 
 
 
Long-Term Debt
   $ 11,678      $ 12,040  
    
 
 
    
 
 
 
During the three months ended April 29, 2023 and April 30, 2022, we recognized $248,000 and $53,000 of interest expense, respectively, which was included in other expense in the accompanying condensed consolidated income statement.
The schedule of required principal payments remaining during the next five years on long-term debt outstanding as of April 29, 2023 is as follows:
 
(In thousands)
      
Fiscal 2024, remainder
   $ 1,725  
Fiscal 2025
     2,700  
Fiscal 2026
     2,700  
Fiscal 2027
     2,700  
Fiscal 2028
     4,050  
    
 
 
 
     $ 13,875  
    
 
 
 
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.1
Royalty Obligation
3 Months Ended
Apr. 29, 2023
Royalty Obligation Disclosure [Abstract]  
Royalty Obligation
Note 10 –
Royalty Obligation
In fiscal 2018, we entered into an Asset Purchase and License Agreement with Honeywell International, Inc. (“Honeywell”) to acquire an exclusive, perpetual, world-wide license to manufacture Honeywell’s narrow-format flight deck printers for two aircraft families along with certain inventory used in the manufacturing of the licensed printers. The purchase price included a guaranteed minimum royalty payment of $15.0 million, to be paid over
ten years
, based on gross revenues from the sales of the printers, paper and repair services of the licensed products. The royalty rates vary based on the year in which they are paid or earned, and product sold or service provided, and range from single-digit to mid double-digit percentages of gross revenue.
The guaranteed minimum royalty payment obligation was recorded at the present value of the minimum annual royalty payments. As of April 29, 2023, we had paid an aggregate of $10.0 million of the guaranteed minimum royalty obligation. At April 29, 2023, the current portion of the outstanding guaranteed minimum royalty obligation of $1.5 million is to be paid over the next twelve months and is reported as a current liability and the remainder of $2.7 million is reported as a long-term liability on our condensed consolidated balance sheet. We incurred $0.4 million in excess royalty expense for the three-month period ended April 29, 2023, which is included in cost of revenue in our consolidated statements of income. A total of $0.4 million in excess royalties was paid in the first quarter of the current fiscal year
,
and there are $0.4 million in excess royalty payables due as a result of this agreement for the quarter ended April 29, 2023.
In fiscal 2023, AstroNova, Inc. entered into a second Asset Purchase and License Agreement with Honeywell International, Inc. as further discussed in Note 3 “Acquisitions”.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.1
Leases
3 Months Ended
Apr. 29, 2023
Leases [Abstract]  
Leases
Note 11 – Leases
We enter into lease contracts for certain of our facilities at various locations worldwide. Our leases have remaining lease terms of one to six years.
Balance sheet and other information related to our leases is as follows:
 
Operating Leases
(In thousands)
  
Balance Sheet Classification
 
  
April 29,
2023
 
  
January 31,
2023
 
Lease Assets
  
 
Right of Use Assets
 
  
$
858
 
  
$
794
 
Lease Liabilities – Current
  
 
Other Liabilities and Accrued Expenses
 
  
 
312
 
  
$
275
 
Lease Liabilities – Long Term
  
 
Lease Liabilities
 
  
 
581
 
  
$
555
 
 
Lease cost information is as follows:
 
 
  
 
 
  
Three Months Ended
 
Operating Leases
(In thousands)
  
Statement of Income Classification
 
  
April 29,
2023
 
  
April 30,
2022
 
Operating Lease Costs
     General and Administrative Expense      $ 133      $ 113  
Maturities of operating lease liabilities are as follows:
 
(In thousands)
  
April 29,
2023
 
2024, remaining
   $ 263  
2025
     258  
2026
     199  
2027
     151  
2028
     93  
Thereafter
     —    
    
 
 
 
Total Lease Payments
     964  
Less: Imputed Interest
     (71
    
 
 
 
Total Lease Liabilities
   $ 893  
    
 
 
 
As of April 29, 2023, the weighted-average remaining lease term and weighted-average discount rate for our operating leases are 3.5 years and 4.37%, respectively. We calculated the weighted-average discount rate using incremental borrowing rates, which equal the rates of interest that we would pay to borrow funds on a fully collateralized basis over a similar term.
Supplemental cash flow information related to leases is as follows:
 
    
Three Months Ended
 
(In thousands)
  
April 29,
2023
    
April 30,
2022
 
Cash paid for amounts included in the measurement of lease liabilities:
                 
Operating cash flows for operating leases
   $ 93      $ 83  
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Accumulated Other Comprehensive Loss
3 Months Ended
Apr. 29, 2023
Equity [Abstract]  
Accumulated Other Comprehensive Loss
Note 1
2
– Accumulated Other Comprehensive Loss
The changes in the balance of accumulated other comprehensive loss (“AOCL”) by component are as follows:
 
(In thousands)
  
Foreign Currency
Translation
Adjustments
    
Total
 
Balance at January 31, 2023
   $ (2,238    $ (2,238
Other Comprehensive Income before reclassification
     210        210  
    
 
 
    
 
 
 
Balance at April 29, 2023
   $ (2,028    $ (2,028
    
 
 
    
 
 
 
The amounts presented above in other comprehensive loss are net of taxes except for translation adjustments associated with our German and Danish subsidiaries.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Share-Based Compensation
3 Months Ended
Apr. 29, 2023
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Share-Based Compensation
Note 1
3
– Share-Based Compensation
We have one equity incentive plan from which we are authorized to grant equity awards, the AstroNova, Inc. 2018 Equity Incentive Plan (the “2018 Plan”). The 2018 Plan provides for, among other things, the issuance of awards, including incentive stock options,
non-qualified
stock options, stock appreciation rights, time-based restricted stock units (“RSUs”), or performance-based restricted stock units (“PSUs”) and restricted stock awards (“RSAs”). The 2018 Plan authorizes the issuance of up to 950,000
shares of common stock, plus an additional number of shares equal to the number of shares subject to awards granted under previous equity incentive plans that are forfeited, cancelled, satisfied without the issuance of stock, otherwise terminated (other than by exercise), or,
for shares of stock issued pursuant to any unvested award, that are reacquired by us at not more than the grantee’s purchase price (other than by exercise). Under the 2018 Plan, all awards to employees generally have a minimum vesting period of one year. Options granted under the 2018 Plan must be issued at an exercise price of not less than the fair market value of our common stock on the date of grant and expire after ten years. Under the 2018 Plan, there were
124,439 unvested RSUs; 188,633 unvested PSUs; 21,172 unvested RSAs and options to purchase an aggregate of 135,500 shares outstanding as of April 29,
2023.
 
In addition to the 2018 Plan, we previously granted equity awards under our 2015 Equity Incentive Plan (the “2015 Plan”) and our 2007 Equity Incentive Plan (the “2007 Plan”). No new awards may be issued under either the 2007 Plan or 2015 Plan, but outstanding awards will continue to be governed by those plans. As of April 29, 2023, options to purchase an aggregate of
270,649 shares were outstanding under the 2007 Plan and options to purchase an aggregate of 134,950 shares were outstanding under the 2015 Plan.
We also have a
Non-Employee
Director Annual Compensation Program (the “Program”), under which each of our
non-employee
directors automatically receives a grant of restricted stock on the date of their
re-election
to our board of directors. The number of whole shares granted is equal to the number calculated by dividing the stock component of the director compensation amount determined by the compensation committee for that year by the fair market value of our stock on that day. The value of the restricted stock award for fiscal 2024 is approximately $65,000. Shares of restricted stock granted under the Program become vested on the first anniversary of the date of grant, conditioned upon the recipient’s continued service on our board of directors through that date.
Share-based compensation expense was recognized as follows:
 
    
Three Months Ended
 
(In thousands)
  
April 29,
2023
    
April 30,
2022
 
Stock Options
   $ —        $ 6  
Restricted Stock Awards and Restricted Stock Units
     352        328  
Employee Stock Purchase Plan
     4        3  
    
 
 
    
 
 
 
Total
   $ 356      $ 337  
    
 
 
    
 
 
 
Stock Options
Aggregated information regarding stock option activity for the three months ended April 29, 2023 is summarized below:
 
    
Number of
Options
    
Weighted Average
Exercise Price
 
Outstanding at January 31, 2023
     547,199      $ 15.16  
Granted
     —          —    
Exercised
     (1,700      10.50  
Forfeited
     (175      18.35  
Canceled
     (4,225      10.50  
    
 
 
    
 
 
 
Outstanding at April 29, 2023
     541,099      $ 15.21  
    
 
 
    
 
 
 
Set forth below is a summary of options outstanding at April 29, 2023:
 
Outstanding
 
  
Exercisable
 
Range of
Exercise prices
  
Number
of
Shares
 
  
Weighted-
Average
Exercise
Price
 
  
Weighted-
Average
Remaining
Contractual Life
 
  
Number
of
Shares
 
  
Weighted-
Average
Exercise
Price
 
  
Weighted
Average
Remaining
Contractual
Life
 
$5.00-10.00
     —        $ —          —          —        $ —          —    
$10.01-15.00
     326,924      $ 13.74        2.7        326,924      $ 13.74        2.7  
$15.01-20.00
     214,175      $ 17.45        4.6        214,175      $ 17.45        4.6  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
       541,099      $ 15.21        3.5        541,099      $ 15.21        3.5  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
 
There were no
stock options granted in fiscal 2023 and fiscal 2022, or in the first quarter of fiscal 2024, and as of April 29, 2023, there was
no unrecognized compensation expense related to stock options.
Restricted Stock Units (RSUs), Performance-Based Stock Units (PSUs) and Restricted Stock Awards (RSAs)
Aggregated information regarding RSU and RSA activity for the three months ended April 29, 2023 is summarized below:
 
 
  
RSUs, PSUs & RSAs
 
  
Weighted Average
Grant Date Fair Value
 
Outstanding at January 31, 2023
     274,927      $ 12.82  
Granted
     142,811        12.48  
Vested
     (78,817      11.85  
Forfeited
     (4,677      12.49  
    
 
 
    
 
 
 
Outstanding at April 29, 2023
     334,244      $ 12.90  
    
 
 
    
 
 
 
As of April 29, 2023, there was approximately $2.5 million of unrecognized compensation expense related to RSUs, PSUs and RSAs, which is expected to be recognized over a weighted average period of 1.2 years.

Employee Stock Purchase Plan
On June 7, 2022, we adopted the AstroNova Inc. 2022 Employee Stock Purchase Plan (“2022 ESPP”) to replace our previous Employee Stock Purchase Plan (the “Prior ESPP”). The 2022 ESPP allows eligible employees to purchase shares of common stock at a 15% discount from fair value on the first or last day of an offering period, whichever is less. A total of 40,000
shares were reserved for issuance under the 2022 ESPP and
5,045 shares were purchased under the 2022 ES
P
P during the year ended January 31, 2023. During the three months ended April 29, 2023, there were 2,394 shares purchased under the 2022 ESPP. During the three months ended April 30, 2022, there were 1,550 shares purchased under the Prior ESPP, and no additional purchases may be made under the Prior ESPP. As of April 29, 2023, 32,560 shares remain available for purchase under the 2022 ESPP.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes
3 Months Ended
Apr. 29, 2023
Income Tax Disclosure [Abstract]  
Income Taxes
Note 1
4
– Income Taxes
Our effective tax rates are as follows:
 
    
First Quarter
Ended
 
Fiscal 2024
     17.4
Fiscal 2023
     12.4
We determine our estimated annual effective tax rate at the end of each interim period based on full-year forecasted
pre-tax
income and facts known at that time. The estimated annual effective tax rate is applied to the
year-to-date
pre-tax
income at the end of each interim period with the cumulative effect of any changes in the estimated annual effective tax rate being recorded in the fiscal quarter in which the change is determined. The tax effect of significant unusual items is reflected in the period in which they occur.
During the three months ended April 29, 2023, we recognized an income tax expense of approximately $179,000. The effective tax rate in this period was directly impacted by a $77,000 tax benefit related to the expiration of the statute of limitations on a previously uncertain tax position and a $29,000
tax benefit arising from windfall tax benefits related to our stock. During the three months ended April 30, 2022, we recognized an income tax expense of approximately $
60,000. The effective tax rate in this period was directly impacted by a $38,000 tax benefit related to the expiration of the statute of limitations on a previously uncertain tax position and a $30,000
tax benefit arising from windfall tax benefits related to our stock.
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.1
Segment Information
3 Months Ended
Apr. 29, 2023
Segment Reporting [Abstract]  
Segment Information
Note 1
5
– Segment Information
We report two segments: PI and T&M. We evaluate segment performance based on the segment profit before corporate expenses.
 
Summarized below are the Revenue and Segment Operating Profit for each reporting segment:
 
 
  
Three Months Ended
 
 
  
Revenue
 
  
Segment Operating Profit
 
(In thousands)
  
April 29,
2023
 
  
April 30,
2022
 
  
April 29,
2023
 
  
April 30,
2022
 
PI
   $ 25,095      $ 21,724      $ 2,515      $ 1,413  
T&M
     10,324        9,286        2,072        1,911  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total
   $ 35,419      $ 31,010        4,587        3,324  
    
 
 
    
 
 
                   
Corporate Expenses
              3,126        2,560  
             
 
 
    
 
 
 
Operating Income
              1,461        764  
Other Expense, Net
              434        279  
             
 
 
    
 
 
 
Income Before Income Taxes
              1,027        485  
Income Tax Provision
              179        60  
             
 
 
    
 
 
 
Net Income
            $ 848      $ 425  
             
 
 
    
 
 
 
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value
3 Months Ended
Apr. 29, 2023
Fair Value Disclosures [Abstract]  
Fair Value
Note 1
6
– Fair Value
Assets and Liabilities Not Recorded at Fair Value
Our long-term debt, including the current portion of long-term debt not reflected in the financial statements at fair value, is reflected in the table below:
 
    
April 29, 2023
 
    
Fair Value Measurement
        
(In thousands)
  
Level 1
    
Level 2
    
Level 3
    
Total
    
Carrying
Value
 
Long-Term debt and related current maturities
   $ —        $ —        $ 13,937      $ 13,937      $ 13,875  
 
    
January 31, 2023
 
    
Fair Value Measurement
        
(In thousands)
  
Level 1
    
Level 2
    
Level 3
    
Total
    
Carrying
Value
 
Long-Term debt and related current maturities
   $ —        $ —        $ 14,310      $ 14,310      $ 14,250  
The fair value of our long-term debt, including the current portion, is estimated by discounting the future cash flows using current interest rates at which similar loans with the same maturities would be made to borrowers with similar credit ratings and is classified as Level 3.
 
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies Update (Policies)
3 Months Ended
Apr. 29, 2023
Accounting Policies [Abstract]  
Principles of Consolidation
Principles of Consolidation
The accompanying condensed consolidated financial statements include the accounts of AstroNova, Inc. and its wholly-owned subsidiaries. All significant intercompany accounts and transactions are eliminated in consolidation.
Recently Adopted Accounting Pronouncements
Recently Adopted Accounting Pronouncements
No new accounting pronouncements, issued or effective during the first three months of the current year, have had or are expected to have a material impact on our consolidated financial statements.
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions (Tables)
3 Months Ended
Apr. 29, 2023
Business Combinations [Abstract]  
Summary of Purchase Price of Acquisition Allocated on Basis of Fair Value
The following table sets forth the final purchase price allocation of the Astro Machine acquisition for the estimated fair value of the net assets acquired and liabilities assumed as of the date of acquisition:
 
(In thousands)       
Cash
   $ 91  
Accounts Receivable
     3,393  
Inventory
     5,715  
Property, Plant and Equipment
     4,200  
Identifiable Intangible Assets
     3,480  
Goodwill
     2,730  
Accounts Payable and Other Current Liabilities
     (2,484
    
 
 
 
Total Purchase Price
   $ 17,125  
    
 
 
 
Summary of Fair Value of the Acquired Identifiable Intangible Assets and Related Estimated Useful Lives
The following table sets forth the fair value of the acquired identifiable intangible assets and related estimated useful lives:
 
(In thousands)   
Fair
Value
    
Useful Life
(years)
 
Customer Relations
   $ 3,060        5  
Trademarks/Tradenames
     420        5  
    
 
 
          
Total
   $ 3,480           
    
 
 
          
Summary of Revenue and Earnings Before Taxes
The amounts of revenue and earnings before taxes included in our consolidated statement of income for the quarter ended April 29, 2023:
 
(In thousands)
      
Revenue
   $ 4,229  
Earnings before Taxes
     689  
Summary of Acquired Identifiable Intangible Asset
The acquired identifiable intangible asset is as follows:
 
(In thousands)   
Fair
Value
    
Useful Life
(Years)
 
Customer Contract Relationships
   $ 530        20  
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue Recognition (Tables)
3 Months Ended
Apr. 29, 2023
Revenue from Contract with Customer [Abstract]  
Summary of Revenues Disaggregated by Primary Geographic Markets and Major Product Type
Primary geographical markets:
 
    
Three Months Ended
 
(In thousands)   
April 29,
2023
    
April 30,
2022
 
United States
   $ 22,834      $ 19,651  
Europe
     7,964        7,419  
Canada
     1,825        1,854  
Asia
     1,294        937  
Central and South America
     1,199        888  
Other
     303        261  
    
 
 
    
 
 
 
Total Revenue
   $ 35,419      $ 31,010  
    
 
 
    
 
 
 
 
Major product types:
 
    
Three Months Ended
 
(In thousands)   
April 29,
2023
    
April 30,
2022
 
Hardware
     11,667      $ 9,301  
Supplies
     19,070        17,944  
Service and Other
     4,682        3,765  
    
 
 
    
 
 
 
Total Revenue
   $ 35,419      $ 31,010  
    
 
 
    
 
 
 
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.1
Net Income Per Common Share (Tables)
3 Months Ended
Apr. 29, 2023
Earnings Per Share [Abstract]  
Summary of Basic and Diluted Net Income Per Share A reconciliation of the shares used in calculating basic and diluted net income per share is as follows:
    
Three Months Ended
 
    
April 29,
2023
    
April 30,
2022
 
Weighted Average Common Shares Outstanding – Basic
     7,369,930        7,262,797  
Effect of Dilutive Options, Restricted Stock Awards and Restricted Stock Units
     80,122        97,713  
    
 
 
    
 
 
 
Weighted Average Common Shares Outstanding – Diluted
     7,450,052        7,360,510  
    
 
 
    
 
 
 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Intangible Assets (Tables)
3 Months Ended
Apr. 29, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Fair Value of Acquired Identifiable Intangible Assets and Related Estimated Useful Lives
Intangible assets are as follows:
 
    
April 29, 2023
    
January 31, 2023
 
(In thousands)   
Gross
Carrying
Amount
    
Accumulated
Amortization
   
Currency
Translation
Adjustment
    
Net
Carrying
Amount
    
Gross
Carrying
Amount
    
Accumulated
Amortization
   
Currency
Translation
Adjustment
    
Net
Carrying
Amount
 
Miltope:
                                                                     
Customer Contract Relationships
   $ 3,100      $ (2,857   $ —        $ 243      $ 3,100      $ (2,777   $ —        $ 323  
RITEC:
                                                                     
Customer Contract Relationships
     2,830        (1,639     —          1,191        2,830        (1,623     —          1,207  
TrojanLabel:
                                                                     
Existing Technology
     2,327        (2,171     97        253        2,327        (2,087     94        334  
Distributor Relations
     937        (616     36        357        937        (588     27        376  
Honeywell:
                                                                     
Customer Contract Relationships
     27,773        (12,145     —          15,628        27,773        (11,913     —          15,860  
Astro Machine:
                                                                     
Customer Contract Relationships
     3,060        (459     —          2,601        3,060        (306     —          2,754  
Trademarks
     420        (63     —          357        420        (42     —          378  
    
 
 
    
 
 
   
 
 
    
 
 
    
 
 
    
 
 
   
 
 
    
 
 
 
Intangible Assets, net
   $ 40,447      $ (19,950   $ 133      $ 20,630      $ 40,447      $ (19,336   $ 121      $ 21,232  
    
 
 
    
 
 
   
 
 
    
 
 
    
 
 
    
 
 
   
 
 
    
 
 
 
Summary of Estimated Amortization Expense
Estimated amortization expense for the next five fiscal years is as follows:
 
(In thousands)
  
Remaining
2024
 
  
2025
 
  
2026
 
  
2027
 
  
2028
 
Estimated amortization expense
   $ 1,786      $ 1,723      $ 1,723      $ 1,723      $ 1,281  
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Inventories (Tables)
3 Months Ended
Apr. 29, 2023
Inventory Disclosure [Abstract]  
Components of Inventories The components of inventories are as follows:
 
(In thousands)
  
April 29, 2023
 
  
January 31, 2023
 
Materials and Supplies
   $ 40,624      $ 38,387  
Work-In-Process
     1,485        1,146  
Finished Goods
     22,221        23,221  
    
 
 
    
 
 
 
       64,330        62,754  
Inventory Reserve
     (11,204      (11,430
    
 
 
    
 
 
 
     $ 53,126      $ 51,324  
    
 
 
    
 
 
 
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Property, Plant and Equipment (Tables)
3 Months Ended
Apr. 29, 2023
Property, Plant and Equipment [Abstract]  
Summary of Property, Plant and Equipment
Property, plant and equipment consist of the following:
 
 
  
April 29,

2023
 
  
January 31,

2023
 
(In thousands)
  
 
 
  
 
 
Land and Land Improvements
   $ 2,304      $ 2,304  
Buildings and Leasehold Improvements
     14,162        14,158  
Machinery and Equipment
     25,012        24,960  
Computer Equipment and Software
     13,996        13,972  
    
 
 
    
 
 
 
Gross Property, Plant and Equipment
     55,474        55,394  
Accumulated Depreciation
     (41,556      (41,106
    
 
 
    
 
 
 
Net Property Plant and Equipment
   $ 13,918      $ 14,288  
    
 
 
    
 
 
 
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Credit Agreement and Long-Term Debt (Tables)
3 Months Ended
Apr. 29, 2023
Debt Disclosure [Abstract]  
Schedule of Long Term Debt in the Accompanying Condensed Consolidated Balance Sheets
Long-term debt in the accompanying condensed consolidated balance sheets is as follows:
 
(In thousands)
  
April 29,

2023
 
  
January 31,

2023
 
USD Term Loan (7.24% as of April 29, 2023 and 6.78% as of January 31, 2023); maturity date of August 4, 2027
   $ 13,875      $ 14,250  
    
 
 
    
 
 
 
       13,875        14,250  
Debt Issuance Costs, net of accumulated amortization
     (97      (110
Current Portion of Term Loan
     (2,100      (2,100
    
 
 
    
 
 
 
Long-Term Debt
   $ 11,678      $ 12,040  
    
 
 
    
 
 
 
Schedule of Required Principal Payments Remaining on Long Term Debt Outstanding
The schedule of required principal payments remaining during the next five years on long-term debt outstanding as of April 29, 2023 is as follows:
 
(In thousands)
      
Fiscal 2024, remainder
   $ 1,725  
Fiscal 2025
     2,700  
Fiscal 2026
     2,700  
Fiscal 2027
     2,700  
Fiscal 2028
     4,050  
    
 
 
 
     $ 13,875  
    
 
 
 
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.1
Leases (Tables)
3 Months Ended
Apr. 29, 2023
Leases [Abstract]  
Schedule Of Balance Sheet And Other Information Related To Operating Leases
Balance sheet and other information related to our leases is as follows:
 
Operating Leases
(In thousands)
  
Balance Sheet Classification
 
  
April 29,
2023
 
  
January 31,
2023
 
Lease Assets
  
 
Right of Use Assets
 
  
$
858
 
  
$
794
 
Lease Liabilities – Current
  
 
Other Liabilities and Accrued Expenses
 
  
 
312
 
  
$
275
 
Lease Liabilities – Long Term
  
 
Lease Liabilities
 
  
 
581
 
  
$
555
 
Schedule Lease Cost Information
Lease cost information is as follows:
 
 
  
 
 
  
Three Months Ended
 
Operating Leases
(In thousands)
  
Statement of Income Classification
 
  
April 29,
2023
 
  
April 30,
2022
 
Operating Lease Costs
     General and Administrative Expense      $ 133      $ 113  
Schedule of Maturities Of Lease Liabilities
Maturities of operating lease liabilities are as follows:
 
(In thousands)
  
April 29,
2023
 
2024, remaining
   $ 263  
2025
     258  
2026
     199  
2027
     151  
2028
     93  
Thereafter
     —    
    
 
 
 
Total Lease Payments
     964  
Less: Imputed Interest
     (71
    
 
 
 
Total Lease Liabilities
   $ 893  
    
 
 
 
Supplemental Cash Flow Information Related To Leases
Supplemental cash flow information related to leases is as follows:
 
    
Three Months Ended
 
(In thousands)
  
April 29,
2023
    
April 30,
2022
 
Cash paid for amounts included in the measurement of lease liabilities:
                 
Operating cash flows for operating leases
   $ 93      $ 83  
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Accumulated Other Comprehensive Loss (Tables)
3 Months Ended
Apr. 29, 2023
Equity [Abstract]  
Changes in Balance of Accumulated Other Comprehensive Loss
The changes in the balance of accumulated other comprehensive loss (“AOCL”) by component are as follows:
 
(In thousands)
  
Foreign Currency
Translation
Adjustments
    
Total
 
Balance at January 31, 2023
   $ (2,238    $ (2,238
Other Comprehensive Income before reclassification
     210        210  
    
 
 
    
 
 
 
Balance at April 29, 2023
   $ (2,028    $ (2,028
    
 
 
    
 
 
 
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.1
Share-Based Compensation (Tables)
3 Months Ended
Apr. 29, 2023
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Share-Based Compensation Expense
Share-based compensation expense was recognized as follows:
 
    
Three Months Ended
 
(In thousands)
  
April 29,
2023
    
April 30,
2022
 
Stock Options
   $ —        $ 6  
Restricted Stock Awards and Restricted Stock Units
     352        328  
Employee Stock Purchase Plan
     4        3  
    
 
 
    
 
 
 
Total
   $ 356      $ 337  
    
 
 
    
 
 
 
Aggregated Information Regarding Stock Option Activity
Aggregated information regarding stock option activity for the three months ended April 29, 2023 is summarized below:
 
    
Number of
Options
    
Weighted Average
Exercise Price
 
Outstanding at January 31, 2023
     547,199      $ 15.16  
Granted
     —          —    
Exercised
     (1,700      10.50  
Forfeited
     (175      18.35  
Canceled
     (4,225      10.50  
    
 
 
    
 
 
 
Outstanding at April 29, 2023
     541,099      $ 15.21  
    
 
 
    
 
 
 
Summary of Options Outstanding
Set forth below is a summary of options outstanding at April 29, 2023:
 
Outstanding
 
  
Exercisable
 
Range of
Exercise prices
  
Number
of
Shares
 
  
Weighted-
Average
Exercise
Price
 
  
Weighted-
Average
Remaining
Contractual Life
 
  
Number
of
Shares
 
  
Weighted-
Average
Exercise
Price
 
  
Weighted
Average
Remaining
Contractual
Life
 
$5.00-10.00
     —        $ —          —          —        $ —          —    
$10.01-15.00
     326,924      $ 13.74        2.7        326,924      $ 13.74        2.7  
$15.01-20.00
     214,175      $ 17.45        4.6        214,175      $ 17.45        4.6  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
       541,099      $ 15.21        3.5        541,099      $ 15.21        3.5  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Aggregated Information Regarding RSU and RSA Activity
Aggregated information regarding RSU and RSA activity for the three months ended April 29, 2023 is summarized below:
 
 
  
RSUs, PSUs & RSAs
 
  
Weighted Average
Grant Date Fair Value
 
Outstanding at January 31, 2023
     274,927      $ 12.82  
Granted
     142,811        12.48  
Vested
     (78,817      11.85  
Forfeited
     (4,677      12.49  
    
 
 
    
 
 
 
Outstanding at April 29, 2023
     334,244      $ 12.90  
    
 
 
    
 
 
 
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes (Tables)
3 Months Ended
Apr. 29, 2023
Income Tax Disclosure [Abstract]  
Projected Effective Tax Rates
Our effective tax rates are as follows:
 
    
First Quarter
Ended
 
Fiscal 2024
     17.4
Fiscal 2023
     12.4
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.1
Segment Information (Tables)
3 Months Ended
Apr. 29, 2023
Segment Reporting [Abstract]  
Net Sales and Segment Operating Profit (Loss) for Each Reporting Segment
Summarized below are the Revenue and Segment Operating Profit for each reporting segment:
 
 
  
Three Months Ended
 
 
  
Revenue
 
  
Segment Operating Profit
 
(In thousands)
  
April 29,
2023
 
  
April 30,
2022
 
  
April 29,
2023
 
  
April 30,
2022
 
PI
   $ 25,095      $ 21,724      $ 2,515      $ 1,413  
T&M
     10,324        9,286        2,072        1,911  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total
   $ 35,419      $ 31,010        4,587        3,324  
    
 
 
    
 
 
                   
Corporate Expenses
              3,126        2,560  
             
 
 
    
 
 
 
Operating Income
              1,461        764  
Other Expense, Net
              434        279  
             
 
 
    
 
 
 
Income Before Income Taxes
              1,027        485  
Income Tax Provision
              179        60  
             
 
 
    
 
 
 
Net Income
            $ 848      $ 425  
             
 
 
    
 
 
 
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value (Tables)
3 Months Ended
Apr. 29, 2023
Fair Value Disclosures [Abstract]  
Summary of Changes in Fair value of Level 3 Financial Liability
Our long-term debt, including the current portion of long-term debt not reflected in the financial statements at fair value, is reflected in the table below:
 
    
April 29, 2023
 
    
Fair Value Measurement
        
(In thousands)
  
Level 1
    
Level 2
    
Level 3
    
Total
    
Carrying
Value
 
Long-Term debt and related current maturities
   $ —        $ —        $ 13,937      $ 13,937      $ 13,875  
 
    
January 31, 2023
 
    
Fair Value Measurement
        
(In thousands)
  
Level 1
    
Level 2
    
Level 3
    
Total
    
Carrying
Value
 
Long-Term debt and related current maturities
   $ —        $ —        $ 14,310      $ 14,310      $ 14,250  
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.23.1
Business and Basis of Presentation - Additional Information (Detail)
3 Months Ended
Apr. 29, 2023
Segment
Number of Operating Segments 2
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions - Summary of Purchase Price of Acquisition Allocated on Basis of Fair Value (Detail)
$ in Thousands
Aug. 04, 2022
USD ($)
Business Acquisition [Line Items]  
Cash $ 91
Accounts Receivable 3,393
Inventory 5,715
Property, Plant and Equipment 4,200
Identifiable Intangible Assets 3,480
Goodwill 2,730
Accounts Payable and Other Current Liabilities (2,484)
Total Purchase Price $ 17,125
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions - Summary of Fair Value of the Acquired Identifiable Intangible Assets and Related Estimated Useful Lives (Detail)
$ in Thousands
Aug. 04, 2022
USD ($)
Acquired Finite-Lived Intangible Assets [Line Items]  
Fair Value $ 3,480
Customer Relationships [Member]  
Acquired Finite-Lived Intangible Assets [Line Items]  
Fair Value $ 3,060
Useful Life (Years) 5 years
Trademarks and Trade Names [Member]  
Acquired Finite-Lived Intangible Assets [Line Items]  
Fair Value $ 420
Useful Life (Years) 5 years
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions - Summary of Revenue and Earnings Before Taxes (Detail) - Agreement With Astro Machine For Asset Acquisitions [Member]
$ in Thousands
3 Months Ended
Apr. 29, 2023
USD ($)
Business Acquisition Pro Forma Information [Line Items]  
Revenue $ 4,229
Earnings before Taxes $ 689
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions - Summary of Acquired Identifiable Intangible Asset (Detail) - Customer Contract Relationships [Member]
$ in Thousands
3 Months Ended
Apr. 29, 2023
USD ($)
Acquired Finite-Lived Intangible Assets [Line Items]  
Fair Value $ 530
Useful Life (Years) 20 years
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions - Additional Information (Detail)
3 Months Ended 12 Months Ended
Aug. 04, 2022
USD ($)
ft²
Apr. 29, 2023
USD ($)
Jan. 31, 2023
USD ($)
Business Acquisition [Line Items]      
Area of Land | ft² 34,460    
Goodwill   $ 14,760,000 $ 14,658,000
Royalty expense   100,000 100,000
Royalty guarantee commitement due current and non current discounted value   500,000 500,000
Royalty Payments Due In Next Twelve Months [Member]      
Business Acquisition [Line Items]      
Royalty guarantee commitement amount   100,000  
Royalty Payments Due Year Two [Member]      
Business Acquisition [Line Items]      
Royalty guarantee commitement amount   200,000  
Royalty Payments Due Year Three [Member]      
Business Acquisition [Line Items]      
Royalty guarantee commitement amount   233,000  
Royalty Payments Due Year Four [Member]      
Business Acquisition [Line Items]      
Royalty guarantee commitement amount   233,000  
Royalty Payments Due Year Five [Member]      
Business Acquisition [Line Items]      
Royalty guarantee commitement amount   234,000  
Non Current Liability [Member]      
Business Acquisition [Line Items]      
Royalty guarantees commitments amount non current   $ 100,000  
Measurement Input Royalty Rate [Member]      
Business Acquisition [Line Items]      
Fair Value Of Intangible Assets Measurement Input   0.0075  
Measurement Input Customer Attrition Rate [Member]      
Business Acquisition [Line Items]      
Fair Value Of Intangible Assets Measurement Input   0.18  
Measurement Input, Discount Rate [Member]      
Business Acquisition [Line Items]      
Fair Value Of Intangible Assets Measurement Input   0.19  
Agreement With Astro Machine For Asset Acquisitions [Member]      
Business Acquisition [Line Items]      
Purchase price of acquisition $ 15,600,000    
Business Combination, Consideration Transferred $ 17,100,000    
Payments to Acquire Businesses, Gross 100.00%    
Purchase price into an escrow account $ 300,000    
Payments to Acquire Additional Interest in Subsidiaries $ 1,500,000    
Number of Acres of land   1.26  
Goodwill   $ 2,730,000  
Agreement With Astro Machine For Asset Acquisitions [Member] | General and Administrative Expense [Member]      
Business Acquisition [Line Items]      
Business Combination, Acquisition Related Costs     $ 700,000
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue Recognition - Summary of Revenues Disaggregated by Primary Geographic Markets (Detail) - USD ($)
$ in Thousands
3 Months Ended
Apr. 29, 2023
Apr. 30, 2022
Disaggregation of Revenue [Line Items]    
Total Revenue $ 35,419 $ 31,010
United States [Member]    
Disaggregation of Revenue [Line Items]    
Total Revenue 22,834 19,651
Europe [Member]    
Disaggregation of Revenue [Line Items]    
Total Revenue 7,964 7,419
Canada [Member]    
Disaggregation of Revenue [Line Items]    
Total Revenue 1,825 1,854
Asia [Member]    
Disaggregation of Revenue [Line Items]    
Total Revenue 1,294 937
Central and South America [Member]    
Disaggregation of Revenue [Line Items]    
Total Revenue 1,199 888
Other [Member]    
Disaggregation of Revenue [Line Items]    
Total Revenue $ 303 $ 261
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue Recognition - Summary of Revenues Disaggregated by Primary Product Type (Detail) - USD ($)
$ in Thousands
3 Months Ended
Apr. 29, 2023
Apr. 30, 2022
Disaggregation of Revenue [Line Items]    
Total Revenue $ 35,419 $ 31,010
Hardware [Member]    
Disaggregation of Revenue [Line Items]    
Total Revenue 11,667 9,301
Supplies [Member]    
Disaggregation of Revenue [Line Items]    
Total Revenue 19,070 17,944
Service and Other [Member]    
Disaggregation of Revenue [Line Items]    
Total Revenue $ 4,682 $ 3,765
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue Recognition - Additional Information (Detail) - USD ($)
3 Months Ended 12 Months Ended
Apr. 29, 2023
Apr. 30, 2022
Jan. 31, 2023
Dec. 31, 2022
Contract liabilities and extended warranties $ 443,000   $ 412,000  
Revenue recognized     143,000  
Contract assets balance 1,300,000   1,400,000  
Amortization of incremental direct costs 19,000 $ 16,000    
Deferred incremental direct contract costs reported in other current assets $ 100,000      
Capitalized contract costs amounts incurred amortization period 18 years      
Aerospace Customer [Member]        
Deferred incremental direct contract costs reported in other current assets $ 1,200,000      
Contract with customer liability       $ 3,250,000
Deferred Revenue     2,150,000  
Revenue recognized $ 400,000   $ 1,100,000  
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.23.1
Net Income Per Common Share - Reconciliation of Shares Used in Calculating Basic and Diluted (Detail) - shares
3 Months Ended
Apr. 29, 2023
Apr. 30, 2022
Weighted Average Common Shares Outstanding – Basic 7,369,930 7,262,797
Effect of Dilutive Options, Restricted Stock Awards and Restricted Stock Units 80,122 97,713
Weighted Average Number of Common Shares Outstanding—Diluted 7,450,052 7,360,510
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.23.1
Net Income Per Common Share - Additional Information (Detail) - shares
3 Months Ended
Apr. 29, 2023
Apr. 30, 2022
Number of common equivalent shares 656,554 310,588
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.23.1
Intangible Assets - Fair Value of Acquired Identifiable Intangible Assets and Related Estimated Useful Lives (Detail) - USD ($)
$ in Thousands
Apr. 29, 2023
Jan. 31, 2023
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount $ 40,447 $ 40,447
Accumulated Amortization (19,950) (19,336)
Currency Translation Adjustment 133 121
Net Carrying Amount 20,630 21,232
Customer Contract Relationships [Member] | Honeywell Asset Purchase and License Agreement [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 27,773 27,773
Accumulated Amortization (12,145) (11,913)
Net Carrying Amount 15,628 15,860
Customer Contract Relationships [Member] | Miltope [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 3,100 3,100
Accumulated Amortization (2,857) (2,777)
Net Carrying Amount 243 323
Customer Contract Relationships [Member] | RITEC [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 2,830 2,830
Accumulated Amortization (1,639) (1,623)
Net Carrying Amount 1,191 1,207
Customer Contract Relationships [Member] | Agreement With Astro Machine For Asset Acquisitions [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 3,060 3,060
Accumulated Amortization (459) (306)
Net Carrying Amount 2,601 2,754
Existing Technology [Member] | TrojanLabel ApS [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 2,327 2,327
Accumulated Amortization (2,171) (2,087)
Currency Translation Adjustment 97 94
Net Carrying Amount 253 334
Distributor Relations [Member] | TrojanLabel ApS [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 937 937
Accumulated Amortization (616) (588)
Currency Translation Adjustment 36 27
Net Carrying Amount 357 376
Trademarks [Member] | Agreement With Astro Machine For Asset Acquisitions [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 420 420
Accumulated Amortization (63) (42)
Net Carrying Amount $ 357 $ 378
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.23.1
Intangible Assets - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended
Apr. 29, 2023
Apr. 30, 2022
Intangible Assets [Line Items]    
Impairments of intangible assets $ 0 $ 0
Amortization expense $ 600 $ 400
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.23.1
Intangible Assets - Summary of Estimated Amortization Expense (Detail)
$ in Thousands
Apr. 29, 2023
USD ($)
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]  
2024 $ 1,786
2025 1,723
2026 1,723
2027 1,723
2028 $ 1,281
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.23.1
Inventories - Components of Inventories (Detail) - USD ($)
$ in Thousands
Apr. 29, 2023
Jan. 31, 2023
Inventory Disclosure [Abstract]    
Materials and Supplies $ 40,624 $ 38,387
Work-In-Progress 1,485 1,146
Finished Goods 22,221 23,221
Inventory, Gross 64,330 62,754
Inventory Reserve (11,204) (11,430)
Inventories $ 53,126 $ 51,324
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.23.1
Property, Plant and Equipment - Summary of Property, Plant and Equipment (Detail) - USD ($)
$ in Thousands
Apr. 29, 2023
Jan. 31, 2023
Land and Land Improvements $ 2,304 $ 2,304
Buildings and Leasehold Improvements 14,162 14,158
Machinery and Equipment 25,012 24,960
Computer Equipment and Software 13,996 13,972
Gross Property, Plant and Equipment 55,474 55,394
Accumulated Depreciation (41,556) (41,106)
Net Property Plant and Equipment $ 13,918 $ 14,288
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.23.1
Property, Plant and Equipment - Additional Information (Detail) - USD ($)
$ in Millions
3 Months Ended
Apr. 29, 2023
Apr. 30, 2022
Depreciation expense on property, plant and equipment $ 0.4 $ 0.4
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.23.1
Credit Agreement and Long- Term Debt - Schedule of Long Term Debt in the Accompanying Condensed Consolidated Balance Sheets (Detail) - USD ($)
$ in Thousands
Apr. 29, 2023
Jan. 31, 2023
Debt Instrument [Line Items]    
USD Term Loan $ 13,875 $ 14,250
Debt Issuance Costs, net of accumulated amortization (97) (110)
Current Portion of Term Loan (2,100) (2,100)
Long-Term Debt 11,678 12,040
Term Loan Due August 4, 2027 [Member]    
Debt Instrument [Line Items]    
USD Term Loan $ 13,875 $ 14,250
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.23.1
Credit Agreement and Long- Term Debt - Schedule of Required Principal Payments Remaining on Long Term Debt Outstanding (Detail) - Term Loan [Member]
$ in Thousands
Apr. 29, 2023
USD ($)
Debt Instrument [Line Items]  
Fiscal 2024, remainder $ 1,725
Fiscal 2025 2,700
Fiscal 2026 2,700
Fiscal 2027 2,700
Fiscal 2028 4,050
Long-term Debt $ 13,875
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.23.1
Credit Agreement and Long- Term Debt - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 42 Months Ended
Aug. 04, 2022
Apr. 29, 2023
Apr. 30, 2022
Jul. 31, 2023
Apr. 30, 2027
Debt Instrument [Line Items]          
Revolving loan outstanding   $ 15,900      
Interest Expense, Debt   $ 248,000 $ 53,000    
Revolving Credit Facility [Member]          
Debt Instrument [Line Items]          
Variable interest rate   0.50      
LIBOR [Member] | Revolving Credit Facility [Member]          
Debt Instrument [Line Items]          
Interest rate   1.00%      
Federal Funds Effective Swap Rate [Member] | Revolving Credit Facility [Member]          
Debt Instrument [Line Items]          
Interest rate   0.50%      
Minimum [Member] | Revolving Credit Facility [Member]          
Debt Instrument [Line Items]          
Commitment fee rate   0.15%      
Percentage added to variable rate   0.60%      
Minimum [Member] | LIBOR [Member] | Revolving Credit Facility [Member]          
Debt Instrument [Line Items]          
Interest rate   1.60%      
Maximum [Member] | Revolving Credit Facility [Member]          
Debt Instrument [Line Items]          
Commitment fee rate   0.35%      
Percentage added to variable rate   1.50%      
Maximum [Member] | LIBOR [Member] | Revolving Credit Facility [Member]          
Debt Instrument [Line Items]          
Interest rate   2.50%      
Bank of America, N.A. [Member] | Term Loan [Member]          
Debt Instrument [Line Items]          
Debt Instrument, principal Periodic payment       $ 375,000 $ 675,000
Bank of America, N.A. [Member] | Term Loan [Member] | Second Amendment Credit Agreement [Member]          
Debt Instrument [Line Items]          
Proceeds from long term line of credit $ 6,000        
Bank of America, N.A. [Member] | Term Loan [Member] | Additional Term Loan Availed [Member] | Second Amendment Credit Agreement [Member]          
Debt Instrument [Line Items]          
Principal amount of debt 6,000        
Bank of America, N.A. [Member] | Term Loan [Member] | Before Amendment To The Credit Agreement [Member]          
Debt Instrument [Line Items]          
Principal amount of debt 9,000        
Bank of America, N.A. [Member] | Revolving Credit Facility [Member]          
Debt Instrument [Line Items]          
Line of Credit Facility, Remaining Borrowing Capacity   $ 9,100      
Long term debt weighted average interest rate over a period of time   6.93% 4.26%    
Bank of America, N.A. [Member] | Revolving Credit Facility [Member] | Second Amendment Credit Agreement [Member]          
Debt Instrument [Line Items]          
Maximum borrowing capacity   $ 25,000      
Proceeds from long term line of credit $ 12,400        
Bank of America, N.A. [Member] | Revolving Credit Facility [Member] | Before Amendment To The Credit Agreement [Member]          
Debt Instrument [Line Items]          
Maximum borrowing capacity     $ 22,500    
Bank of America, N.A. [Member] | Revolving Credit Facility [Member] | Other Expense [Member]          
Debt Instrument [Line Items]          
Interest Expense, Debt   292,000 23,000    
Line of Credit Facility, Commitment Fee Amount   $ 8,000 $ 10,000    
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.23.1
Royalty Obligation - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended
Jan. 31, 2018
Apr. 29, 2023
Jan. 31, 2023
Guaranteed Minimum Royalty Payments   $ 10,000  
Royalty Obligation, Current   1,600 $ 1,725
Royalty Obligation Non Current   3,102 3,415
Accrued Royalties, Current, Excess Royalty Payment Due   379 $ 562
Honeywell Asset Purchase and License Agreement [Member]      
Payment Term Period 10 years    
Minimum Royalty Payment Obligation $ 15,000    
Royalty Obligation, Current   1,500  
Royalty Obligation Non Current   2,700  
Excess Royalty Payments   400  
Accrued Royalties, Current, Excess Royalty Payment Due   400  
Accrued Royalties Current Excess Royalty Payments Due   $ 400  
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.23.1
Leases - Additional Information (Detail)
Apr. 29, 2023
Operating Lease, Weighted Average Remaining Lease Term 3 years 6 months
Operating Lease, Weighted Average Discount Rate, Percent 4.37%
XML 70 R60.htm IDEA: XBRL DOCUMENT v3.23.1
Leases - Schedule Of Balance Sheet And Other Information Related To Operating Leases (Detail) - USD ($)
$ in Thousands
Apr. 29, 2023
Jan. 31, 2023
Operating Leases [Abstract]    
Right of Use Assets $ 858 $ 794
Other Liabilities and Accrued Expenses 312 275
Lease Liabilities $ 581 $ 555
XML 71 R61.htm IDEA: XBRL DOCUMENT v3.23.1
Leases - Lease Cost Information (Detail) - USD ($)
$ in Thousands
3 Months Ended
Apr. 29, 2023
Apr. 30, 2022
General and Administrative Expense [Member]    
Operating Lease Costs $ 133 $ 113
XML 72 R62.htm IDEA: XBRL DOCUMENT v3.23.1
Leases - Maturities of lease liabilities (Detail)
$ in Thousands
Apr. 29, 2023
USD ($)
Leases [Abstract]  
2024, remaining $ 263
2025 258
2026 199
2027 151
2028 93
Thereafter 0
Total Lease Payments 964
Less: Imputed Interest (71)
Total Lease Liabilities $ 893
XML 73 R63.htm IDEA: XBRL DOCUMENT v3.23.1
Leases - Supplemental cash flow information (Detail) - USD ($)
$ in Thousands
3 Months Ended
Apr. 29, 2023
Apr. 30, 2022
Cash paid for amounts included in the measurement of lease liabilities [Abstract]    
Operating cash flows for operating leases $ 93 $ 83
XML 74 R64.htm IDEA: XBRL DOCUMENT v3.23.1
Accumulated Other Comprehensive Loss - Changes in Balance of Accumulated Other Comprehensive Loss (Detail)
$ in Thousands
3 Months Ended
Apr. 29, 2023
USD ($)
Schedule of Capitalization, Equity [Line Items]  
Beginning Balance $ 84,367
Ending Balance 85,474
Foreign Currency Translation Adjustments [Member]  
Schedule of Capitalization, Equity [Line Items]  
Beginning Balance (2,238)
Other Comprehensive Income before reclassification 210
Ending Balance (2,028)
Accumulated Other Comprehensive Income (Loss) [Member]  
Schedule of Capitalization, Equity [Line Items]  
Beginning Balance (2,238)
Other Comprehensive Income before reclassification 210
Ending Balance $ (2,028)
XML 75 R65.htm IDEA: XBRL DOCUMENT v3.23.1
Share-Based Compensation - Additional Information (Detail) - USD ($)
3 Months Ended 12 Months Ended
Apr. 29, 2023
Apr. 30, 2022
Jan. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of shares outstanding 541,099   547,199
Number of options granted 0 0  
Reservation of shares under Stock Purchase Plan     40,000
Restricted Stock or Unit Expense $ 352,000 $ 328,000  
Employee Stock Purchase Plan [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Employee Stock Purchase Plan discount rate     15.00%
2007 Equity Incentive Plan [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of shares outstanding 270,649    
2018 Equity Incentive Plan [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Shares authorized for grant under the Plan 950,000    
Number of shares outstanding 135,500    
2022 Employee Stock Purchase Plan      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Shares purchase under Employee Stock Purchase Plan 2,394   5,045
Shares available for grant under the Plan 32,560    
Prior Employee Stock Purchase Plan [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Shares purchase under Employee Stock Purchase Plan   1,550  
Stock Options [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Unrecognized compensation expense related to options $ 0    
Restricted Stock Units (RSUs) [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Unrecognized compensation expense to be recognized, Weighted average period 1 year 2 months 12 days    
Unrecognized compensation expense related to RSUs and RSAs $ 2,500,000    
Restricted Stock Units (RSUs) [Member] | 2018 Equity Incentive Plan [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of unvested shares 124,439    
RSA [Member] | 2015 Equity Incentive Plan [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of shares outstanding 134,950    
RSA [Member] | 2018 Equity Incentive Plan [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of unvested shares 21,172    
Performance Based RSUs [Member] | 2018 Equity Incentive Plan [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of unvested shares 188,633    
Restricted Stock Award [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Restricted Stock or Unit Expense $ 65,000    
XML 76 R66.htm IDEA: XBRL DOCUMENT v3.23.1
Share-Based Compensation - Share-Based Compensation Expense (Detail) - USD ($)
$ in Thousands
3 Months Ended
Apr. 29, 2023
Apr. 30, 2022
Share-based Compensation [Abstract]    
Stock Options $ 0 $ 6
Restricted Stock Awards and Restricted Stock Units 352 328
Employee Stock Purchase Plan 4 3
Total $ 356 $ 337
XML 77 R67.htm IDEA: XBRL DOCUMENT v3.23.1
Share-Based Compensation - Aggregated Information Regarding Stock Option Activity (Detail) - $ / shares
3 Months Ended
Apr. 29, 2023
Apr. 30, 2022
Share-based Compensation [Abstract]    
Beginning balance, Number of Options 547,199  
Granted, Number of Options 0 0
Exercised, Number of Options (1,700)  
Forfeited, Number of Options (175)  
Canceled, Number of Options (4,225)  
Ending balance, Number of Options 541,099  
Beginning balance, Weighted-Average Exercise Price $ 15.16  
Granted, Weighted-Average Exercise Price 0  
Exercised, Weighted-Average Exercise Price 10.5  
Forfeited, Weighted-Average Exercise Price 18.35  
Cancelled, Weighted-Average Exercise Price 10.5  
Ending balance, Weighted-Average Exercise Price $ 15.21  
XML 78 R68.htm IDEA: XBRL DOCUMENT v3.23.1
Share-Based Compensation - Summary of Options Outstanding (Detail) - $ / shares
3 Months Ended
Apr. 29, 2023
Jan. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of shares outstanding, total 541,099 547,199
Outstanding, Weighted Average Exercise Price $ 15.21  
Exercisable, Weighted Average Exercise Price $ 15.21  
Outstanding Remaining Contractual Life 3 years 6 months  
Number of shares exercisable, total 541,099  
Exercisable Remaining Contractual Life 3 years 6 months  
$5.00 - $10.00 [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Outstanding Range of Exercise prices, Lower Limit $ 5  
Outstanding Range of Exercise prices, Upper Limit $ 10  
Outstanding, Number of shares 0  
Outstanding, Weighted Average Exercise Price $ 0  
Exercisable, Weighted Average Exercise Price $ 0  
Exercisable, Number of shares 0  
$10.01 - $15.00 [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Outstanding Range of Exercise prices, Lower Limit $ 10.01  
Outstanding Range of Exercise prices, Upper Limit $ 15  
Outstanding, Number of shares 326,924  
Outstanding, Weighted Average Exercise Price $ 13.74  
Exercisable, Weighted Average Exercise Price $ 13.74  
Outstanding Remaining Contractual Life 2 years 8 months 12 days  
Exercisable, Number of shares 326,924  
Exercisable Remaining Contractual Life 2 years 8 months 12 days  
$15.01 - $20.00 [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Outstanding Range of Exercise prices, Lower Limit $ 15.01  
Outstanding Range of Exercise prices, Upper Limit $ 20  
Outstanding, Number of shares 214,175  
Outstanding, Weighted Average Exercise Price $ 17.45  
Exercisable, Weighted Average Exercise Price $ 17.45  
Outstanding Remaining Contractual Life 4 years 7 months 6 days  
Exercisable, Number of shares 214,175  
Exercisable Remaining Contractual Life 4 years 7 months 6 days  
XML 79 R69.htm IDEA: XBRL DOCUMENT v3.23.1
Share-Based Compensation - Aggregated Information Regarding RSU and RSA Activity (Detail) - Restricted Stock Award Preferred Stock Unit And Restricted Stock Unit [Member]
3 Months Ended
Apr. 29, 2023
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Beginning balance, Outstanding Restricted Stock Units and Restricted Stock Awards | shares 274,927
Granted, Restricted Stock Units and Restricted Stock Awards | shares 142,811
Vested, Restricted Stock Units and Restricted Stock Awards | shares (78,817)
Forfeited, Restricted Stock Units and Restricted Stock Awards | shares (4,677)
Ending balance, Outstanding Restricted Stock Units and Restricted Stock Awards | shares 334,244
Beginning balance, Weighted Average Grant Date Fair Value | $ / shares $ 12.82
Granted, Weighted Average Grant Date Fair Value | $ / shares 12.48
Vested, Weighted Average Grant Date Fair Value | $ / shares 11.85
Forfeited, Weighted Average Grant Date Fair Value | $ / shares 12.49
Ending balance, Weighted Average Grant Date Fair Value | $ / shares $ 12.9
XML 80 R70.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes - Projected Effective Tax Rates (Detail)
3 Months Ended
Apr. 29, 2023
Apr. 30, 2022
Income Tax Disclosure [Abstract]    
Effective tax rates for income from continuing operations 17.40% 12.40%
XML 81 R71.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes - Additional Information (Detail) - USD ($)
3 Months Ended
Apr. 29, 2023
Apr. 30, 2022
Income tax expense (benefit) $ 179,000 $ 60,000
Tax expenses benefits resulting from provisional adjustments 29,000 30,000
Effective income tax reconciliation tax expense due to revaluation of deferred tax assets $ 77,000 $ 38,000
XML 82 R72.htm IDEA: XBRL DOCUMENT v3.23.1
Segment Information - Net Sales and Segment Operating Profit (Loss) for Each Reporting Segment (Detail) - USD ($)
3 Months Ended
Apr. 29, 2023
Apr. 30, 2022
Segment Reporting Information [Line Items]    
Revenue $ 35,419,000 $ 31,010,000
Corporate Expenses 3,126,000 2,560,000
Operating Income 1,461,000 764,000
Other Expense, Net 434,000 279,000
Income Before Income Taxes 1,027,000 485,000
Income Tax Provision 179,000 60,000
Net Income 848,000 425,000
PI [Member]    
Segment Reporting Information [Line Items]    
Revenue 25,095,000 21,724,000
T&M [Member]    
Segment Reporting Information [Line Items]    
Revenue 10,324,000 9,286,000
Operating Segments [Member]    
Segment Reporting Information [Line Items]    
Operating Income 4,587,000 3,324,000
Operating Segments [Member] | PI [Member]    
Segment Reporting Information [Line Items]    
Operating Income 2,515,000 1,413,000
Operating Segments [Member] | T&M [Member]    
Segment Reporting Information [Line Items]    
Operating Income 2,072,000 1,911,000
Corporate Expenses [Member]    
Segment Reporting Information [Line Items]    
Corporate Expenses $ 3,126,000 $ 2,560,000
XML 83 R73.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value - Schedule of Company's Long-Term Debt Including the Current Portion Not Reflected in Financial Statements at Fair Value (Detail) - USD ($)
$ in Thousands
Apr. 29, 2023
Jan. 31, 2023
Fair Value [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Long-Term debt and related current maturities $ 13,937 $ 14,310
Fair Value [Member] | Level 3 [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Long-Term debt and related current maturities 13,937 14,310
Carrying Value [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Long-Term debt and related current maturities $ 13,875 $ 14,250
XML 84 d292174d10q_htm.xml IDEA: XBRL DOCUMENT 0000008146 2023-02-01 2023-04-29 0000008146 2022-02-01 2022-04-30 0000008146 2023-04-29 0000008146 2023-01-31 0000008146 2022-08-04 0000008146 2022-08-04 2022-08-04 0000008146 2022-02-01 2023-01-31 0000008146 2023-06-02 0000008146 2022-01-31 0000008146 2022-04-30 0000008146 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-01-31 0000008146 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-01-31 0000008146 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-01-31 0000008146 alot:MiltopeCorporationMember us-gaap:CustomerContractsMember 2023-01-31 0000008146 alot:RuggedInformationTechnologyEquipmentCorporationMember us-gaap:CustomerContractsMember 2023-01-31 0000008146 alot:TrojanlabelApSMember alot:ExistingTechnologyMember 2023-01-31 0000008146 alot:TrojanlabelApSMember alot:DistributorRelationsMember 2023-01-31 0000008146 us-gaap:CustomerContractsMember alot:HoneywellAssetPurchaseAndLicenseAgreementMember 2023-01-31 0000008146 alot:AgreementWithAstroMachineForAssetAcquisitionsMember us-gaap:CustomerContractsMember 2023-01-31 0000008146 alot:AgreementWithAstroMachineForAssetAcquisitionsMember us-gaap:TrademarksMember 2023-01-31 0000008146 alot:TermLoanDueAugustFourthTwoThousandAndTwentySevenMember 2023-01-31 0000008146 alot:AerospaceCustomerMember 2023-01-31 0000008146 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-04-29 0000008146 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-04-29 0000008146 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-04-29 0000008146 alot:MiltopeCorporationMember us-gaap:CustomerContractsMember 2023-04-29 0000008146 alot:RuggedInformationTechnologyEquipmentCorporationMember us-gaap:CustomerContractsMember 2023-04-29 0000008146 alot:TrojanlabelApSMember alot:ExistingTechnologyMember 2023-04-29 0000008146 alot:TrojanlabelApSMember alot:DistributorRelationsMember 2023-04-29 0000008146 us-gaap:CustomerContractsMember alot:HoneywellAssetPurchaseAndLicenseAgreementMember 2023-04-29 0000008146 alot:AgreementWithAstroMachineForAssetAcquisitionsMember us-gaap:CustomerContractsMember 2023-04-29 0000008146 alot:AgreementWithAstroMachineForAssetAcquisitionsMember us-gaap:TrademarksMember 2023-04-29 0000008146 alot:TermLoanDueAugustFourthTwoThousandAndTwentySevenMember 2023-04-29 0000008146 alot:TwoThousandEighteenEquityIncentivePlanMember 2023-04-29 0000008146 alot:TwoThousandSevenEquityIncentivePlanMember 2023-04-29 0000008146 us-gaap:RestrictedStockMember alot:TwoThousandFifteenEquityIncentivePlanMember 2023-04-29 0000008146 alot:TermLoanMember 2023-04-29 0000008146 alot:RangeThreeMember 2023-04-29 0000008146 alot:RangeFourMember 2023-04-29 0000008146 alot:RangeFiveMember 2023-04-29 0000008146 us-gaap:RestrictedStockUnitsRSUMember alot:TwoThousandEighteenEquityIncentivePlanMember 2023-04-29 0000008146 us-gaap:PerformanceSharesMember alot:TwoThousandEighteenEquityIncentivePlanMember 2023-04-29 0000008146 us-gaap:RestrictedStockMember alot:TwoThousandEighteenEquityIncentivePlanMember 2023-04-29 0000008146 us-gaap:EmployeeStockOptionMember 2023-04-29 0000008146 us-gaap:RestrictedStockUnitsRSUMember 2023-04-29 0000008146 alot:TwoThousandAndTwentyTwoEmployeeStockPurchasePlanMember 2023-04-29 0000008146 alot:AerospaceCustomerMember 2023-04-29 0000008146 alot:HoneywellAssetPurchaseAndLicenseAgreementMember 2023-04-29 0000008146 alot:SecondAmendmentCreditAgreementMember us-gaap:RevolvingCreditFacilityMember alot:BankOfAmericaMember 2023-04-29 0000008146 us-gaap:RevolvingCreditFacilityMember alot:BankOfAmericaMember 2023-04-29 0000008146 alot:MeasurementInputRoyaltyRateMember 2023-04-29 0000008146 alot:MeasurementInputCustomerAttritionRateMember 2023-04-29 0000008146 us-gaap:MeasurementInputDiscountRateMember 2023-04-29 0000008146 alot:AgreementWithAstroMachineForAssetAcquisitionsMember 2023-04-29 0000008146 us-gaap:CustomerRelatedIntangibleAssetsMember 2023-04-29 0000008146 alot:NonCurrentLiabilityMember 2023-04-29 0000008146 alot:RoyaltyPaymentsDueInNextTwelveMonthsMember 2023-04-29 0000008146 alot:RoyaltyPaymentsDueYearTwoMember 2023-04-29 0000008146 alot:RoyaltyPaymentsDueYearFiveMember 2023-04-29 0000008146 alot:RoyaltyPaymentsDueYearFourMember 2023-04-29 0000008146 alot:RoyaltyPaymentsDueYearThreeMember 2023-04-29 0000008146 alot:RangeThreeMember 2023-02-01 2023-04-29 0000008146 alot:RangeFourMember 2023-02-01 2023-04-29 0000008146 alot:RangeFiveMember 2023-02-01 2023-04-29 0000008146 country:US 2023-02-01 2023-04-29 0000008146 srt:EuropeMember 2023-02-01 2023-04-29 0000008146 country:CA 2023-02-01 2023-04-29 0000008146 srt:AsiaMember 2023-02-01 2023-04-29 0000008146 alot:CentralAndSouthAmericaMember 2023-02-01 2023-04-29 0000008146 alot:OthersCountriesMember 2023-02-01 2023-04-29 0000008146 alot:HardwareProductsMember 2023-02-01 2023-04-29 0000008146 alot:SuppliesMember 2023-02-01 2023-04-29 0000008146 alot:ServiceAndOtherMember 2023-02-01 2023-04-29 0000008146 us-gaap:AccumulatedTranslationAdjustmentMember 2023-02-01 2023-04-29 0000008146 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-02-01 2023-04-29 0000008146 alot:RestrictedStockAwardPreferredStockUnitAndRestrictedStockUnitMember 2023-02-01 2023-04-29 0000008146 us-gaap:AdditionalPaidInCapitalMember 2023-02-01 2023-04-29 0000008146 us-gaap:CommonStockMember 2023-02-01 2023-04-29 0000008146 us-gaap:TreasuryStockMember 2023-02-01 2023-04-29 0000008146 us-gaap:RetainedEarningsMember 2023-02-01 2023-04-29 0000008146 us-gaap:RestrictedStockUnitsRSUMember 2023-02-01 2023-04-29 0000008146 alot:ProductIdentificationMember 2023-02-01 2023-04-29 0000008146 alot:TestAndMeasurementMember 2023-02-01 2023-04-29 0000008146 us-gaap:CorporateNonSegmentMember 2023-02-01 2023-04-29 0000008146 us-gaap:OperatingSegmentsMember alot:ProductIdentificationMember 2023-02-01 2023-04-29 0000008146 us-gaap:OperatingSegmentsMember alot:TestAndMeasurementMember 2023-02-01 2023-04-29 0000008146 us-gaap:OperatingSegmentsMember 2023-02-01 2023-04-29 0000008146 alot:TwoThousandAndTwentyTwoEmployeeStockPurchasePlanMember 2023-02-01 2023-04-29 0000008146 alot:RestrictedStockAwardMember 2023-02-01 2023-04-29 0000008146 alot:HoneywellAssetPurchaseAndLicenseAgreementMember 2023-02-01 2023-04-29 0000008146 us-gaap:GeneralAndAdministrativeExpenseMember 2023-02-01 2023-04-29 0000008146 us-gaap:RevolvingCreditFacilityMember us-gaap:OtherExpenseMember alot:BankOfAmericaMember 2023-02-01 2023-04-29 0000008146 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember 2023-02-01 2023-04-29 0000008146 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember 2023-02-01 2023-04-29 0000008146 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2023-02-01 2023-04-29 0000008146 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2023-02-01 2023-04-29 0000008146 us-gaap:RevolvingCreditFacilityMember us-gaap:FederalFundsEffectiveSwapRateMember 2023-02-01 2023-04-29 0000008146 us-gaap:RevolvingCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2023-02-01 2023-04-29 0000008146 us-gaap:RevolvingCreditFacilityMember 2023-02-01 2023-04-29 0000008146 alot:AgreementWithAstroMachineForAssetAcquisitionsMember 2023-02-01 2023-04-29 0000008146 us-gaap:RevolvingCreditFacilityMember alot:BankOfAmericaMember 2023-02-01 2023-04-29 0000008146 alot:AerospaceCustomerMember 2023-02-01 2023-04-29 0000008146 us-gaap:CustomerRelatedIntangibleAssetsMember 2023-02-01 2023-04-29 0000008146 us-gaap:CustomerRelationshipsMember 2022-08-04 2022-08-04 0000008146 us-gaap:TrademarksAndTradeNamesMember 2022-08-04 2022-08-04 0000008146 alot:AgreementWithAstroMachineForAssetAcquisitionsMember 2022-08-04 2022-08-04 0000008146 alot:SecondAmendmentCreditAgreementMember alot:TermLoanMember alot:BankOfAmericaMember 2022-08-04 2022-08-04 0000008146 alot:SecondAmendmentCreditAgreementMember us-gaap:RevolvingCreditFacilityMember alot:BankOfAmericaMember 2022-08-04 2022-08-04 0000008146 alot:SecondAmendmentCreditAgreementMember alot:AdditionalTermLoanAvailedMember alot:TermLoanMember alot:BankOfAmericaMember 2022-08-04 0000008146 alot:BeforeAmendmentToTheCreditAgreementMember alot:TermLoanMember alot:BankOfAmericaMember 2022-08-04 0000008146 alot:AgreementWithAstroMachineForAssetAcquisitionsMember 2022-08-04 0000008146 alot:AerospaceCustomerMember 2022-12-31 0000008146 alot:TermLoanMember alot:BankOfAmericaMember 2022-10-31 2023-07-31 0000008146 alot:TermLoanMember alot:BankOfAmericaMember 2023-10-31 2027-04-30 0000008146 country:US 2022-02-01 2022-04-30 0000008146 srt:EuropeMember 2022-02-01 2022-04-30 0000008146 country:CA 2022-02-01 2022-04-30 0000008146 srt:AsiaMember 2022-02-01 2022-04-30 0000008146 alot:CentralAndSouthAmericaMember 2022-02-01 2022-04-30 0000008146 alot:OthersCountriesMember 2022-02-01 2022-04-30 0000008146 alot:HardwareProductsMember 2022-02-01 2022-04-30 0000008146 alot:SuppliesMember 2022-02-01 2022-04-30 0000008146 alot:ServiceAndOtherMember 2022-02-01 2022-04-30 0000008146 us-gaap:AdditionalPaidInCapitalMember 2022-02-01 2022-04-30 0000008146 us-gaap:CommonStockMember 2022-02-01 2022-04-30 0000008146 us-gaap:TreasuryStockMember 2022-02-01 2022-04-30 0000008146 us-gaap:RetainedEarningsMember 2022-02-01 2022-04-30 0000008146 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-02-01 2022-04-30 0000008146 alot:ProductIdentificationMember 2022-02-01 2022-04-30 0000008146 alot:TestAndMeasurementMember 2022-02-01 2022-04-30 0000008146 us-gaap:CorporateNonSegmentMember 2022-02-01 2022-04-30 0000008146 us-gaap:OperatingSegmentsMember alot:ProductIdentificationMember 2022-02-01 2022-04-30 0000008146 us-gaap:OperatingSegmentsMember alot:TestAndMeasurementMember 2022-02-01 2022-04-30 0000008146 us-gaap:OperatingSegmentsMember 2022-02-01 2022-04-30 0000008146 alot:PriorEmployeeStockPurchasePlanMember 2022-02-01 2022-04-30 0000008146 us-gaap:GeneralAndAdministrativeExpenseMember 2022-02-01 2022-04-30 0000008146 us-gaap:RevolvingCreditFacilityMember us-gaap:OtherExpenseMember alot:BankOfAmericaMember 2022-02-01 2022-04-30 0000008146 us-gaap:RevolvingCreditFacilityMember alot:BankOfAmericaMember 2022-02-01 2022-04-30 0000008146 alot:BeforeAmendmentToTheCreditAgreementMember us-gaap:RevolvingCreditFacilityMember alot:BankOfAmericaMember 2022-04-30 0000008146 alot:HoneywellAssetPurchaseAndLicenseAgreementMember 2018-01-31 0000008146 alot:HoneywellAssetPurchaseAndLicenseAgreementMember 2018-01-31 2018-01-31 0000008146 alot:EmployeeStockPurchasePlanMember 2022-02-01 2023-01-31 0000008146 alot:TwoThousandAndTwentyTwoEmployeeStockPurchasePlanMember 2022-02-01 2023-01-31 0000008146 alot:AgreementWithAstroMachineForAssetAcquisitionsMember us-gaap:GeneralAndAdministrativeExpenseMember 2022-02-01 2023-01-31 0000008146 alot:AerospaceCustomerMember 2022-02-01 2023-01-31 0000008146 alot:RestrictedStockAwardPreferredStockUnitAndRestrictedStockUnitMember 2023-01-31 0000008146 us-gaap:CommonStockMember 2023-01-31 0000008146 us-gaap:AdditionalPaidInCapitalMember 2023-01-31 0000008146 us-gaap:RetainedEarningsMember 2023-01-31 0000008146 us-gaap:TreasuryStockMember 2023-01-31 0000008146 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-31 0000008146 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-31 0000008146 alot:RestrictedStockAwardPreferredStockUnitAndRestrictedStockUnitMember 2023-04-29 0000008146 us-gaap:CommonStockMember 2023-04-29 0000008146 us-gaap:AdditionalPaidInCapitalMember 2023-04-29 0000008146 us-gaap:RetainedEarningsMember 2023-04-29 0000008146 us-gaap:TreasuryStockMember 2023-04-29 0000008146 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-29 0000008146 us-gaap:AccumulatedTranslationAdjustmentMember 2023-04-29 0000008146 us-gaap:CommonStockMember 2022-01-31 0000008146 us-gaap:AdditionalPaidInCapitalMember 2022-01-31 0000008146 us-gaap:RetainedEarningsMember 2022-01-31 0000008146 us-gaap:TreasuryStockMember 2022-01-31 0000008146 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-31 0000008146 us-gaap:CommonStockMember 2022-04-30 0000008146 us-gaap:AdditionalPaidInCapitalMember 2022-04-30 0000008146 us-gaap:RetainedEarningsMember 2022-04-30 0000008146 us-gaap:TreasuryStockMember 2022-04-30 0000008146 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-30 iso4217:USD shares utr:Year pure utr:sqft iso4217:USD shares alot:Segment false Q1 0000008146 --01-31 10-Q true 2023-04-29 2023 false 0-13200 AstroNova, Inc. RI 05-0318215 600 East Greenwich Avenue West Warwick RI 02893 401 828-4000 Common Stock ALOT NASDAQ Yes Yes Accelerated Filer true false false 7417715 5413000 3946000 19285000 21598000 53126000 51324000 2678000 2894000 80502000 79762000 13918000 14288000 20630000 21232000 14760000 14658000 6907000 6907000 858000 794000 1621000 1566000 139196000 139207000 8000000 8479000 3267000 2750000 3484000 3308000 15900000 15900000 2100000 2100000 1600000 1725000 379000 562000 730000 786000 1971000 1888000 37431000 37498000 11678000 12040000 3102000 3415000 581000 555000 491000 491000 267000 674000 172000 167000 53722000 54840000 10 10 100000 100000 0 0 0 0 0.05 0.05 13000000 10780934 10676851 538000 534000 61526000 61131000 60023000 59175000 3368219 3342032 34585000 34235000 -2028000 -2238000 85474000 84367000 139196000 139207000 35419000 31010000 23034000 20281000 12385000 10729000 6010000 5883000 1788000 1522000 3126000 2560000 10924000 9965000 1461000 764000 615000 175000 186000 -135000 -5000 31000 -434000 -279000 1027000 485000 179000 60000 848000 425000 0.12 0.06 0.11 0.06 7370000 7263000 7450000 7361000 848000 425000 210000 -933000 0 -16000 210000 -917000 1058000 -492000 10566404 528000 59692000 56514000 -33974000 -1748000 81012000 337000 337000 11164 1000 87000 0 88000 61513 3000 -3000 -249000 -249000 425000 425000 -917000 -917000 10639081 532000 60113000 56939000 -34223000 -2665000 80696000 10676851 534000 61131000 59175000 -34235000 -2238000 84367000 356000 356000 4094 0 43000 43000 99989 4000 -4000 -350000 -350000 848000 848000 210000 210000 10780934 538000 61526000 60023000 -34585000 -2028000 85474000 848000 425000 1055000 912000 6000 7000 356000 337000 -2324000 1489000 0 -3135000 1756000 2650000 38000 502000 8000 -2843000 237000 -50000 2642000 -1614000 48000 50000 -48000 -50000 18000 69000 25000 19000 350000 249000 0 3000000 500000 500000 375000 250000 -1182000 2089000 55000 53000 1467000 478000 3946000 5276000 5413000 5754000 538000 53000 235000 -440000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 1 – Business and Basis of Presentation </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Overview </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Headquartered in West Warwick, Rhode Island, AstroNova, Inc. leverages its expertise in data visualization technologies to design, develop, manufacture and distribute a broad range of specialty printers and data acquisition and analysis systems. Our products are employed around the world in a wide range of applications in the aerospace, apparel, automotive, avionics, chemical, computer peripherals, communications, distribution, food and beverage, general manufacturing, packaging and transportation industries. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our business consists of two </div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">segments, Product Identification (“PI”) and Test &amp; Measurement (“T&amp;M”). The PI segment includes specialty printing systems and related supplies sold under the QuickLabel<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">®</div>, TrojanLabel<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">®</div> and GetLabels<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">™</div> brand names. The T&amp;M segment consists of our line of aerospace products, including flight deck printers, networking hardware, and related accessories as well as T&amp;M data acquisition systems sold under the AstroNova<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">®</div> brand name. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August 4, 2022, we acquired Astro Machine LLC (“Astro Machine”), an Illinois-based manufacturer of printing equipment, including label printers and related accessories, tabbers, conveyors, and envelope feeders. We reported Astro Machine as a part of our PI segment beginning in the third quarter of fiscal 2023. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">PI products sold under the QuickLabel, TrojanLabel and GetLabels brands are used in brand owner and commercial applications to provide product packaging, marketing, tracking, branding, and labeling solutions to a wide array of industries. The PI segment offers a variety of digital color label tabletop printers and light commercial label printers, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">direct-to-package</div></div> printers, high-volume presses, and specialty original equipment manufacturer (“OEM”) printing systems, as well as a wide range of label, tag and flexible packaging material substrates and other supplies, including ink and toner, allowing customers to mark, track, protect and enhance the appearance of their products. PI products sold under the Astro Machine brand also include a variety of label printers, envelope and packaging printing, and related processing and handling equipment. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the T&amp;M segment, we have a long history of using our technologies to provide networking systems and high-resolution flight deck and cabin printers for the aerospace market. In addition, the T&amp;M segment includes data acquisition recorders, sold under the AstroNova brand, to enable our customers to acquire and record visual and electronic signal data from local and networked data streams and sensors. The recorded data is processed, analyzed, stored and presented in various visual output formats. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our PI products are sold by direct field salespersons as well as independent dealers and representatives, while our T&amp;M products are sold predominantly through direct sales and manufacturers’ representatives. In the United States, we have factory-trained direct field salespeople located throughout the country specializing in PI products. We also have direct field sales or service centers in Canada, China, Denmark, France, Germany, Malaysia, Mexico, Singapore, and the United Kingdom staffed by our own employees and dedicated third party contractors. Additionally, we utilize over 100 independent dealers and representatives selling and marketing our products in over 60 countries. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Unless otherwise indicated, references to “AstroNova”, “we,” “our,” and “us” in this Quarterly Report on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form 10-Q</div> refer to AstroNova, Inc. and its consolidated subsidiaries. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles and reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair presentation of the results of the interim periods included herein. These financial statements do not include all disclosures associated with annual financial statements and, accordingly, should be read in conjunction with our Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the fiscal year ended January 31, 2023. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">The presentation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported and disclosed in the condensed consolidated financial statements and accompanying notes, including those that require consideration of forecasted financial information using information that is reasonably available to us at this time. Some of the more significant estimates relate to revenue recognition; the allowances for doubtful accounts; inventory valuation; income taxes; valuation of long-lived assets, intangible assets and goodwill; share-based compensation; and warranty reserves. Management’s estimates are based on the facts and circumstances available at the time estimates are made, historical experience, risk of loss, general economic conditions and trends, and management’s assessments of the probable future outcome of these matters, including our expectations at the time regarding the ongoing impact from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. Consequently, actual results could differ from those estimates. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Results of operations for the interim periods presented herein are not necessarily indicative of the results that may be expected for the full year. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain amounts in the prior year’s financial statements have been reclassified to conform to the current year’s presentation. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Principles of Consolidation </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying condensed consolidated financial statements include the accounts of AstroNova, Inc. and its wholly-owned subsidiaries. All significant intercompany accounts and transactions are eliminated in consolidation. </div></div> 2 <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Principles of Consolidation </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying condensed consolidated financial statements include the accounts of AstroNova, Inc. and its wholly-owned subsidiaries. All significant intercompany accounts and transactions are eliminated in consolidation. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 2 – Summary of Significant Accounting Policies Update </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The accounting policies used in preparing the condensed consolidated financial statements in this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> are the same as those used in preparing our consolidated financial statements included in our Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the fiscal year ended January 31, 2023. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recently Adopted Accounting Pronouncements </div></div></div></div><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No new accounting pronouncements, issued or effective during the first three months of the current year, have had or are expected to have a material impact on our consolidated financial statements. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recently Adopted Accounting Pronouncements </div></div></div></div><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No new accounting pronouncements, issued or effective during the first three months of the current year, have had or are expected to have a material impact on our consolidated financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 3 – Acquisitions </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Astro Machine </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August 4, 2022, we acquired Astro Machine LLC (“Astro Machine”), an Illinois-based manufacturer of printing equipment, including label printers, tabbers, conveyors, and envelope feeders, for aggregate consideration of $17.1 million. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The acquisition was accomplished pursuant to an Equity Interest Purchase Agreement dated as of August 4, 2022 (the “Purchase Agreement”) by and among us, GSND Holding Corporation (“GSND”), the parent company of Astro Machine, and Astro Machine. Pursuant to the Purchase Agreement, we purchased 100% of the issued and outstanding equity interests of Astro Machine from GSND for a purchase price of $15.6 million. The acquisition was funded using borrowings under our credit facility. We obtained a representation and warranty insurance policy and placed $300,000 of the purchase price into an escrow account, which pursuant to the terms and conditions of the Purchase Agreement, are our sole recourse for breaches of representations and warranties by GSND. Upon the closing of the transaction, Astro Machine became a wholly owned subsidiary of AstroNova, Inc. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concurrently with the signing of the Purchase Agreement, our newly acquired subsidiary, Astro Machine, entered into a Purchase and Sale Agreement with Selak Real Estate Limited Partnership (“SRE”), pursuant to which Astro Machine purchased certain real property assets of SRE for a purchase price, paid in cash, of $1.5 million. These real estate assets are comprised of a 34,460 square foot industrial manufacturing building (including offices) on 1.26 acres of land, which is Astro Machine’s principal place of business. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This transaction was a business combination and accounted for using the acquisition method of accounting prescribed by ASC 805, “Business Combinations” (“ASC 805”), whereby the results of operations, including the revenues and earnings of Astro Machine, are included in our financial statements from the date of acquisition. The purchase price of Astro Machine was allocated to the tangible and intangible assets acquired and liabilities assumed and recognized at their fair value based on widely accepted valuation techniques in accordance with ASC 820, “Fair Value Measurement,” as of the acquisition date. The process for estimating fair values requires the use of significant estimates, assumptions and judgments, including determining the timing and estimates of future cash flows and developing appropriate discount rates. The excess of the purchase price over the fair value of the net identified assets acquired and liabilities assumed was recorded as goodwill. ASC 805 establishes a measurement period to provide companies with a reasonable amount of time to obtain the information necessary to identify and measure various items in a business combination and cannot extend beyond one year from the acquisition date. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the final purchase price allocation of the Astro Machine acquisition for the estimated fair value of the net assets acquired and liabilities assumed as of the date of acquisition: </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 88%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;">(In thousands)</td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">91</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts Receivable</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,393</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,715</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, Plant and Equipment</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,200</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identifiable Intangible Assets</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,480</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,730</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts Payable and Other Current Liabilities</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,484</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Purchase Price</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,125</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table><div style="clear: both; max-height: 0px;"/><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the intangible assets acquired was estimated by applying the income approach. This fair value measurement is based on significant inputs that are not observable in the market and therefore represents a Level 3 measurement as defined in ASC 820, “Fair Value Measurement.” Key assumptions in estimating the fair value of the intangibles include (1) remaining useful life of the tradename/trademarks and customer relations (2) royalty rate of </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">0.75%, (3) customer attrition rate of 18.0%, (4) discount rate of 19.0</div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% and (5) a range of revenue and net income projections for fiscal years 2023 through 2026. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the fair value of the acquired identifiable intangible assets and related estimated useful lives: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 80%;"/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">(In thousands)</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Useful Life<br/> (years)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer Relations</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,060</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trademarks/Tradenames</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">420</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,480</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td></tr></table><div style="clear: both; max-height: 0px;"/><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Customer Relations intangible asset represents the relationships that will be maintained with certain historical customers of Astro Machine. The trademark/tradename intangible assets reflect the industry reputation of the Astro Machine name and the registered trademarks held by Astro Machine for the use of several marks and logos. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill of $2.73 </div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million, which is not deductible for tax purposes, represents the excess of the purchase price over the estimated fair value assigned to the tangible and identifiable intangible assets acquired and liabilities assumed from Astro Machine. The goodwill recognized under ASC 805 is attributable to synergies which are expected to enhance and expand our overall product portfolio, opportunities in new and existing markets, future technologies that have yet to be determined and Astro Machine’s assembled workforce. The carrying amount of the goodwill was allocated to the PI segment. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total acquisition-related costs of $0.7 million were included in general and administrative expenses in our consolidated statement of income for the year ended January 31, 2023. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amounts of revenue and earnings before taxes included in our consolidated statement of income for the quarter ended April 29, 2023: </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 90%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(In thousands)</div></div></td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,229</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnings before Taxes</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">689</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr></table><div style="clear: both; max-height: 0px;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Astro Machine results are reported as part of the PI segment. Proforma results are not provided, as disclosure of such amounts was impractical to determine as the acquired business had insufficient financial records and no audit history prior to the transaction. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Honeywell Asset Purchase and License Agreement </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">On June 30, 2022, we entered into an Asset Purchase and License Agreement with Honeywell International Inc. (“New HW Agreement”) to acquire an exclusive, perpetual, world-wide license to manufacture Honeywell’s flight deck printers for the Boeing 787 aircraft. The New HW Agreement provides for royalty payments to Honeywell based on gross revenues from the sales of the printers, paper and repair services of the licensed products in perpetuity. The royalty rates vary based on the year in which they are paid or earned and as products are sold or as services are provided and range from single-digit to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-double-digit</div> percentages of gross revenue. The New HW Agreement includes a provision for guaranteed minimum royalty payments to be paid in the event that the royalties earned by Honeywell do not meet the minimum for the preceding calendar year as follows: $</div>100,000 in 2024, $200,000 in 2025, $233,000 in 2026 and 2027, and $234,000 in 2028. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This transaction was evaluated under ASC 805, “Business Combinations,” and was accounted for as an asset acquisition. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The purchase price was allocated to the customer relationship intangible, which was the only asset acquired as a result of this transaction. This asset will be amortized over the useful life of the intangible. The minimum royalty payment obligation and related customer relationships intangible were recorded at the present value of the minimum royalty payments. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The acquired identifiable intangible asset is as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 81%;"/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">(In thousands)</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Useful Life<br/> (Years)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer Contract Relationships</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">530</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr></table><div style="clear: both; max-height: 0px;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The minimum royalty payment due was discounted based on the payment schedule and applicable discount rate, resulting in an outstanding royalty obligation of $0.5 million as of January 31, 2023, including $0.1 million recorded as a current liability. As of April 29, 2023, the current outstanding royalty obligation remains $0.5 million, including $0.1 million recorded as a current liability in the accompanying balance sheet. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional royalties based on sales activity will be recorded in the period that the associated revenue is earned. During fiscal 2023, we incurred $0.1 </div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million in excess royalty expense, which was recorded as a current liability in our consolidated balance sheet at January 31, 2023 and was paid in the first quarter of the current fiscal year. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> 17100000 1 15600000 300000 1500000 34460 1.26 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the final purchase price allocation of the Astro Machine acquisition for the estimated fair value of the net assets acquired and liabilities assumed as of the date of acquisition: </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 88%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;">(In thousands)</td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">91</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts Receivable</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,393</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,715</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, Plant and Equipment</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,200</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Identifiable Intangible Assets</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,480</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,730</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts Payable and Other Current Liabilities</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,484</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Purchase Price</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,125</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> 91000 3393000 5715000 4200000 3480000 2730000 2484000 17125000 0.0075 0.18 0.19 <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the fair value of the acquired identifiable intangible assets and related estimated useful lives: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 80%;"/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">(In thousands)</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Useful Life<br/> (years)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer Relations</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,060</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trademarks/Tradenames</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">420</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,480</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td></tr></table> 3060000 P5Y 420000 P5Y 3480000 2730000 700000 <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amounts of revenue and earnings before taxes included in our consolidated statement of income for the quarter ended April 29, 2023: </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 90%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(In thousands)</div></div></td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,229</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnings before Taxes</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">689</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr></table> 4229000 689000 100000 200000 233000 233000 234000 <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The acquired identifiable intangible asset is as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 81%;"/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">(In thousands)</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Useful Life<br/> (Years)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer Contract Relationships</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">530</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr></table> 530000 P20Y 500000 100000 500000 100000 100000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 4 – Revenue Recognition </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We derive revenue from the sale of (i) hardware, including digital color label printers and specialty OEM printing systems, portable data acquisition systems and airborne printers and networking hardware used in the flight deck and cabin of military, commercial and business aircraft, (ii) related supplies required in the operation of the hardware, (iii) repairs and maintenance of hardware and (iv) service agreements. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenues disaggregated by primary geographic markets and major product types are as follows: </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Primary geographical markets: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 80%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">(In thousands)</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 29,<br/> 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 30,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,834</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,651</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Europe</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,964</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,419</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Canada</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,825</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,854</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asia</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,294</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">937</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Central and South America</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,199</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">888</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">303</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">261</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Revenue</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,419</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,010</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table><div style="clear: both; max-height: 0px;"/><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Major product types: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 80%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">(In thousands)</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 29,<br/> 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 30,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hardware</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,667</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,301</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplies</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,070</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,944</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service and Other</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,682</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,765</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Revenue</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,419</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,010</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2022, we entered into an amended contract with one of our T&amp;M customers that provided for a total payment of $3.25 </div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">million to us as a result of our claims allowable under French law relating to additional component costs we have incurred and will continue to incur in order to supply aerospace printers under the contract for the period beginning in April 2022 and continuing through 2025. Revenue from this arrangement will be recognized in proportion to the total estimated shipments through the end of the contract period. As of January 31, 2023, we have recognized $</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1.1 </div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">million in revenue and the remainder $</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2.15 </div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">million balance was recorded as deferred revenue. During the first quarter of fiscal 2024, we recognized an additional $</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">0.4 </div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million in revenue which is included in the condensed consolidated statement of income for the quarter ended April 29, 2023. The remaining revenue to be recognized will be based on our shipments of the printers during the remainder of fiscal years 2024 and 2025. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contract Assets and Liabilities </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We normally do not have contract assets, which are primarily unbilled accounts receivable that are conditional on something other than the passage of time. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our contract liabilities, which represent billings in excess of revenue recognized, are related to advanced billings for purchased service agreements and extended warranties. Contract liabilities were $443,000 and $412,000 at April 29, 2023 and January 31, 2023, respectively, and are recorded as deferred revenue in the accompanying condensed consolidated balance sheet. The increase in the deferred revenue balance during the three months ended April 29, 2023 is due to cash payments received in advance of satisfying performance obligations in the current period which was partially offset by $143,000 of revenue recognized during the period that was included in the deferred revenue balance at January 31, 2023. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contract Costs </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recognize an asset for the incremental costs of obtaining a contract with a customer if we expect the benefit of those costs to be longer than one year. We have determined that certain costs related to obtaining sales contracts for our aerospace printer products meet the requirement to be capitalized. These costs are deferred and amortized over the remaining useful life of these contracts, which we currently estimate to be approximately 18 years as of April 29, 2023. The balance of these contract assets at January 31, 2023 was $1.4 million. We amortized $19,000 and $16,000 of direct costs during the three months ended April 29, 2023 and April 30, 2022, respectively. The balance of deferred incremental direct costs net of accumulated amortization at April 29, 2023 was $1.3 million, of which $0.1 million is reported in other current assets and $1.2 million is reported in other assets in the accompanying condensed consolidated balance sheet. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Primary geographical markets: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 80%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">(In thousands)</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 29,<br/> 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 30,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,834</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,651</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Europe</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,964</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,419</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Canada</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,825</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,854</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asia</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,294</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">937</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Central and South America</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,199</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">888</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">303</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">261</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Revenue</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,419</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,010</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table><div style="clear: both; max-height: 0px;"/><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Major product types: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 80%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">(In thousands)</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 29,<br/> 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 30,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hardware</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,667</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,301</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplies</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,070</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,944</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service and Other</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,682</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,765</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Revenue</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,419</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,010</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> 22834000 19651000 7964000 7419000 1825000 1854000 1294000 937000 1199000 888000 303000 261000 35419000 31010000 11667000 9301000 19070000 17944000 4682000 3765000 35419000 31010000 3250000 1100000 2150000 400000 443000 412000 143000 P18Y 1400000 19000 16000 1300000 100000 1200000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 5 – Net Income Per Common Share </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net income per share is calculated by dividing net income by the weighted average number of shares outstanding during the period. Diluted net income per share is calculated by dividing net income by the weighted average number of shares and, if dilutive, common equivalent shares, determined using the treasury stock method for stock options, restricted stock awards and restricted stock units outstanding during the period. A reconciliation of the shares used in calculating basic and diluted net income per share is as follows: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 76%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 29,<br/> 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 30,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted Average Common Shares Outstanding – Basic</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,369,930</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,262,797</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of Dilutive Options, Restricted Stock Awards and Restricted Stock Units</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80,122</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">97,713</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted Average Common Shares Outstanding – Diluted</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,450,052</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,360,510</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="clear:both;max-height:0pt;"/> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the three months ended April 29, 2023 and April 30, 2022, the diluted per share amounts do not reflect common equivalent shares outstanding of 656,554 and 310,588, respectively, because of their anti-dilutive effect.</div></div> A reconciliation of the shares used in calculating basic and diluted net income per share is as follows: <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 76%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 29,<br/> 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 30,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted Average Common Shares Outstanding – Basic</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,369,930</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,262,797</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of Dilutive Options, Restricted Stock Awards and Restricted Stock Units</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80,122</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">97,713</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted Average Common Shares Outstanding – Diluted</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,450,052</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,360,510</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> 7369930 7262797 80122 97713 7450052 7360510 656554 310588 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 6 – Intangible Assets </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 38%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 29, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">(In thousands)</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Carrying<br/> Amount</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Amortization</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Currency<br/> Translation<br/> Adjustment</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net<br/> Carrying<br/> Amount</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Carrying<br/> Amount</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Amortization</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Currency<br/> Translation<br/> Adjustment</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net<br/> Carrying<br/> Amount</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Miltope:</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer Contract Relationships</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,100</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,857</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">243</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,100</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,777</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">323</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RITEC:</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer Contract Relationships</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,830</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,639</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,191</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,830</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,623</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,207</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TrojanLabel:</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Existing Technology</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,327</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,171</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">97</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">253</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,327</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,087</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">94</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">334</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distributor Relations</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">937</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(616</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">36</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">357</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">937</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(588</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">376</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Honeywell:</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer Contract Relationships</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,773</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,145</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,628</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,773</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,913</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,860</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Astro Machine:</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer Contract Relationships</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,060</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(459</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,601</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,060</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(306</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,754</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trademarks</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">420</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(63</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">357</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">420</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(42</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">378</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible Assets, net</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,447</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(19,950</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">133</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,630</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,447</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(19,336</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">121</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,232</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no impairments to intangible assets during the periods ended April 29, 2023 and April 30, 2022. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">With respect to the acquired intangibles included in the table above, amortization expense of $<div style="letter-spacing: 0px; top: 0px;;display:inline;">0.6<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div>million and $0.4 million has been included in the condensed consolidated statements of income for the three months ended April 29, 2023 and April 30, 2022, respectively. </div><br/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated amortization expense for the next five fiscal years is as follows: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 70%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(In thousands)</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remaining<br/>2024</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2025</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2026</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2027</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2028</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated amortization expense</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,786</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,723</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,723</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,723</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,281</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr></table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 38%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 29, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">(In thousands)</td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Carrying<br/> Amount</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Amortization</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Currency<br/> Translation<br/> Adjustment</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net<br/> Carrying<br/> Amount</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Carrying<br/> Amount</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Amortization</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Currency<br/> Translation<br/> Adjustment</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net<br/> Carrying<br/> Amount</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Miltope:</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer Contract Relationships</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,100</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,857</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">243</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,100</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,777</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">323</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RITEC:</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer Contract Relationships</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,830</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,639</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,191</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,830</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,623</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,207</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TrojanLabel:</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Existing Technology</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,327</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,171</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">97</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">253</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,327</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,087</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">94</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">334</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distributor Relations</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">937</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(616</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">36</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">357</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">937</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(588</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">376</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Honeywell:</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer Contract Relationships</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,773</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,145</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,628</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,773</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,913</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,860</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Astro Machine:</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer Contract Relationships</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,060</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(459</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,601</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,060</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(306</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,754</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trademarks</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">420</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(63</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">357</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">420</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(42</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">378</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible Assets, net</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,447</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(19,950</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">133</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,630</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,447</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(19,336</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">121</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,232</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> 3100000 2857000 243000 3100000 2777000 323000 2830000 1639000 1191000 2830000 1623000 1207000 2327000 2171000 97000 253000 2327000 2087000 94000 334000 937000 616000 36000 357000 937000 588000 27000 376000 27773000 12145000 15628000 27773000 11913000 15860000 3060000 459000 2601000 3060000 306000 2754000 420000 63000 357000 420000 42000 378000 40447000 19950000 133000 20630000 40447000 19336000 121000 21232000 0 0 600000 400000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated amortization expense for the next five fiscal years is as follows: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 70%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(In thousands)</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remaining<br/>2024</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2025</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2026</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2027</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2028</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated amortization expense</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,786</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,723</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,723</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,723</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,281</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr></table> 1786000 1723000 1723000 1723000 1281000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 7 – Inventories </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventories are stated at the lower of cost (standard and average methods) or net realizable value and include material, labor and manufacturing overhead. The components of inventories are as follows: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 69%;"/> <td style="width: 9%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 8%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(In thousands)</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 29, 2023</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31, 2023</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Materials and Supplies</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,624</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38,387</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Work-In-Process</div></div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,485</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,146</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finished Goods</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,221</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,221</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">64,330</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">62,754</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory Reserve</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,204</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,430</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53,126</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">51,324</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> The components of inventories are as follows:<div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 69%;"/> <td style="width: 9%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 8%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(In thousands)</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 29, 2023</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31, 2023</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Materials and Supplies</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,624</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38,387</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Work-In-Process</div></div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,485</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,146</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finished Goods</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,221</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,221</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">64,330</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">62,754</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory Reserve</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,204</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,430</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53,126</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">51,324</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> 40624000 38387000 1485000 1146000 22221000 23221000 64330000 62754000 11204000 11430000 53126000 51324000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 8 – Property, Plant and Equipment </div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, plant and equipment consist of the following: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 77%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 29,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/>(In thousands)<div style="letter-spacing: 0px; top: 0px;;display:inline;"/></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Land and Land Improvements</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,304</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,304</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Buildings and Leasehold Improvements</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,162</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,158</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Machinery and Equipment</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,012</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24,960</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer Equipment and Software</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,996</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,972</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross Property, Plant and Equipment</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55,474</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55,394</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated Depreciation</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(41,556</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(41,106</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Property Plant and Equipment</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,918</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,288</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> <div style="clear: both; max-height: 0px;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation expense on property, plant and equipment was $0.4 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million for the each of the quarters ended April 29, 2023 and April 30, 2022. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, plant and equipment consist of the following: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 77%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 29,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/>(In thousands)<div style="letter-spacing: 0px; top: 0px;;display:inline;"/></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Land and Land Improvements</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,304</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,304</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Buildings and Leasehold Improvements</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,162</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,158</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Machinery and Equipment</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,012</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24,960</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer Equipment and Software</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,996</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,972</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross Property, Plant and Equipment</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55,474</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55,394</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated Depreciation</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(41,556</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(41,106</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Property Plant and Equipment</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,918</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,288</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> 2304000 2304000 14162000 14158000 25012000 24960000 13996000 13972000 55474000 55394000 41556000 41106000 13918000 14288000 400000 400000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 9 – Credit Agreement and Long-Term Debt </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the purchase of Astro Machine, on August 4, 2022, we entered into a Second Amendment to the Amended and Restated Credit Agreement (the “Second Amendment”) with Bank of America, N.A., as lender (the “Lender”). The Second Amendment amended the Amended and Restated Credit Agreement dated as of July 30, 2020, as amended by the First Amendment to Amended and Restated Credit Agreement, dated as of March 24, 2021, and the LIBOR Transition Amendment, dated as of December 24, 2021 (the “Existing Credit Agreement,” and the Existing Credit Agreement as amended by the Second Amendment, the “Amended Credit Agreement”), between us and the Lender. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Amended Credit Agreement provides for (i) a new term loan in the principal amount of $6.0 million, which term loan was in addition to the existing term loan outstanding under the Existing Credit Agreement in the principal amount of $9.0 million as of the effective date of the Second Amendment, and (ii) an increase in the aggregate principal amount of the revolving credit facility available thereunder from $22.5 million to $25.0 million. At the closing of the Second Amendment, we borrowed the entire $6.0 million term loan and $12.4 million under the revolving credit facility, and the proceeds of such borrowings were used in part to pay the purchase price payable under the Purchase Agreement and certain related transaction costs. The revolving credit facility may otherwise be used for corporate purposes. </div><br/></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Amended Credit Agreement requires that the term loan be paid in quarterly installments on the last day of each of our fiscal quarters over the term of the Amended Credit Agreement on the following repayment schedule: the principal amount of each quarterly installment required to be paid on the last day of each of our fiscal quarters ending on or about October 31, 2022 through July 31, 2023 is $</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">375,000; and the principal amount of each quarterly installment required to be paid on the last day of each of our fiscal quarters ending on or about October 31, 2023 through April 30, 2027 is $675,000. The entire remaining principal balance of the term loan is required to be paid on August 4, 2027. We may voluntarily prepay the term loan, in whole or in part, from time to time without premium or penalty (other than customary breakage costs, if applicable). We may repay borrowings under the revolving credit facility at any time without premium or penalty (other than customary breakage costs, if applicable), but in any event no later than August 4, 2027, and any outstanding revolving loans thereunder will be due and payable in full, and the revolving credit facility will terminate, on such date. We may reduce or terminate the revolving line of credit at any time, subject to certain thresholds and conditions, without premium or penalty. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The interest rates under the Amended Credit Agreement are as follows: the term loan and revolving credit loans bear interest at a rate per annum equal to, at our option, either (a) the BSBY Rate as defined in the Amended Credit Agreement (or, in the case of revolving credit loans denominated in a currency other than U.S. Dollars, the applicable quoted rate), plus a margin that varies within a range of 1.60% to 2.50% based on our consolidated leverage ratio, or (b) a fluctuating reference rate equal to the highest of (i) the federal fund rate plus 0.50%, (ii) Bank of America’s publicly announced prime rate, (iii) the BSBY Rate plus 1.00%, or (iv) 0.50%, plus a margin that varies within a range of 0.60% to 1.50% based on our consolidated leverage ratio. In addition to certain other fees and expenses that we are required to pay to the Lender, we are required to pay a commitment fee on the undrawn portion of the revolving credit facility that varies within a range of 0.15% and 0.35% based on our consolidated leverage ratio. The loans under the Amended Credit Agreement are subject to certain mandatory prepayments, subject to various exceptions, from (a) net cash proceeds from certain dispositions of property, (b) net cash proceeds from certain issuances of equity, (c) net cash proceeds from certain issuances of additional debt and (d) net cash proceeds from certain extraordinary receipts.</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts repaid under the revolving credit facility may be reborrowed, subject to our continued compliance with the Amended Credit Agreement. No amount of the term loan that is repaid may be reborrowed. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We must comply with various customary financial and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> covenants under the Amended Credit Agreement. The financial covenants under the Amended Credit Agreement consist of a maximum consolidated leverage ratio, a minimum consolidated fixed charge coverage ratio and a minimum consolidated asset coverage ratio. The primary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> covenants limit our and our subsidiaries’ ability to incur future indebtedness, to place liens on assets, to pay dividends or distributions on our or our subsidiaries’ capital stock, to repurchase or acquire our or our subsidiaries’ capital stock, to conduct mergers or acquisitions, to sell assets, to alter our or our subsidiaries’ capital structure, to make investments and loans, to change the nature of our or our subsidiaries’ business, and to prepay subordinated indebtedness, in each case subject to certain exceptions and thresholds as set forth in the Amended Credit Agreement, certain of which provisions were modified by the Second Amendment. As of April 29, 2023, we believe we are in compliance with all of the covenants in the Credit Agreement. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Lender is entitled to accelerate repayment of the loans and to terminate its revolving credit commitment under the Amended Credit Agreement upon the occurrence of any of various customary events of default, which include, among other events, the following (which are subject, in some cases, to certain grace periods): failure to pay when due any principal, interest or other amounts in respect of the loans, breach of any of our covenants or representations under the loan documents, default under any other of our or our subsidiaries’ significant indebtedness agreements, a bankruptcy, insolvency or similar event with respect to us or any of our subsidiaries, a significant unsatisfied judgment against us or any of our subsidiaries, or a change of control. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our obligations under the Amended Credit Agreement continue to be secured by substantially all of our personal property assets (including a pledge of the equity interests we hold in ANI ApS, AstroNova GmbH and AstroNova SAS), subject to certain exceptions, and by a mortgage on our owned real property in West Warwick, Rhode Island, and are guaranteed by, and secured by substantially all of the personal property assets of Astro Machine. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary of Outstanding Debt </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At April 29, 2023, we ha<div style="letter-spacing: 0px; top: 0px;;display:inline;">d</div> an outstanding balance of $15.9 million on our revolving line of credit. The balance outstanding under the revolving line of credit bore interest at a weighted average annual rate of 6.93% and 4.26% and we incurred $292,000 and $23,000 for interest on this obligation during the quarters ended April 29, 2023 and April 30, 2022, respectively. Additionally, during the quarters ended April 29, 2023 and April 30, 2022, we incurred $8,000 and $10,000, respectively, of commitment fees on the undrawn portion of our revolving credit facility. Both the interest expense and commitment fees are included as interest expense in the accompanying condensed consolidated income statement for the quarters ended April 29, 2023 and April 30, 2022. At April 29, 2023, there <div style="letter-spacing: 0px; top: 0px;;display:inline;">wa</div>s $9.1 million remaining available for borrowing under the revolving line of credit. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"/><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term debt in the accompanying condensed consolidated balance sheets is as follows: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 77%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/>(In thousands)<div style="letter-spacing: 0px; top: 0px;;display:inline;"/></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 29,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">USD Term Loan (7.24% as of April 29, 2023 and 6.78% as of January 31, 2023); maturity date of August 4, 2027</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,875</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,250</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,875</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,250</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt Issuance Costs, net of accumulated amortization</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(97</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(110</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current Portion of Term Loan</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,100</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,100</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-Term Debt</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,678</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,040</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the three months ended April 29, 2023 and April 30, 2022, we recognized $248,000 and $53,000 of interest expense, respectively, which was included in other expense in the accompanying condensed consolidated income statement. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The schedule of required principal payments remaining during the next five years on long-term debt outstanding as of April 29, 2023 is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 88%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(In thousands)</div></div></td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fiscal 2024, remainder</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,725</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fiscal 2025</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,700</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fiscal 2026</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,700</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fiscal 2027</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,700</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fiscal 2028</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,050</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,875</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> 6000000 9000000 22500000 25000000 6000000 12400000 375000000 675000000 0.016 0.025 0.005 0.01 0.50 0.006 0.015 0.0015 0.0035 15900000 0.0693 0.0426 292000000 23000000 8000000 10000000 9100000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term debt in the accompanying condensed consolidated balance sheets is as follows: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 77%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/>(In thousands)<div style="letter-spacing: 0px; top: 0px;;display:inline;"/></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 29,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">USD Term Loan (7.24% as of April 29, 2023 and 6.78% as of January 31, 2023); maturity date of August 4, 2027</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,875</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,250</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,875</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,250</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt Issuance Costs, net of accumulated amortization</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(97</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(110</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current Portion of Term Loan</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,100</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,100</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-Term Debt</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,678</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,040</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> 13875000 14250000 13875000 14250000 97000 110000 2100000 2100000 11678000 12040000 248000000 53000000 <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The schedule of required principal payments remaining during the next five years on long-term debt outstanding as of April 29, 2023 is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 88%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(In thousands)</div></div></td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fiscal 2024, remainder</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,725</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fiscal 2025</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,700</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fiscal 2026</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,700</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fiscal 2027</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,700</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fiscal 2028</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,050</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,875</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> 1725000 2700000 2700000 2700000 4050000 13875000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 10 – </div></div><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Royalty Obligation </div></div></div> <div style="clear: both; max-height: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In fiscal 2018, we entered into an Asset Purchase and License Agreement with Honeywell International, Inc. (“Honeywell”) to acquire an exclusive, perpetual, world-wide license to manufacture Honeywell’s narrow-format flight deck printers for two aircraft families along with certain inventory used in the manufacturing of the licensed printers. The purchase price included a guaranteed minimum royalty payment of $15.0 million, to be paid over <div style="letter-spacing: 0px; top: 0px;;display:inline;">ten years</div>, based on gross revenues from the sales of the printers, paper and repair services of the licensed products. The royalty rates vary based on the year in which they are paid or earned, and product sold or service provided, and range from single-digit to mid double-digit percentages of gross revenue. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The guaranteed minimum royalty payment obligation was recorded at the present value of the minimum annual royalty payments. As of April 29, 2023, we had paid an aggregate of $10.0 million of the guaranteed minimum royalty obligation. At April 29, 2023, the current portion of the outstanding guaranteed minimum royalty obligation of $1.5 million is to be paid over the next twelve months and is reported as a current liability and the remainder of $2.7 million is reported as a long-term liability on our condensed consolidated balance sheet. We incurred $0.4 million in excess royalty expense for the three-month period ended April 29, 2023, which is included in cost of revenue in our consolidated statements of income. A total of $0.4 million in excess royalties was paid in the first quarter of the current fiscal year<div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div> and there are $0.4 million in excess royalty payables due as a result of this agreement for the quarter ended April 29, 2023. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In fiscal 2023, AstroNova, Inc. entered into a second Asset Purchase and License Agreement with Honeywell International, Inc. as further discussed in Note 3 “Acquisitions”. </div></div></div> 15000000 P10Y 10000000 1500000 2700000 400000 400000 400000 <div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 11 – Leases </div></div></div></div> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We enter into lease contracts for certain of our facilities at various locations worldwide. Our leases have remaining lease terms of one to six years. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance sheet and other information related to our leases is as follows: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 44%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating Leases</div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance Sheet Classification</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 29,<br/>2023</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31,<br/>2023</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 44%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease Assets</div></div></div></td> <td style="vertical-align: bottom; width: 5%;"><div style="display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">Right of Use Assets</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; width: 5%;"><div style="display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td> <td style="vertical-align: bottom;;text-align:right;">858</td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; width: 5%;"><div style="display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td> <td style="vertical-align: bottom;;text-align:right;">794</td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 44%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease Liabilities – Current</div></div></div></td> <td style="vertical-align: bottom; width: 5%;"><div style="display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">Other Liabilities and Accrued Expenses</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; width: 5%;"><div style="display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;;text-align:right;">312</td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; width: 5%;"><div style="display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td> <td style="vertical-align: bottom;;text-align:right;">275</td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 44%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease Liabilities – Long Term</div></div></div></td> <td style="vertical-align: bottom; width: 5%;"><div style="display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">Lease Liabilities</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; width: 5%;"><div style="display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;;text-align:right;">581</td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; width: 5%;"><div style="display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td> <td style="vertical-align: bottom;;text-align:right;">555</td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> </div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease cost information is as follows: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 50%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating Leases</div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Statement of Income Classification</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 29,<br/>2023</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 30,<br/>2022</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating Lease Costs</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">General and Administrative Expense</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">133</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">113</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr></table><div style="clear: both; max-height: 0px;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturities of operating lease liabilities are as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 89%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 29,<br/> 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024, remaining</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">263</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">258</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">199</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2027</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">151</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2028</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">93</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Lease Payments</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">964</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Imputed Interest</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(71</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Lease Liabilities</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">893</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"/><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of April 29, 2023, the weighted-average remaining lease term and weighted-average discount rate for our operating leases are 3.5 years and 4.37%, respectively. We calculated the weighted-average discount rate using incremental borrowing rates, which equal the rates of interest that we would pay to borrow funds on a fully collateralized basis over a similar term. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental cash flow information related to leases is as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 80%;"/> <td style="width: 8%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 8%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 29,<br/> 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 30,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for amounts included in the measurement of lease liabilities:</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating cash flows for operating leases</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">93</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">83</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr></table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance sheet and other information related to our leases is as follows: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 44%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating Leases</div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance Sheet Classification</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 29,<br/>2023</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31,<br/>2023</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 44%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease Assets</div></div></div></td> <td style="vertical-align: bottom; width: 5%;"><div style="display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">Right of Use Assets</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; width: 5%;"><div style="display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td> <td style="vertical-align: bottom;;text-align:right;">858</td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; width: 5%;"><div style="display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td> <td style="vertical-align: bottom;;text-align:right;">794</td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 44%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease Liabilities – Current</div></div></div></td> <td style="vertical-align: bottom; width: 5%;"><div style="display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">Other Liabilities and Accrued Expenses</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; width: 5%;"><div style="display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;;text-align:right;">312</td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; width: 5%;"><div style="display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td> <td style="vertical-align: bottom;;text-align:right;">275</td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 44%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease Liabilities – Long Term</div></div></div></td> <td style="vertical-align: bottom; width: 5%;"><div style="display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">Lease Liabilities</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; width: 5%;"><div style="display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom;;text-align:right;">581</td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; width: 5%;"><div style="display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;">$</div></td> <td style="vertical-align: bottom;;text-align:right;">555</td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="display:inline;"> </div></td></tr></table> 858000 794000 312000 275000 581000 555000 <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease cost information is as follows: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 50%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating Leases</div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Statement of Income Classification</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 29,<br/>2023</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 30,<br/>2022</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating Lease Costs</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">General and Administrative Expense</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">133</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">113</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr></table> 133000 113000 <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturities of operating lease liabilities are as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 89%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 29,<br/> 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024, remaining</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">263</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">258</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">199</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2027</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">151</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2028</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">93</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Lease Payments</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">964</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Imputed Interest</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(71</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Lease Liabilities</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">893</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> 263000 258000 199000 151000 93000 0 964000 71000 893000 P3Y6M 0.0437 <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental cash flow information related to leases is as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 80%;"/> <td style="width: 8%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 8%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 29,<br/> 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 30,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for amounts included in the measurement of lease liabilities:</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating cash flows for operating leases</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">93</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">83</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr></table> 93000 83000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div></div> – Accumulated Other Comprehensive Loss </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The changes in the balance of accumulated other comprehensive loss (“AOCL”) by component are as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 73%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 8%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign Currency<br/> Translation<br/> Adjustments</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at January 31, 2023</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,238</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,238</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Other Comprehensive Income before reclassification</div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">210</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">210</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at April 29, 2023</div></div></td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(2,028</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(2,028</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">  </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">  </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="background-color: rgba(255, 255, 255, 0);"> </td></tr></table> <div style="clear: both; max-height: 0px;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amounts presented above in other comprehensive loss are net of taxes except for translation adjustments associated with our German and Danish subsidiaries. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The changes in the balance of accumulated other comprehensive loss (“AOCL”) by component are as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 73%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 8%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign Currency<br/> Translation<br/> Adjustments</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at January 31, 2023</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,238</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,238</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Other Comprehensive Income before reclassification</div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">210</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">210</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at April 29, 2023</div></div></td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(2,028</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(2,028</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">  </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">  </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="background-color: rgba(255, 255, 255, 0);"> </td></tr></table> -2238000 -2238000 210000 210000 -2028000 -2028000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div> – Share-Based Compensation </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have one equity incentive plan from which we are authorized to grant equity awards, the AstroNova, Inc. 2018 Equity Incentive Plan (the “2018 Plan”). The 2018 Plan provides for, among other things, the issuance of awards, including incentive stock options, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-qualified</div> stock options, stock appreciation rights, time-based restricted stock units (“RSUs”), or performance-based restricted stock units (“PSUs”) and restricted stock awards (“RSAs”). The 2018 Plan authorizes the issuance of up to 950,000 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">shares of common stock, plus an additional number of shares equal to the number of shares subject to awards granted under previous equity incentive plans that are forfeited, cancelled, satisfied without the issuance of stock, otherwise terminated (other than by exercise), or, </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">for shares of stock issued pursuant to any unvested award, that are reacquired by us at not more than the grantee’s purchase price (other than by exercise). Under the 2018 Plan, all awards to employees generally have a minimum vesting period of one year. Options granted under the 2018 Plan must be issued at an exercise price of not less than the fair market value of our common stock on the date of grant and expire after ten years. Under the 2018 Plan, there were </div></div>124,439 unvested RSUs; 188,633 unvested PSUs; 21,172 unvested RSAs and options to purchase an aggregate of 135,500 shares outstanding as of April 29, <div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:#ffffff;;display:inline;">2023. </div></div></div></div><div style="FONT-SIZE: 8pt; MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:#ffffff;;display:inline;"> </div></div></div></div><div style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 0pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-ALIGN: center"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:#ffffff;;display:inline;"> </div></div></div></div><div style="background-color:#ffffff;;display:inline;"> </div><div style="MARGIN-BOTTOM: 0em; MARGIN-TOP: 1em; PAGE-BREAK-BEFORE: always"/><div style="background-color:#ffffff;;display:inline;"> </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to the 2018 Plan, we previously granted equity awards under our 2015 Equity Incentive Plan (the “2015 Plan”) and our 2007 Equity Incentive Plan (the “2007 Plan”). No new awards may be issued under either the 2007 Plan or 2015 Plan, but outstanding awards will continue to be governed by those plans. As of April 29, 2023, options to purchase an aggregate of </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">270,649 shares were outstanding under the 2007 Plan and options to purchase an aggregate of 134,950 shares were outstanding under the 2015 Plan. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We also have a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Employee</div> Director Annual Compensation Program (the “Program”), under which each of our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors automatically receives a grant of restricted stock on the date of their <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-election</div> to our board of directors. The number of whole shares granted is equal to the number calculated by dividing the stock component of the director compensation amount determined by the compensation committee for that year by the fair market value of our stock on that day. The value of the restricted stock award for fiscal 2024 is approximately $65,000. Shares of restricted stock granted under the Program become vested on the first anniversary of the date of grant, conditioned upon the recipient’s continued service on our board of directors through that date. <br/></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expense was recognized as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 80%;"/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(In thousands)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 29,<br/> 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 30,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock Options</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted Stock Awards and Restricted Stock Units</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">352</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">328</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee Stock Purchase Plan</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">356</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">337</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> <div style="clear: both; max-height: 0px;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Options </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Aggregated information regarding stock option activity for the three months ended April 29, 2023 is summarized below: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 72%;"/> <td style="width: 8%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Options</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted Average<br/> Exercise Price</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at January 31, 2023</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">547,199</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15.16</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,700</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.50</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(175</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18.35</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Canceled</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,225</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.50</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at April 29, 2023</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">541,099</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15.21</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> <div style="clear: both; max-height: 0px;"/><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Set forth below is a summary of options outstanding at April 29, 2023: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 56%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td colspan="12" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding</div></div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercisable</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Range of</div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise prices</div></div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number<br/>of<br/>Shares</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/>Average<br/>Exercise<br/>Price</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/>Average<br/>Remaining<br/>Contractual Life</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number<br/>of<br/>Shares</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/>Average<br/>Exercise<br/>Price</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">$5.00-10.00</div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">$10.01-15.00</div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">326,924</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.74</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.7</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">326,924</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.74</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.7</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">$15.01-20.00</div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">214,175</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17.45</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.6</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">214,175</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17.45</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.6</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">541,099</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15.21</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.5</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">541,099</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15.21</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.5</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> <div style="clear: both; max-height: 0px;"/><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="clear:both;max-height:0pt;"/><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">stock options granted in fiscal 2023 and fiscal 2022, or in the first quarter of fiscal 2024, and as of April 29, 2023, there was</div> no unrecognized compensation expense related to stock options. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Units (RSUs), Performance-Based Stock Units (PSUs) and Restricted Stock Awards (RSAs) </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Aggregated information regarding RSU and RSA activity for the three months ended April 29, 2023 is summarized below: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 60%;"/> <td style="width: 14%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 13%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RSUs, PSUs &amp; RSAs</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted Average<br/>Grant Date Fair Value</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at January 31, 2023</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">274,927</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.82</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">142,811</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.48</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(78,817</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.85</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,677</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.49</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at April 29, 2023</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">334,244</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.90</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> <div style="clear: both; max-height: 0px;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of April 29, 2023, there was approximately $2.5 million of unrecognized compensation expense related to RSUs, PSUs and RSAs, which is expected to be recognized over a weighted average period of 1.2 years. </div><br/></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Employee Stock Purchase Plan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June 7, 2022, we adopted the AstroNova Inc. 2022 Employee Stock Purchase Plan (“2022 ESPP”) to replace our previous Employee Stock Purchase Plan (the “Prior ESPP”). The 2022 ESPP allows eligible employees to purchase shares of common stock at a 15% discount from fair value on the first or last day of an offering period, whichever is less. A total of 40,000 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">shares were reserved for issuance under the 2022 ESPP and </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5,045 shares were purchased under the 2022 ES<div style="letter-spacing: 0px; top: 0px;;display:inline;">P</div>P during the year ended January 31, 2023. During the three months ended April 29, 2023, there were 2,394 shares purchased under the 2022 ESPP. During the three months ended April 30, 2022, there were 1,550 shares purchased under the Prior ESPP, and no additional purchases may be made under the Prior ESPP. As of April 29, 2023, 32,560 shares remain available for purchase under the 2022 ESPP. </div></div> 950000 124439 188633 21172 135500 270649 134950 65000 <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expense was recognized as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 80%;"/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(In thousands)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 29,<br/> 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 30,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock Options</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted Stock Awards and Restricted Stock Units</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">352</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">328</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee Stock Purchase Plan</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">356</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">337</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> 0 6000 352000 328000 4000 3000 356000 337000 <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Aggregated information regarding stock option activity for the three months ended April 29, 2023 is summarized below: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 72%;"/> <td style="width: 8%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Options</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted Average<br/> Exercise Price</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at January 31, 2023</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">547,199</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15.16</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,700</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.50</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(175</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18.35</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Canceled</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,225</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.50</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at April 29, 2023</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">541,099</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15.21</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> 547199 15.16 0 0 1700 10.5 175 18.35 4225 10.5 541099 15.21 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Set forth below is a summary of options outstanding at April 29, 2023: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 56%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td colspan="12" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding</div></div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercisable</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Range of</div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise prices</div></div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number<br/>of<br/>Shares</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/>Average<br/>Exercise<br/>Price</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/>Average<br/>Remaining<br/>Contractual Life</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number<br/>of<br/>Shares</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/>Average<br/>Exercise<br/>Price</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">$5.00-10.00</div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">$10.01-15.00</div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">326,924</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.74</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.7</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">326,924</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.74</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.7</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">$15.01-20.00</div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">214,175</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17.45</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.6</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">214,175</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17.45</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.6</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">541,099</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15.21</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.5</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">541,099</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15.21</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.5</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> 5 10 0 0 0 0 10.01 15 326924 13.74 P2Y8M12D 326924 13.74 P2Y8M12D 15.01 20 214175 17.45 P4Y7M6D 214175 17.45 P4Y7M6D 541099 15.21 P3Y6M 541099 15.21 P3Y6M 0 0 0 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Aggregated information regarding RSU and RSA activity for the three months ended April 29, 2023 is summarized below: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 60%;"/> <td style="width: 14%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 13%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RSUs, PSUs &amp; RSAs</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted Average<br/>Grant Date Fair Value</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at January 31, 2023</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">274,927</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.82</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">142,811</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.48</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(78,817</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.85</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,677</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.49</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at April 29, 2023</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">334,244</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.90</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> 274927 12.82 142811 12.48 78817 11.85 4677 12.49 334244 12.9 2500000 P1Y2M12D 0.15 40000 5045 2394 1550 32560 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div> – Income Taxes </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our effective tax rates are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 85%;"/> <td style="width: 12%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">First Quarter<br/> Ended</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fiscal 2024</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17.4</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fiscal 2023</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.4</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We determine our estimated annual effective tax rate at the end of each interim period based on full-year forecasted <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> income and facts known at that time. The estimated annual effective tax rate is applied to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-to-date</div></div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> income at the end of each interim period with the cumulative effect of any changes in the estimated annual effective tax rate being recorded in the fiscal quarter in which the change is determined. The tax effect of significant unusual items is reflected in the period in which they occur. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the three months ended April 29, 2023, we recognized an income tax expense of approximately $179,000. The effective tax rate in this period was directly impacted by a $77,000 tax benefit related to the expiration of the statute of limitations on a previously uncertain tax position and a $29,000 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">tax benefit arising from windfall tax benefits related to our stock. During the three months ended April 30, 2022, we recognized an income tax expense of approximately $</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">60,000. The effective tax rate in this period was directly impacted by a $38,000 tax benefit related to the expiration of the statute of limitations on a previously uncertain tax position and a $30,000 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">tax benefit arising from windfall tax benefits related to our stock. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our effective tax rates are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 85%;"/> <td style="width: 12%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">First Quarter<br/> Ended</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fiscal 2024</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17.4</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fiscal 2023</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.4</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> </table> 0.174 0.124 179000 77000 29000 60000 38000 30000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div> – Segment Information </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We report two segments: PI and T&amp;M. We evaluate segment performance based on the segment profit before corporate expenses.</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Summarized below are the Revenue and Segment Operating Profit for each reporting segment: </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 66%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">  </div></td> <td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenue</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Segment Operating Profit</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></div></div></div> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 29,<br/>2023</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 30,<br/>2022</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 29,<br/>2023</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 30,<br/>2022</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">PI</div> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,095</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,724</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,515</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,413</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">T&amp;M</div></div> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,324</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,286</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,072</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,911</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 66%;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,419</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,010</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,587</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,324</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 66%;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Expenses</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td colspan="5" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,126</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,560</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td colspan="5" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating Income</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td colspan="5" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,461</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">764</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Expense, Net</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td colspan="5" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">434</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">279</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td colspan="5" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Before Income Taxes</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td colspan="5" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,027</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">485</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Income Tax Provision</div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td colspan="5" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">179</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td colspan="5" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Income</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td colspan="5" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">848</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">425</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td colspan="5" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Summarized below are the Revenue and Segment Operating Profit for each reporting segment: </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 66%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">  </div></td> <td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenue</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Segment Operating Profit</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></div></div></div> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 29,<br/>2023</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 30,<br/>2022</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 29,<br/>2023</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 30,<br/>2022</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">PI</div> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,095</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,724</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,515</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,413</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">T&amp;M</div></div> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,324</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,286</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,072</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,911</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 66%;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 66%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,419</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,010</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,587</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,324</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 66%;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Expenses</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td colspan="5" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,126</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,560</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td colspan="5" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating Income</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td colspan="5" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,461</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">764</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Expense, Net</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td colspan="5" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">434</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">279</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td colspan="5" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Before Income Taxes</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td colspan="5" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,027</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">485</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Income Tax Provision</div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td colspan="5" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">179</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td colspan="5" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Income</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td colspan="5" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">848</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">425</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td colspan="5" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td> </td> </tr> </table> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> 25095000 21724000 2515000 1413000 10324000 9286000 2072000 1911000 35419000 31010000 4587000 3324000 3126000 2560000 1461000 764000 -434000 -279000 1027000 485000 179000 60000 848000 425000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 1<div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div> – Fair Value </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets and Liabilities Not Recorded at Fair Value </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our long-term debt, including the current portion of long-term debt not reflected in the financial statements at fair value, is reflected in the table below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 69%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="18" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 29, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurement</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></div></div> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-Term debt and related current maturities</div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,937</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,937</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,875</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 69%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="18" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurement</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></div></div> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-Term debt and related current maturities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,310</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,310</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,250</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of our long-term debt, including the current portion, is estimated by discounting the future cash flows using current interest rates at which similar loans with the same maturities would be made to borrowers with similar credit ratings and is classified as Level 3. </div></div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our long-term debt, including the current portion of long-term debt not reflected in the financial statements at fair value, is reflected in the table below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 69%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="18" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">April 29, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurement</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></div></div> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-Term debt and related current maturities</div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,937</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,937</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,875</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 69%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="18" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurement</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></div></div> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-Term debt and related current maturities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,310</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,310</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,250</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> </table> 13937000 13937000 13875000 14310000 14310000 14250000 EXCEL 85 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 86 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 87 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 88 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 169 312 1 false 72 0 false 7 false false R1.htm 1001 - Document - Cover Page Sheet http://astro-med.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1002 - Statement - Condensed Consolidated Balance Sheets Sheet http://astro-med.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://astro-med.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1004 - Statement - Condensed Consolidated Statements of Income Sheet http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome Condensed Consolidated Statements of Income Statements 4 false false R5.htm 1005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) Sheet http://astro-med.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss Condensed Consolidated Statements of Comprehensive Income (Loss) Statements 5 false false R6.htm 1006 - Statement - Consolidated Statements of Changes in Shareholders' Equity Sheet http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity Consolidated Statements of Changes in Shareholders' Equity Statements 6 false false R7.htm 1007 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 1008 - Disclosure - Business and Basis of Presentation Sheet http://astro-med.com/role/BusinessAndBasisOfPresentation Business and Basis of Presentation Notes 8 false false R9.htm 1009 - Disclosure - Summary of Significant Accounting Policies Update Sheet http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesUpdate Summary of Significant Accounting Policies Update Notes 9 false false R10.htm 1010 - Disclosure - Acquisitions Sheet http://astro-med.com/role/Acquisitions Acquisitions Notes 10 false false R11.htm 1011 - Disclosure - Revenue Recognition Sheet http://astro-med.com/role/RevenueRecognition Revenue Recognition Notes 11 false false R12.htm 1012 - Disclosure - Net Income Per Common Share Sheet http://astro-med.com/role/NetIncomePerCommonShare Net Income Per Common Share Notes 12 false false R13.htm 1013 - Disclosure - Intangible Assets Sheet http://astro-med.com/role/IntangibleAssets Intangible Assets Notes 13 false false R14.htm 1014 - Disclosure - Inventories Sheet http://astro-med.com/role/Inventories Inventories Notes 14 false false R15.htm 1015 - Disclosure - Property, Plant and Equipment Sheet http://astro-med.com/role/PropertyPlantAndEquipment Property, Plant and Equipment Notes 15 false false R16.htm 1016 - Disclosure - Credit Agreement and Long-Term Debt Sheet http://astro-med.com/role/CreditAgreementAndLongTermDebt Credit Agreement and Long-Term Debt Notes 16 false false R17.htm 1017 - Disclosure - Royalty Obligation Sheet http://astro-med.com/role/RoyaltyObligation Royalty Obligation Notes 17 false false R18.htm 1018 - Disclosure - Leases Sheet http://astro-med.com/role/Leases Leases Notes 18 false false R19.htm 1019 - Disclosure - Accumulated Other Comprehensive Loss Sheet http://astro-med.com/role/AccumulatedOtherComprehensiveLoss Accumulated Other Comprehensive Loss Notes 19 false false R20.htm 1020 - Disclosure - Share-Based Compensation Sheet http://astro-med.com/role/ShareBasedCompensation Share-Based Compensation Notes 20 false false R21.htm 1021 - Disclosure - Income Taxes Sheet http://astro-med.com/role/IncomeTaxes Income Taxes Notes 21 false false R22.htm 1022 - Disclosure - Segment Information Sheet http://astro-med.com/role/SegmentInformation Segment Information Notes 22 false false R23.htm 1023 - Disclosure - Fair Value Sheet http://astro-med.com/role/FairValue Fair Value Notes 23 false false R24.htm 1024 - Disclosure - Summary of Significant Accounting Policies Update (Policies) Sheet http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesUpdatePolicies Summary of Significant Accounting Policies Update (Policies) Policies http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesUpdate 24 false false R25.htm 1025 - Disclosure - Acquisitions (Tables) Sheet http://astro-med.com/role/AcquisitionsTables Acquisitions (Tables) Tables http://astro-med.com/role/Acquisitions 25 false false R26.htm 1026 - Disclosure - Revenue Recognition (Tables) Sheet http://astro-med.com/role/RevenueRecognitionTables Revenue Recognition (Tables) Tables http://astro-med.com/role/RevenueRecognition 26 false false R27.htm 1027 - Disclosure - Net Income Per Common Share (Tables) Sheet http://astro-med.com/role/NetIncomePerCommonShareTables Net Income Per Common Share (Tables) Tables http://astro-med.com/role/NetIncomePerCommonShare 27 false false R28.htm 1028 - Disclosure - Intangible Assets (Tables) Sheet http://astro-med.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://astro-med.com/role/IntangibleAssets 28 false false R29.htm 1029 - Disclosure - Inventories (Tables) Sheet http://astro-med.com/role/InventoriesTables Inventories (Tables) Tables http://astro-med.com/role/Inventories 29 false false R30.htm 1030 - Disclosure - Property, Plant and Equipment (Tables) Sheet http://astro-med.com/role/PropertyPlantAndEquipmentTables Property, Plant and Equipment (Tables) Tables http://astro-med.com/role/PropertyPlantAndEquipment 30 false false R31.htm 1031 - Disclosure - Credit Agreement and Long-Term Debt (Tables) Sheet http://astro-med.com/role/CreditAgreementAndLongTermDebtTables Credit Agreement and Long-Term Debt (Tables) Tables http://astro-med.com/role/CreditAgreementAndLongTermDebt 31 false false R32.htm 1032 - Disclosure - Leases (Tables) Sheet http://astro-med.com/role/LeasesTables Leases (Tables) Tables http://astro-med.com/role/Leases 32 false false R33.htm 1033 - Disclosure - Accumulated Other Comprehensive Loss (Tables) Sheet http://astro-med.com/role/AccumulatedOtherComprehensiveLossTables Accumulated Other Comprehensive Loss (Tables) Tables http://astro-med.com/role/AccumulatedOtherComprehensiveLoss 33 false false R34.htm 1034 - Disclosure - Share-Based Compensation (Tables) Sheet http://astro-med.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://astro-med.com/role/ShareBasedCompensation 34 false false R35.htm 1035 - Disclosure - Income Taxes (Tables) Sheet http://astro-med.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://astro-med.com/role/IncomeTaxes 35 false false R36.htm 1036 - Disclosure - Segment Information (Tables) Sheet http://astro-med.com/role/SegmentInformationTables Segment Information (Tables) Tables http://astro-med.com/role/SegmentInformation 36 false false R37.htm 1037 - Disclosure - Fair Value (Tables) Sheet http://astro-med.com/role/FairValueTables Fair Value (Tables) Tables http://astro-med.com/role/FairValue 37 false false R38.htm 1038 - Disclosure - Business and Basis of Presentation - Additional Information (Detail) Sheet http://astro-med.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail Business and Basis of Presentation - Additional Information (Detail) Details 38 false false R39.htm 1039 - Disclosure - Acquisitions - Summary of Purchase Price of Acquisition Allocated on Basis of Fair Value (Detail) Sheet http://astro-med.com/role/AcquisitionsSummaryOfPurchasePriceOfAcquisitionAllocatedOnBasisOfFairValueDetail Acquisitions - Summary of Purchase Price of Acquisition Allocated on Basis of Fair Value (Detail) Details 39 false false R40.htm 1040 - Disclosure - Acquisitions - Summary of Fair Value of the Acquired Identifiable Intangible Assets and Related Estimated Useful Lives (Detail) Sheet http://astro-med.com/role/AcquisitionsSummaryOfFairValueOfTheAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail Acquisitions - Summary of Fair Value of the Acquired Identifiable Intangible Assets and Related Estimated Useful Lives (Detail) Details 40 false false R41.htm 1041 - Disclosure - Acquisitions - Summary of Revenue and Earnings Before Taxes (Detail) Sheet http://astro-med.com/role/AcquisitionsSummaryOfRevenueAndEarningsBeforeTaxesDetail Acquisitions - Summary of Revenue and Earnings Before Taxes (Detail) Details 41 false false R42.htm 1042 - Disclosure - Acquisitions - Summary of Acquired Identifiable Intangible Asset (Detail) Sheet http://astro-med.com/role/AcquisitionsSummaryOfAcquiredIdentifiableIntangibleAssetDetail Acquisitions - Summary of Acquired Identifiable Intangible Asset (Detail) Details 42 false false R43.htm 1043 - Disclosure - Acquisitions - Additional Information (Detail) Sheet http://astro-med.com/role/AcquisitionsAdditionalInformationDetail Acquisitions - Additional Information (Detail) Details 43 false false R44.htm 1044 - Disclosure - Revenue Recognition - Summary of Revenues Disaggregated by Primary Geographic Markets (Detail) Sheet http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryGeographicMarketsDetail Revenue Recognition - Summary of Revenues Disaggregated by Primary Geographic Markets (Detail) Details 44 false false R45.htm 1045 - Disclosure - Revenue Recognition - Summary of Revenues Disaggregated by Primary Product Type (Detail) Sheet http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryProductTypeDetail Revenue Recognition - Summary of Revenues Disaggregated by Primary Product Type (Detail) Details 45 false false R46.htm 1046 - Disclosure - Revenue Recognition - Additional Information (Detail) Sheet http://astro-med.com/role/RevenueRecognitionAdditionalInformationDetail Revenue Recognition - Additional Information (Detail) Details 46 false false R47.htm 1047 - Disclosure - Net Income Per Common Share - Reconciliation of Shares Used in Calculating Basic and Diluted (Detail) Sheet http://astro-med.com/role/NetIncomePerCommonShareReconciliationOfSharesUsedInCalculatingBasicAndDilutedDetail Net Income Per Common Share - Reconciliation of Shares Used in Calculating Basic and Diluted (Detail) Details 47 false false R48.htm 1048 - Disclosure - Net Income Per Common Share - Additional Information (Detail) Sheet http://astro-med.com/role/NetIncomePerCommonShareAdditionalInformationDetail Net Income Per Common Share - Additional Information (Detail) Details 48 false false R49.htm 1049 - Disclosure - Intangible Assets - Fair Value of Acquired Identifiable Intangible Assets and Related Estimated Useful Lives (Detail) Sheet http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail Intangible Assets - Fair Value of Acquired Identifiable Intangible Assets and Related Estimated Useful Lives (Detail) Details 49 false false R50.htm 1050 - Disclosure - Intangible Assets - Additional Information (Detail) Sheet http://astro-med.com/role/IntangibleAssetsAdditionalInformationDetail Intangible Assets - Additional Information (Detail) Details 50 false false R51.htm 1051 - Disclosure - Intangible Assets - Summary of Estimated Amortization Expense (Detail) Sheet http://astro-med.com/role/IntangibleAssetsSummaryOfEstimatedAmortizationExpenseDetail Intangible Assets - Summary of Estimated Amortization Expense (Detail) Details 51 false false R52.htm 1052 - Disclosure - Inventories - Components of Inventories (Detail) Sheet http://astro-med.com/role/InventoriesComponentsOfInventoriesDetail Inventories - Components of Inventories (Detail) Details 52 false false R53.htm 1053 - Disclosure - Property, Plant and Equipment - Summary of Property, Plant and Equipment (Detail) Sheet http://astro-med.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail Property, Plant and Equipment - Summary of Property, Plant and Equipment (Detail) Details 53 false false R54.htm 1054 - Disclosure - Property, Plant and Equipment - Additional Information (Detail) Sheet http://astro-med.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail Property, Plant and Equipment - Additional Information (Detail) Details 54 false false R55.htm 1055 - Disclosure - Credit Agreement and Long- Term Debt - Schedule of Long Term Debt in the Accompanying Condensed Consolidated Balance Sheets (Detail) Sheet http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsDetail Credit Agreement and Long- Term Debt - Schedule of Long Term Debt in the Accompanying Condensed Consolidated Balance Sheets (Detail) Details 55 false false R56.htm 1056 - Disclosure - Credit Agreement and Long- Term Debt - Schedule of Required Principal Payments Remaining on Long Term Debt Outstanding (Detail) Sheet http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfRequiredPrincipalPaymentsRemainingOnLongTermDebtOutstandingDetail Credit Agreement and Long- Term Debt - Schedule of Required Principal Payments Remaining on Long Term Debt Outstanding (Detail) Details 56 false false R57.htm 1057 - Disclosure - Credit Agreement and Long- Term Debt - Additional Information (Detail) Sheet http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail Credit Agreement and Long- Term Debt - Additional Information (Detail) Details 57 false false R58.htm 1058 - Disclosure - Royalty Obligation - Additional Information (Detail) Sheet http://astro-med.com/role/RoyaltyObligationAdditionalInformationDetail Royalty Obligation - Additional Information (Detail) Details 58 false false R59.htm 1059 - Disclosure - Leases - Additional Information (Detail) Sheet http://astro-med.com/role/LeasesAdditionalInformationDetail Leases - Additional Information (Detail) Details 59 false false R60.htm 1060 - Disclosure - Leases - Schedule Of Balance Sheet And Other Information Related To Operating Leases (Detail) Sheet http://astro-med.com/role/LeasesScheduleOfBalanceSheetAndOtherInformationRelatedToOperatingLeasesDetail Leases - Schedule Of Balance Sheet And Other Information Related To Operating Leases (Detail) Details 60 false false R61.htm 1061 - Disclosure - Leases - Lease Cost Information (Detail) Sheet http://astro-med.com/role/LeasesLeaseCostInformationDetail Leases - Lease Cost Information (Detail) Details 61 false false R62.htm 1062 - Disclosure - Leases - Maturities of lease liabilities (Detail) Sheet http://astro-med.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail Leases - Maturities of lease liabilities (Detail) Details 62 false false R63.htm 1063 - Disclosure - Leases - Supplemental cash flow information (Detail) Sheet http://astro-med.com/role/LeasesSupplementalCashFlowInformationDetail Leases - Supplemental cash flow information (Detail) Details 63 false false R64.htm 1064 - Disclosure - Accumulated Other Comprehensive Loss - Changes in Balance of Accumulated Other Comprehensive Loss (Detail) Sheet http://astro-med.com/role/AccumulatedOtherComprehensiveLossChangesInBalanceOfAccumulatedOtherComprehensiveLossDetail Accumulated Other Comprehensive Loss - Changes in Balance of Accumulated Other Comprehensive Loss (Detail) Details 64 false false R65.htm 1065 - Disclosure - Share-Based Compensation - Additional Information (Detail) Sheet http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail Share-Based Compensation - Additional Information (Detail) Details 65 false false R66.htm 1066 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Detail) Sheet http://astro-med.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetail Share-Based Compensation - Share-Based Compensation Expense (Detail) Details 66 false false R67.htm 1067 - Disclosure - Share-Based Compensation - Aggregated Information Regarding Stock Option Activity (Detail) Sheet http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingStockOptionActivityDetail Share-Based Compensation - Aggregated Information Regarding Stock Option Activity (Detail) Details 67 false false R68.htm 1068 - Disclosure - Share-Based Compensation - Summary of Options Outstanding (Detail) Sheet http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail Share-Based Compensation - Summary of Options Outstanding (Detail) Details 68 false false R69.htm 1069 - Disclosure - Share-Based Compensation - Aggregated Information Regarding RSU and RSA Activity (Detail) Sheet http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingRsuAndRsaActivityDetail Share-Based Compensation - Aggregated Information Regarding RSU and RSA Activity (Detail) Details 69 false false R70.htm 1070 - Disclosure - Income Taxes - Projected Effective Tax Rates (Detail) Sheet http://astro-med.com/role/IncomeTaxesProjectedEffectiveTaxRatesDetail Income Taxes - Projected Effective Tax Rates (Detail) Details 70 false false R71.htm 1071 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail Income Taxes - Additional Information (Detail) Details 71 false false R72.htm 1072 - Disclosure - Segment Information - Net Sales and Segment Operating Profit (Loss) for Each Reporting Segment (Detail) Sheet http://astro-med.com/role/SegmentInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail Segment Information - Net Sales and Segment Operating Profit (Loss) for Each Reporting Segment (Detail) Details 72 false false R73.htm 1073 - Disclosure - Fair Value - Schedule of Company's Long-Term Debt Including the Current Portion Not Reflected in Financial Statements at Fair Value (Detail) Sheet http://astro-med.com/role/FairValueScheduleOfCompanysLongTermDebtIncludingTheCurrentPortionNotReflectedInFinancialStatementsAtFairValueDetail Fair Value - Schedule of Company's Long-Term Debt Including the Current Portion Not Reflected in Financial Statements at Fair Value (Detail) Details 73 false false All Reports Book All Reports [dq-0542-Deprecated-Concept] Concept TreasuryStockShares in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. d292174d10q.htm 758 [dq-0542-Deprecated-Concept] Concept TreasuryStockMember in us-gaap/2022 used in 7 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. d292174d10q.htm 1408, 1468, 1498, 1618, 1687, 1777, 1897 [dq-0542-Deprecated-Concept] Concept LondonInterbankOfferedRateLIBORMember in us-gaap/2022 used in 3 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. d292174d10q.htm 3693 d292174d10q.htm alot-20230429.xsd alot-20230429_cal.xml alot-20230429_def.xml alot-20230429_lab.xml alot-20230429_pre.xml d292174dex311.htm d292174dex312.htm d292174dex321.htm d292174dex322.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 91 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d292174d10q.htm": { "axisCustom": 4, "axisStandard": 21, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 605, "http://xbrl.sec.gov/dei/2022": 29 }, "contextCount": 169, "dts": { "calculationLink": { "local": [ "alot-20230429_cal.xml" ] }, "definitionLink": { "local": [ "alot-20230429_def.xml" ] }, "inline": { "local": [ "d292174d10q.htm" ] }, "labelLink": { "local": [ "alot-20230429_lab.xml" ] }, "presentationLink": { "local": [ "alot-20230429_pre.xml" ] }, "schema": { "local": [ "alot-20230429.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 529, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 4, "total": 4 }, "keyCustom": 30, "keyStandard": 282, "memberCustom": 40, "memberStandard": 32, "nsprefix": "alot", "nsuri": "http://astro-med.com/20230429", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "1001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://astro-med.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1010 - Disclosure - Acquisitions", "menuCat": "Notes", "order": "10", "role": "http://astro-med.com/role/Acquisitions", "shortName": "Acquisitions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1011 - Disclosure - Revenue Recognition", "menuCat": "Notes", "order": "11", "role": "http://astro-med.com/role/RevenueRecognition", "shortName": "Revenue Recognition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1012 - Disclosure - Net Income Per Common Share", "menuCat": "Notes", "order": "12", "role": "http://astro-med.com/role/NetIncomePerCommonShare", "shortName": "Net Income Per Common Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1013 - Disclosure - Intangible Assets", "menuCat": "Notes", "order": "13", "role": "http://astro-med.com/role/IntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1014 - Disclosure - Inventories", "menuCat": "Notes", "order": "14", "role": "http://astro-med.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1015 - Disclosure - Property, Plant and Equipment", "menuCat": "Notes", "order": "15", "role": "http://astro-med.com/role/PropertyPlantAndEquipment", "shortName": "Property, Plant and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1016 - Disclosure - Credit Agreement and Long-Term Debt", "menuCat": "Notes", "order": "16", "role": "http://astro-med.com/role/CreditAgreementAndLongTermDebt", "shortName": "Credit Agreement and Long-Term Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "alot:DisclosureForTheHoneywellRoyaltyObligationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1017 - Disclosure - Royalty Obligation", "menuCat": "Notes", "order": "17", "role": "http://astro-med.com/role/RoyaltyObligation", "shortName": "Royalty Obligation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "alot:DisclosureForTheHoneywellRoyaltyObligationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1018 - Disclosure - Leases", "menuCat": "Notes", "order": "18", "role": "http://astro-med.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1019 - Disclosure - Accumulated Other Comprehensive Loss", "menuCat": "Notes", "order": "19", "role": "http://astro-med.com/role/AccumulatedOtherComprehensiveLoss", "shortName": "Accumulated Other Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn04_29_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002 - Statement - Condensed Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://astro-med.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn04_29_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1020 - Disclosure - Share-Based Compensation", "menuCat": "Notes", "order": "20", "role": "http://astro-med.com/role/ShareBasedCompensation", "shortName": "Share-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1021 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "21", "role": "http://astro-med.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1022 - Disclosure - Segment Information", "menuCat": "Notes", "order": "22", "role": "http://astro-med.com/role/SegmentInformation", "shortName": "Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1023 - Disclosure - Fair Value", "menuCat": "Notes", "order": "23", "role": "http://astro-med.com/role/FairValue", "shortName": "Fair Value", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1024 - Disclosure - Summary of Significant Accounting Policies Update (Policies)", "menuCat": "Policies", "order": "24", "role": "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesUpdatePolicies", "shortName": "Summary of Significant Accounting Policies Update (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1025 - Disclosure - Acquisitions (Tables)", "menuCat": "Tables", "order": "25", "role": "http://astro-med.com/role/AcquisitionsTables", "shortName": "Acquisitions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1026 - Disclosure - Revenue Recognition (Tables)", "menuCat": "Tables", "order": "26", "role": "http://astro-med.com/role/RevenueRecognitionTables", "shortName": "Revenue Recognition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "div", "div", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1027 - Disclosure - Net Income Per Common Share (Tables)", "menuCat": "Tables", "order": "27", "role": "http://astro-med.com/role/NetIncomePerCommonShareTables", "shortName": "Net Income Per Common Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1028 - Disclosure - Intangible Assets (Tables)", "menuCat": "Tables", "order": "28", "role": "http://astro-med.com/role/IntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "div", "div", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1029 - Disclosure - Inventories (Tables)", "menuCat": "Tables", "order": "29", "role": "http://astro-med.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "div", "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn04_29_2023", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://astro-med.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "div", "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn04_29_2023", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1030 - Disclosure - Property, Plant and Equipment (Tables)", "menuCat": "Tables", "order": "30", "role": "http://astro-med.com/role/PropertyPlantAndEquipmentTables", "shortName": "Property, Plant and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1031 - Disclosure - Credit Agreement and Long-Term Debt (Tables)", "menuCat": "Tables", "order": "31", "role": "http://astro-med.com/role/CreditAgreementAndLongTermDebtTables", "shortName": "Credit Agreement and Long-Term Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "alot:ScheduleOfBalanceSheetAndOtherInformationRelatedToOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1032 - Disclosure - Leases (Tables)", "menuCat": "Tables", "order": "32", "role": "http://astro-med.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "alot:ScheduleOfBalanceSheetAndOtherInformationRelatedToOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1033 - Disclosure - Accumulated Other Comprehensive Loss (Tables)", "menuCat": "Tables", "order": "33", "role": "http://astro-med.com/role/AccumulatedOtherComprehensiveLossTables", "shortName": "Accumulated Other Comprehensive Loss (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1034 - Disclosure - Share-Based Compensation (Tables)", "menuCat": "Tables", "order": "34", "role": "http://astro-med.com/role/ShareBasedCompensationTables", "shortName": "Share-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "alot:ScheduleOfProjectedEffectiveTaxRatesForPeriodsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1035 - Disclosure - Income Taxes (Tables)", "menuCat": "Tables", "order": "35", "role": "http://astro-med.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "alot:ScheduleOfProjectedEffectiveTaxRatesForPeriodsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1036 - Disclosure - Segment Information (Tables)", "menuCat": "Tables", "order": "36", "role": "http://astro-med.com/role/SegmentInformationTables", "shortName": "Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1037 - Disclosure - Fair Value (Tables)", "menuCat": "Tables", "order": "37", "role": "http://astro-med.com/role/FairValueTables", "shortName": "Fair Value (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_Segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1038 - Disclosure - Business and Basis of Presentation - Additional Information (Detail)", "menuCat": "Details", "order": "38", "role": "http://astro-med.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail", "shortName": "Business and Basis of Presentation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_Segment", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn08_04_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1039 - Disclosure - Acquisitions - Summary of Purchase Price of Acquisition Allocated on Basis of Fair Value (Detail)", "menuCat": "Details", "order": "39", "role": "http://astro-med.com/role/AcquisitionsSummaryOfPurchasePriceOfAcquisitionAllocatedOnBasisOfFairValueDetail", "shortName": "Acquisitions - Summary of Purchase Price of Acquisition Allocated on Basis of Fair Value (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn08_04_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004 - Statement - Condensed Consolidated Statements of Income", "menuCat": "Statements", "order": "4", "role": "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome", "shortName": "Condensed Consolidated Statements of Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P08_04_2022To08_04_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1040 - Disclosure - Acquisitions - Summary of Fair Value of the Acquired Identifiable Intangible Assets and Related Estimated Useful Lives (Detail)", "menuCat": "Details", "order": "40", "role": "http://astro-med.com/role/AcquisitionsSummaryOfFairValueOfTheAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail", "shortName": "Acquisitions - Summary of Fair Value of the Acquired Identifiable Intangible Assets and Related Estimated Useful Lives (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P08_04_2022To08_04_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023_AgreementWithAstroMachineForAssetAcquisitionsMemberusgaapBusinessAcquisitionAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1041 - Disclosure - Acquisitions - Summary of Revenue and Earnings Before Taxes (Detail)", "menuCat": "Details", "order": "41", "role": "http://astro-med.com/role/AcquisitionsSummaryOfRevenueAndEarningsBeforeTaxesDetail", "shortName": "Acquisitions - Summary of Revenue and Earnings Before Taxes (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023_AgreementWithAstroMachineForAssetAcquisitionsMemberusgaapBusinessAcquisitionAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn04_29_2023_CustomerRelatedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1042 - Disclosure - Acquisitions - Summary of Acquired Identifiable Intangible Asset (Detail)", "menuCat": "Details", "order": "42", "role": "http://astro-med.com/role/AcquisitionsSummaryOfAcquiredIdentifiableIntangibleAssetDetail", "shortName": "Acquisitions - Summary of Acquired Identifiable Intangible Asset (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn04_29_2023_CustomerRelatedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn08_04_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AreaOfLand", "reportCount": 1, "unique": true, "unitRef": "Unit_sqft", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1043 - Disclosure - Acquisitions - Additional Information (Detail)", "menuCat": "Details", "order": "43", "role": "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail", "shortName": "Acquisitions - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn08_04_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AreaOfLand", "reportCount": 1, "unique": true, "unitRef": "Unit_sqft", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1044 - Disclosure - Revenue Recognition - Summary of Revenues Disaggregated by Primary Geographic Markets (Detail)", "menuCat": "Details", "order": "44", "role": "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryGeographicMarketsDetail", "shortName": "Revenue Recognition - Summary of Revenues Disaggregated by Primary Geographic Markets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023_USsrtStatementGeographicalAxis", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1045 - Disclosure - Revenue Recognition - Summary of Revenues Disaggregated by Primary Product Type (Detail)", "menuCat": "Details", "order": "45", "role": "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryProductTypeDetail", "shortName": "Revenue Recognition - Summary of Revenues Disaggregated by Primary Product Type (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023_HardwareProductsMembersrtProductOrServiceAxis", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn04_29_2023", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1046 - Disclosure - Revenue Recognition - Additional Information (Detail)", "menuCat": "Details", "order": "46", "role": "http://astro-med.com/role/RevenueRecognitionAdditionalInformationDetail", "shortName": "Revenue Recognition - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn04_29_2023", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1047 - Disclosure - Net Income Per Common Share - Reconciliation of Shares Used in Calculating Basic and Diluted (Detail)", "menuCat": "Details", "order": "47", "role": "http://astro-med.com/role/NetIncomePerCommonShareReconciliationOfSharesUsedInCalculatingBasicAndDilutedDetail", "shortName": "Net Income Per Common Share - Reconciliation of Shares Used in Calculating Basic and Diluted (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": "0", "lang": null, "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1048 - Disclosure - Net Income Per Common Share - Additional Information (Detail)", "menuCat": "Details", "order": "48", "role": "http://astro-med.com/role/NetIncomePerCommonShareAdditionalInformationDetail", "shortName": "Net Income Per Common Share - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn04_29_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1049 - Disclosure - Intangible Assets - Fair Value of Acquired Identifiable Intangible Assets and Related Estimated Useful Lives (Detail)", "menuCat": "Details", "order": "49", "role": "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail", "shortName": "Intangible Assets - Fair Value of Acquired Identifiable Intangible Assets and Related Estimated Useful Lives (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn04_29_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)", "menuCat": "Statements", "order": "5", "role": "http://astro-med.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1050 - Disclosure - Intangible Assets - Additional Information (Detail)", "menuCat": "Details", "order": "50", "role": "http://astro-med.com/role/IntangibleAssetsAdditionalInformationDetail", "shortName": "Intangible Assets - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn04_29_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1051 - Disclosure - Intangible Assets - Summary of Estimated Amortization Expense (Detail)", "menuCat": "Details", "order": "51", "role": "http://astro-med.com/role/IntangibleAssetsSummaryOfEstimatedAmortizationExpenseDetail", "shortName": "Intangible Assets - Summary of Estimated Amortization Expense (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn04_29_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn04_29_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsAndSupplies", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1052 - Disclosure - Inventories - Components of Inventories (Detail)", "menuCat": "Details", "order": "52", "role": "http://astro-med.com/role/InventoriesComponentsOfInventoriesDetail", "shortName": "Inventories - Components of Inventories (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn04_29_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsAndSupplies", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn04_29_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LandAndLandImprovements", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1053 - Disclosure - Property, Plant and Equipment - Summary of Property, Plant and Equipment (Detail)", "menuCat": "Details", "order": "53", "role": "http://astro-med.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail", "shortName": "Property, Plant and Equipment - Summary of Property, Plant and Equipment (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn04_29_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LandAndLandImprovements", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1054 - Disclosure - Property, Plant and Equipment - Additional Information (Detail)", "menuCat": "Details", "order": "54", "role": "http://astro-med.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail", "shortName": "Property, Plant and Equipment - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn04_29_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1055 - Disclosure - Credit Agreement and Long- Term Debt - Schedule of Long Term Debt in the Accompanying Condensed Consolidated Balance Sheets (Detail)", "menuCat": "Details", "order": "55", "role": "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsDetail", "shortName": "Credit Agreement and Long- Term Debt - Schedule of Long Term Debt in the Accompanying Condensed Consolidated Balance Sheets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn04_29_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn04_29_2023_TermLoanMemberusgaapCreditFacilityAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1056 - Disclosure - Credit Agreement and Long- Term Debt - Schedule of Required Principal Payments Remaining on Long Term Debt Outstanding (Detail)", "menuCat": "Details", "order": "56", "role": "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfRequiredPrincipalPaymentsRemainingOnLongTermDebtOutstandingDetail", "shortName": "Credit Agreement and Long- Term Debt - Schedule of Required Principal Payments Remaining on Long Term Debt Outstanding (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn04_29_2023_TermLoanMemberusgaapCreditFacilityAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn04_29_2023", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LineOfCredit", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1057 - Disclosure - Credit Agreement and Long- Term Debt - Additional Information (Detail)", "menuCat": "Details", "order": "57", "role": "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "shortName": "Credit Agreement and Long- Term Debt - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn04_29_2023", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LineOfCredit", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "div", "div", "alot:DisclosureForTheHoneywellRoyaltyObligationTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": "-5", "first": true, "lang": null, "name": "alot:GuaranteedMinimumRoyaltyPayments", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1058 - Disclosure - Royalty Obligation - Additional Information (Detail)", "menuCat": "Details", "order": "58", "role": "http://astro-med.com/role/RoyaltyObligationAdditionalInformationDetail", "shortName": "Royalty Obligation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "alot:DisclosureForTheHoneywellRoyaltyObligationTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": "-5", "first": true, "lang": null, "name": "alot:GuaranteedMinimumRoyaltyPayments", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1059 - Disclosure - Leases - Additional Information (Detail)", "menuCat": "Details", "order": "59", "role": "http://astro-med.com/role/LeasesAdditionalInformationDetail", "shortName": "Leases - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn01_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006 - Statement - Consolidated Statements of Changes in Shareholders' Equity", "menuCat": "Statements", "order": "6", "role": "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity", "shortName": "Consolidated Statements of Changes in Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn01_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn04_29_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1060 - Disclosure - Leases - Schedule Of Balance Sheet And Other Information Related To Operating Leases (Detail)", "menuCat": "Details", "order": "60", "role": "http://astro-med.com/role/LeasesScheduleOfBalanceSheetAndOtherInformationRelatedToOperatingLeasesDetail", "shortName": "Leases - Schedule Of Balance Sheet And Other Information Related To Operating Leases (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "alot:ScheduleOfBalanceSheetAndOtherInformationRelatedToOperatingLeasesTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn04_29_2023", "decimals": "-3", "lang": null, "name": "us-gaap:OperatingLeaseLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1061 - Disclosure - Leases - Lease Cost Information (Detail)", "menuCat": "Details", "order": "61", "role": "http://astro-med.com/role/LeasesLeaseCostInformationDetail", "shortName": "Leases - Lease Cost Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn04_29_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1062 - Disclosure - Leases - Maturities of lease liabilities (Detail)", "menuCat": "Details", "order": "62", "role": "http://astro-med.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail", "shortName": "Leases - Maturities of lease liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn04_29_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1063 - Disclosure - Leases - Supplemental cash flow information (Detail)", "menuCat": "Details", "order": "63", "role": "http://astro-med.com/role/LeasesSupplementalCashFlowInformationDetail", "shortName": "Leases - Supplemental cash flow information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn01_31_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1064 - Disclosure - Accumulated Other Comprehensive Loss - Changes in Balance of Accumulated Other Comprehensive Loss (Detail)", "menuCat": "Details", "order": "64", "role": "http://astro-med.com/role/AccumulatedOtherComprehensiveLossChangesInBalanceOfAccumulatedOtherComprehensiveLossDetail", "shortName": "Accumulated Other Comprehensive Loss - Changes in Balance of Accumulated Other Comprehensive Loss (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn01_31_2023_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis", "decimals": "-3", "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn04_29_2023", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1065 - Disclosure - Share-Based Compensation - Additional Information (Detail)", "menuCat": "Details", "order": "65", "role": "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail", "shortName": "Share-Based Compensation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2022To01_31_2023", "decimals": "0", "lang": null, "name": "alot:ReservationOfSharesUnderEmployeeStockPurchasePlan", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockOptionPlanExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1066 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Detail)", "menuCat": "Details", "order": "66", "role": "http://astro-med.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetail", "shortName": "Share-Based Compensation - Share-Based Compensation Expense (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockOptionPlanExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn01_31_2023", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1067 - Disclosure - Share-Based Compensation - Aggregated Information Regarding Stock Option Activity (Detail)", "menuCat": "Details", "order": "67", "role": "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingStockOptionActivityDetail", "shortName": "Share-Based Compensation - Aggregated Information Regarding Stock Option Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn04_29_2023", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1068 - Disclosure - Share-Based Compensation - Summary of Options Outstanding (Detail)", "menuCat": "Details", "order": "68", "role": "http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail", "shortName": "Share-Based Compensation - Summary of Options Outstanding (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn04_29_2023", "decimals": "2", "lang": null, "name": "us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn01_31_2023_RestrictedStockAwardPreferredStockUnitAndRestrictedStockUnitMemberusgaapAwardTypeAxis", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1069 - Disclosure - Share-Based Compensation - Aggregated Information Regarding RSU and RSA Activity (Detail)", "menuCat": "Details", "order": "69", "role": "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingRsuAndRsaActivityDetail", "shortName": "Share-Based Compensation - Aggregated Information Regarding RSU and RSA Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn01_31_2023_RestrictedStockAwardPreferredStockUnitAndRestrictedStockUnitMemberusgaapAwardTypeAxis", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1007 - Statement - Condensed Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "7", "role": "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "alot:ScheduleOfProjectedEffectiveTaxRatesForPeriodsTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1070 - Disclosure - Income Taxes - Projected Effective Tax Rates (Detail)", "menuCat": "Details", "order": "70", "role": "http://astro-med.com/role/IncomeTaxesProjectedEffectiveTaxRatesDetail", "shortName": "Income Taxes - Projected Effective Tax Rates (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "alot:ScheduleOfProjectedEffectiveTaxRatesForPeriodsTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1071 - Disclosure - Income Taxes - Additional Information (Detail)", "menuCat": "Details", "order": "71", "role": "http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail", "shortName": "Income Taxes - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": "0", "lang": null, "name": "alot:TaxExpensesBenefitsResultingFromProvisionalAdjustments", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1072 - Disclosure - Segment Information - Net Sales and Segment Operating Profit (Loss) for Each Reporting Segment (Detail)", "menuCat": "Details", "order": "72", "role": "http://astro-med.com/role/SegmentInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail", "shortName": "Segment Information - Net Sales and Segment Operating Profit (Loss) for Each Reporting Segment (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023_ProductIdentificationMemberusgaapStatementBusinessSegmentsAxis", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn04_29_2023_EstimateOfFairValueFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtLongtermAndShorttermCombinedAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1073 - Disclosure - Fair Value - Schedule of Company's Long-Term Debt Including the Current Portion Not Reflected in Financial Statements at Fair Value (Detail)", "menuCat": "Details", "order": "73", "role": "http://astro-med.com/role/FairValueScheduleOfCompanysLongTermDebtIncludingTheCurrentPortionNotReflectedInFinancialStatementsAtFairValueDetail", "shortName": "Fair Value - Schedule of Company's Long-Term Debt Including the Current Portion Not Reflected in Financial Statements at Fair Value (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "PAsOn04_29_2023_EstimateOfFairValueFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtLongtermAndShorttermCombinedAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1008 - Disclosure - Business and Basis of Presentation", "menuCat": "Notes", "order": "8", "role": "http://astro-med.com/role/BusinessAndBasisOfPresentation", "shortName": "Business and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1009 - Disclosure - Summary of Significant Accounting Policies Update", "menuCat": "Notes", "order": "9", "role": "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesUpdate", "shortName": "Summary of Significant Accounting Policies Update", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d292174d10q.htm", "contextRef": "P02_01_2023To04_29_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 72, "tag": { "alot_AccruedRoyaltiesCurrentExcessRoyaltyPaymentDue": { "auth_ref": [], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": 25.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued royalties in excess of guaranteed minimum royalty obligation- amount due within one year.", "label": "Accrued Royalties, Current, Excess Royalty Payment Due", "positiveLabel": "Accrued Royalties, Current, Excess Royalty Payment Due", "verboseLabel": "Current Liability\u2014Excess Royalty Payment Due" } } }, "localname": "AccruedRoyaltiesCurrentExcessRoyaltyPaymentDue", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets", "http://astro-med.com/role/RoyaltyObligationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alot_AccruedRoyaltiesCurrentExcessRoyaltyPaymentsDue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued royalties current excess royalty payments due.", "label": "Accrued Royalties Current Excess Royalty Payments Due", "terseLabel": "Accrued Royalties Current Excess Royalty Payments Due" } } }, "localname": "AccruedRoyaltiesCurrentExcessRoyaltyPaymentsDue", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/RoyaltyObligationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alot_AdditionalTermLoanAvailedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional term loan availed.", "label": "Additional Term Loan Availed [Member]", "terseLabel": "Additional Term Loan Availed [Member]" } } }, "localname": "AdditionalTermLoanAvailedMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_AerospaceCustomerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aerospace customer.", "label": "Aerospace Customer [Member]" } } }, "localname": "AerospaceCustomerMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/RevenueRecognitionAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_AgreementWithAstroMachineForAssetAcquisitionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement with astro machine for asset acquisitions.", "label": "Agreement With Astro Machine For Asset Acquisitions [Member]", "terseLabel": "Agreement With Astro Machine For Asset Acquisitions [Member]" } } }, "localname": "AgreementWithAstroMachineForAssetAcquisitionsMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail", "http://astro-med.com/role/AcquisitionsSummaryOfRevenueAndEarningsBeforeTaxesDetail", "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "domainItemType" }, "alot_BankOfAmericaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bank of america.", "label": "Bank Of America [Member]", "terseLabel": "Bank of America, N.A. [Member]" } } }, "localname": "BankOfAmericaMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_BeforeAmendmentToTheCreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Before amendment to the credit agreement.", "label": "Before Amendment To The Credit Agreement [Member]", "terseLabel": "Before Amendment To The Credit Agreement [Member]" } } }, "localname": "BeforeAmendmentToTheCreditAgreementMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_BusinessAcquisitionProFormaInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business acquisition pro forma information.", "label": "Business Acquisition Pro Forma Information [Line Items]" } } }, "localname": "BusinessAcquisitionProFormaInformationLineItems", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/AcquisitionsSummaryOfRevenueAndEarningsBeforeTaxesDetail" ], "xbrltype": "stringItemType" }, "alot_BusinessAcquisitionProFormaInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business acquisition pro forma information.", "label": "Business Acquisition Pro Forma Information [Table]" } } }, "localname": "BusinessAcquisitionProFormaInformationTable", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/AcquisitionsSummaryOfRevenueAndEarningsBeforeTaxesDetail" ], "xbrltype": "stringItemType" }, "alot_BusinessAndBasisOfPresentationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business and Basis Of Presentation", "label": "Business and Basis Of Presentation [Abstract]" } } }, "localname": "BusinessAndBasisOfPresentationAbstract", "nsuri": "http://astro-med.com/20230429", "xbrltype": "stringItemType" }, "alot_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill": { "auth_ref": [], "calculation": { "http://astro-med.com/role/AcquisitionsSummaryOfPurchasePriceOfAcquisitionAllocatedOnBasisOfFairValueDetail": { "order": 7.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business combination, recognized identifiable assets acquired and liabilities assumed, goodwill.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Goodwill", "terseLabel": "Goodwill" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/AcquisitionsSummaryOfPurchasePriceOfAcquisitionAllocatedOnBasisOfFairValueDetail" ], "xbrltype": "monetaryItemType" }, "alot_CapitalizedContractCostsAmortizationPeriodRemaining": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amortization period remaining for capitalized contract costs.", "label": "Capitalized Contract Costs Amortization Period Remaining", "terseLabel": "Capitalized contract costs amounts incurred amortization period" } } }, "localname": "CapitalizedContractCostsAmortizationPeriodRemaining", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/RevenueRecognitionAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "alot_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash paid for amounts included in the measurement of lease liabilities [Abstract]", "verboseLabel": "Cash paid for amounts included in the measurement of lease liabilities [Abstract]" } } }, "localname": "CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/LeasesSupplementalCashFlowInformationDetail" ], "xbrltype": "stringItemType" }, "alot_CentralAndSouthAmericaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Central and South America.", "label": "Central And South America [Member]", "terseLabel": "Central and South America [Member]" } } }, "localname": "CentralAndSouthAmericaMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryGeographicMarketsDetail" ], "xbrltype": "domainItemType" }, "alot_ContractWithCustomerLiabilityRevenueRecognizedIncludingAdditions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract with customer liability revenue recognized including additions.", "label": "Contract With Customer Liability Revenue Recognized Including Additions", "terseLabel": "Revenue recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognizedIncludingAdditions", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/RevenueRecognitionAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alot_CreditAgreementAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Credit Agreement", "label": "Credit Agreement [Axis]" } } }, "localname": "CreditAgreementAxis", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "alot_CreditAgreementDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Credit Agreement", "label": "Credit Agreement [Domain]" } } }, "localname": "CreditAgreementDomain", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_DebtInstrumentAdditionalBasisSpread": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument additional basis spread.", "label": "Debt Instrument Additional Basis Spread", "verboseLabel": "Percentage added to variable rate" } } }, "localname": "DebtInstrumentAdditionalBasisSpread", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "alot_DetailsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Details [Axis].", "label": "Details [Axis]" } } }, "localname": "DetailsAxis", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "alot_DetailsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Details [Domain].", "label": "Details [Domain]" } } }, "localname": "DetailsDomain", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_DetailsOfIncomeTaxBenefitAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Details Of Income Tax Benefit [Axis]" } } }, "localname": "DetailsOfIncomeTaxBenefitAxis", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "alot_DetailsOfIncomeTaxBenefitDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Details Of Income Tax Benefit [Domain]" } } }, "localname": "DetailsOfIncomeTaxBenefitDomain", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_DetailsOneAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Details One [Axis].", "label": "Details One [Axis]" } } }, "localname": "DetailsOneAxis", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "alot_DetailsOneDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Details One [Domain].", "label": "Details One [Domain]" } } }, "localname": "DetailsOneDomain", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_DisclosureForTheHoneywellRoyaltyObligationTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure for the honeywell royalty obligation.", "label": "Disclosure For The Honeywell Royalty Obligation [Text Block]", "terseLabel": "Royalty Obligation" } } }, "localname": "DisclosureForTheHoneywellRoyaltyObligationTextBlock", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/RoyaltyObligation" ], "xbrltype": "textBlockItemType" }, "alot_DistributorRelationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Distributor relations.", "label": "Distributor Relations [Member]", "terseLabel": "Distributor Relations [Member]" } } }, "localname": "DistributorRelationsMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "domainItemType" }, "alot_EffectiveIncomeTaxReconciliationTaxExpenseDueToUncertainTaxPositions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Effective income tax reconciliation tax expense due to uncertain tax positions.", "label": "Effective income tax reconciliation tax expense due to uncertain tax positions", "verboseLabel": "Effective income tax reconciliation tax expense due to revaluation of deferred tax assets" } } }, "localname": "EffectiveIncomeTaxReconciliationTaxExpenseDueToUncertainTaxPositions", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alot_EmployeeStockPurchasePlanExpense": { "auth_ref": [], "calculation": { "http://astro-med.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetail": { "order": 3.0, "parentTag": "us-gaap_ShareBasedCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Employee stock purchase plan expense.", "label": "Employee Stock Purchase Plan Expense", "verboseLabel": "Employee Stock Purchase Plan" } } }, "localname": "EmployeeStockPurchasePlanExpense", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "alot_EmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee stock purchase plan.", "label": "Employee Stock Purchase Plan [Member]", "terseLabel": "Employee Stock Purchase Plan [Member]" } } }, "localname": "EmployeeStockPurchasePlanMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_ExcessRoyaltyPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of royalty expense paid in excess of guaranteed minimum payments.", "label": "Excess Royalty Payments" } } }, "localname": "ExcessRoyaltyPayments", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/RoyaltyObligationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alot_ExistingTechnologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Existing technology.", "label": "Existing Technology [Member]", "terseLabel": "Existing Technology [Member]" } } }, "localname": "ExistingTechnologyMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "domainItemType" }, "alot_FairValueOfIntangibleAssetsMeasurementInput": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair value of intangible assets measurement input.", "label": "Fair Value Of Intangible Assets Measurement Input", "terseLabel": "Fair Value Of Intangible Assets Measurement Input" } } }, "localname": "FairValueOfIntangibleAssetsMeasurementInput", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "decimalItemType" }, "alot_FiniteLivedIntangibleAssetsForeignCurrencyTranslationAdjustment": { "auth_ref": [], "calculation": { "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finite-lived\u200b intangible assets foreign currency translation adjustment.", "label": "Finite Lived Intangible Assets Foreign Currency Translation Adjustment", "terseLabel": "Currency Translation Adjustment" } } }, "localname": "FiniteLivedIntangibleAssetsForeignCurrencyTranslationAdjustment", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "monetaryItemType" }, "alot_GuaranteedMinimumRoyaltyPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total Amount paid to date on the Guaranteed Minimum Royalty Obligation.", "label": "Guaranteed Minimum Royalty Payments" } } }, "localname": "GuaranteedMinimumRoyaltyPayments", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/RoyaltyObligationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alot_HardwareProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hardware products.", "label": "Hardware Products [Member]", "terseLabel": "Hardware [Member]" } } }, "localname": "HardwareProductsMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryProductTypeDetail" ], "xbrltype": "domainItemType" }, "alot_HoneywellAssetPurchaseAndLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Honeywell Asset Purchase and License Agreement [Member]", "label": "Honeywell Asset Purchase and License Agreement [Member]", "terseLabel": "Honeywell Asset Purchase and License Agreement [Member]", "verboseLabel": "Honeywell Asset Purchase and License Agreement [Member]" } } }, "localname": "HoneywellAssetPurchaseAndLicenseAgreementMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail", "http://astro-med.com/role/RoyaltyObligationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_IntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible Assets [Line Items]", "label": "Intangible Assets [Line Items]" } } }, "localname": "IntangibleAssetsLineItems", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/IntangibleAssetsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "alot_IntangibleAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible Assets [Table]", "label": "Intangible Assets [Table]" } } }, "localname": "IntangibleAssetsTable", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/IntangibleAssetsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "alot_LesseeOperatingLeaseLiabilityPaymentDueYearFiveAndThereafter": { "auth_ref": [], "calculation": { "http://astro-med.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease liability payment due year five and thereafter.", "label": "Lessee Operating Lease Liability Payment Due Year Five And Thereafter", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentDueYearFiveAndThereafter", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "alot_MeasurementInputCustomerAttritionRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input customer attrition rate.", "label": "Measurement Input Customer Attrition Rate [Member]" } } }, "localname": "MeasurementInputCustomerAttritionRateMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_MeasurementInputRoyaltyRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input royalty rate.", "label": "Measurement Input Royalty Rate [Member]" } } }, "localname": "MeasurementInputRoyaltyRateMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_MiltopeCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Miltope Corporation [Member]", "label": "Miltope Corporation [Member]", "terseLabel": "Miltope [Member]" } } }, "localname": "MiltopeCorporationMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "domainItemType" }, "alot_MinimumRoyaltyPaymentObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum Royalty Payment Obligation.", "label": "Minimum Royalty Payment Obligation", "verboseLabel": "Minimum Royalty Payment Obligation" } } }, "localname": "MinimumRoyaltyPaymentObligation", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/RoyaltyObligationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alot_NonCurrentLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non current liability.", "label": "Non Current Liability [Member]" } } }, "localname": "NonCurrentLiabilityMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_NumberOfAcresOfLand": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of acres of land.", "label": "Number of Acres of land", "terseLabel": "Number of Acres of land" } } }, "localname": "NumberOfAcresOfLand", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "alot_OperatingLeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Leases [Abstract]", "verboseLabel": "Operating Leases [Abstract]" } } }, "localname": "OperatingLeasesAbstract", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/LeasesScheduleOfBalanceSheetAndOtherInformationRelatedToOperatingLeasesDetail" ], "xbrltype": "stringItemType" }, "alot_OtherEmployeeRetentionCreditReceivable": { "auth_ref": [], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount currently receivable for refundable payroll taxes to be received from the Employee Retention Credit granted under the CARES act.", "label": "Other Employee Retention Credit Receivable", "negatedLabel": "Other Receivable \u2013 Employee Retention Credit Receivable" } } }, "localname": "OtherEmployeeRetentionCreditReceivable", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "alot_OthersCountriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Others Countries [Member]", "label": "Others Countries [Member]", "terseLabel": "Other [Member]" } } }, "localname": "OthersCountriesMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryGeographicMarketsDetail" ], "xbrltype": "domainItemType" }, "alot_PaymentTermPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Payment term period.", "label": "Payment Term Period" } } }, "localname": "PaymentTermPeriod", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/RoyaltyObligationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "alot_PaymentsOfMinimumGuaranteeRoyaltyObligation": { "auth_ref": [], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash Outflow of Minimum Guarantee Royalty Obligation", "label": "Payments Of Minimum Guarantee Royalty Obligation", "negatedLabel": "Payment of Minimum Guarantee Royalty Obligation" } } }, "localname": "PaymentsOfMinimumGuaranteeRoyaltyObligation", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "alot_PeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period.", "label": "Period [Axis]" } } }, "localname": "PeriodAxis", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/RoyaltyObligationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "alot_PeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period.", "label": "Period [Domain]" } } }, "localname": "PeriodDomain", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/RoyaltyObligationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_PriorEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prior employee stock purchase plan member.", "label": "Prior Employee Stock Purchase Plan [Member]", "terseLabel": "Prior Employee Stock Purchase Plan [Member]" } } }, "localname": "PriorEmployeeStockPurchasePlanMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_ProductIdentificationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Product identification.", "label": "Product Identification [Member]", "verboseLabel": "PI [Member]" } } }, "localname": "ProductIdentificationMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/SegmentInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail" ], "xbrltype": "domainItemType" }, "alot_PurchasePriceIntoAnEscrowAccount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Purchase price into an escrow account.", "label": "Purchase Price Into an Escrow Account", "terseLabel": "Purchase price into an escrow account" } } }, "localname": "PurchasePriceIntoAnEscrowAccount", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alot_RangeFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Range five.", "label": "Range Five [Member]", "terseLabel": "$15.01 - $20.00 [Member]" } } }, "localname": "RangeFiveMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail" ], "xbrltype": "domainItemType" }, "alot_RangeFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Range four.", "label": "Range Four [Member]", "terseLabel": "$10.01 - $15.00 [Member]" } } }, "localname": "RangeFourMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail" ], "xbrltype": "domainItemType" }, "alot_RangeThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Range three.", "label": "Range Three [Member]", "terseLabel": "$5.00 - $10.00 [Member]" } } }, "localname": "RangeThreeMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail" ], "xbrltype": "domainItemType" }, "alot_ReservationOfSharesUnderEmployeeStockPurchasePlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reservation of shares under employee stock purchase plan.", "label": "Reservation Of Shares Under Employee Stock Purchase Plan", "terseLabel": "Reservation of shares under Stock Purchase Plan" } } }, "localname": "ReservationOfSharesUnderEmployeeStockPurchasePlan", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "alot_RestrictedStockAwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted stock award.", "label": "Restricted Stock Award [Member]" } } }, "localname": "RestrictedStockAwardMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_RestrictedStockAwardPreferredStockUnitAndRestrictedStockUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted stock award preferred stock unit and restricted stock unit member.", "label": "Restricted Stock Award Preferred Stock Unit And Restricted Stock Unit [Member]" } } }, "localname": "RestrictedStockAwardPreferredStockUnitAndRestrictedStockUnitMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingRsuAndRsaActivityDetail" ], "xbrltype": "domainItemType" }, "alot_RoyaltyGuaranteeCommitementAmountDueCurrentAndNonCurrentDiscountedValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Royalty guarantee commitement amount due current and non current discounted value.", "label": "Royalty Guarantee Commitement Amount Due Current and Non Current Discounted Value", "terseLabel": "Royalty guarantee commitement due current and non current discounted value" } } }, "localname": "RoyaltyGuaranteeCommitementAmountDueCurrentAndNonCurrentDiscountedValue", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alot_RoyaltyGuaranteesCommitmentsAmountNonCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Royalty guarantees commitments amount non current.", "label": "Royalty Guarantees Commitments Amount Non Current", "terseLabel": "Royalty guarantees commitments amount non current" } } }, "localname": "RoyaltyGuaranteesCommitmentsAmountNonCurrent", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alot_RoyaltyObligationCurrent": { "auth_ref": [], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": 23.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of the short term portion of the guaranteed minimum royalty obligations related to Honeywell Agreements.", "label": "Royalty Obligation, Current", "terseLabel": "Current Liability\u2014Royalty Obligation" } } }, "localname": "RoyaltyObligationCurrent", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets", "http://astro-med.com/role/RoyaltyObligationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alot_RoyaltyObligationDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Royalty Obligation Disclosure [Abstract]", "verboseLabel": "Royalty Obligation Disclosure [Abstract]" } } }, "localname": "RoyaltyObligationDisclosureAbstract", "nsuri": "http://astro-med.com/20230429", "xbrltype": "stringItemType" }, "alot_RoyaltyObligationNonCurrent": { "auth_ref": [], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of the long term portions of the guaranteed minimum royalty obligation related to Honeywell Agreements.", "label": "Royalty Obligation Non Current", "verboseLabel": "Royalty Obligation, net of current portion" } } }, "localname": "RoyaltyObligationNonCurrent", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets", "http://astro-med.com/role/RoyaltyObligationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alot_RoyaltyPaymentsDueAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty payments due.", "label": "Royalty Payments Due [Axis]" } } }, "localname": "RoyaltyPaymentsDueAxis", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "alot_RoyaltyPaymentsDueDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty payments due.", "label": "Royalty Payments Due [Domain]" } } }, "localname": "RoyaltyPaymentsDueDomain", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_RoyaltyPaymentsDueInNextTwelveMonthsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty payments due in next twelve months.", "label": "Royalty Payments Due In Next Twelve Months [Member]" } } }, "localname": "RoyaltyPaymentsDueInNextTwelveMonthsMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_RoyaltyPaymentsDueYearFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty payments due year five.", "label": "Royalty Payments Due Year Five [Member]" } } }, "localname": "RoyaltyPaymentsDueYearFiveMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_RoyaltyPaymentsDueYearFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty payments due year four.", "label": "Royalty Payments Due Year Four [Member]" } } }, "localname": "RoyaltyPaymentsDueYearFourMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_RoyaltyPaymentsDueYearThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty payments due year three.", "label": "Royalty Payments Due Year Three [Member]" } } }, "localname": "RoyaltyPaymentsDueYearThreeMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_RoyaltyPaymentsDueYearTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty payments due year two.", "label": "Royalty Payments Due Year Two [Member]" } } }, "localname": "RoyaltyPaymentsDueYearTwoMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_RuggedInformationTechnologyEquipmentCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rugged Information Technology Equipment Corporation [Member]", "label": "Rugged Information Technology Equipment Corporation [Member]", "terseLabel": "RITEC [Member]" } } }, "localname": "RuggedInformationTechnologyEquipmentCorporationMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "domainItemType" }, "alot_ScheduleOfBalanceSheetAndOtherInformationRelatedToOperatingLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of balance sheet and other information related to operating leases.", "label": "Schedule Of Balance Sheet And Other Information Related To Operating Leases [Table Text Block]", "terseLabel": "Schedule Of Balance Sheet And Other Information Related To Operating Leases" } } }, "localname": "ScheduleOfBalanceSheetAndOtherInformationRelatedToOperatingLeasesTableTextBlock", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "alot_ScheduleOfProjectedEffectiveTaxRatesForPeriodsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of projected effective tax rates for periods.", "label": "Schedule Of Projected Effective Tax Rates For Periods [Table Text Block]", "terseLabel": "Projected Effective Tax Rates" } } }, "localname": "ScheduleOfProjectedEffectiveTaxRatesForPeriodsTableTextBlock", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "alot_SecondAmendmentCreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second amendment credit agreement.", "label": "Second Amendment Credit Agreement [Member]", "terseLabel": "Second Amendment Credit Agreement [Member]" } } }, "localname": "SecondAmendmentCreditAgreementMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_ServiceAndOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Service and other.", "label": "Service And Other [Member]", "terseLabel": "Service and Other [Member]" } } }, "localname": "ServiceAndOtherMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryProductTypeDetail" ], "xbrltype": "domainItemType" }, "alot_SettlementOfContractClaim": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Settlement of contract claim as a result of increased claims allowable under French law.", "label": "Settlement Of Contract Claim", "terseLabel": "Contract with customer liability" } } }, "localname": "SettlementOfContractClaim", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/RevenueRecognitionAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alot_SettlementofContractClaimRevenueRecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized as result of settlement of a contract claim related to additional component costs.", "label": "Settlement of Contract Claim Revenue Recognized", "terseLabel": "Revenue recognized" } } }, "localname": "SettlementofContractClaimRevenueRecognized", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/RevenueRecognitionAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alot_SuppliesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supplies.", "label": "Supplies [Member]", "terseLabel": "Supplies [Member]" } } }, "localname": "SuppliesMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryProductTypeDetail" ], "xbrltype": "domainItemType" }, "alot_TaxExpensesBenefitsResultingFromProvisionalAdjustments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax expenses benefits resulting from provisional adjustments.", "label": "Tax Expenses Benefits Resulting From Provisional Adjustments", "terseLabel": "Tax expenses benefits resulting from provisional adjustments" } } }, "localname": "TaxExpensesBenefitsResultingFromProvisionalAdjustments", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alot_TermLoanDueAugustFourthTwoThousandAndTwentySevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term loan due august fourth two thousand and twenty seven.", "label": "Term Loan Due August Fourth Two Thousand and Twenty Seven [Member]", "terseLabel": "Term Loan Due August 4, 2027 [Member]" } } }, "localname": "TermLoanDueAugustFourthTwoThousandAndTwentySevenMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsDetail" ], "xbrltype": "domainItemType" }, "alot_TermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term loan.", "label": "Term Loan [Member]", "terseLabel": "Term Loan [Member]" } } }, "localname": "TermLoanMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfRequiredPrincipalPaymentsRemainingOnLongTermDebtOutstandingDetail" ], "xbrltype": "domainItemType" }, "alot_TestAndMeasurementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Test and measurement.", "label": "Test And Measurement [Member]", "verboseLabel": "T&M [Member]" } } }, "localname": "TestAndMeasurementMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/SegmentInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail" ], "xbrltype": "domainItemType" }, "alot_TrojanlabelApSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "TrojanLabel ApS.", "label": "Trojanlabel ApS [Member]", "terseLabel": "TrojanLabel ApS [Member]" } } }, "localname": "TrojanlabelApSMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "domainItemType" }, "alot_TwoThousandAndTwentyTwoEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand and twenty two employee stock purchase plan member.", "label": "Two Thousand And Twenty Two Employee Stock Purchase Plan [Member]", "terseLabel": "2022 Employee Stock Purchase Plan" } } }, "localname": "TwoThousandAndTwentyTwoEmployeeStockPurchasePlanMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_TwoThousandEighteenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2018 Equity Incentive Plan.", "label": "Two Thousand Eighteen Equity Incentive Plan [Member]", "terseLabel": "2018 Equity Incentive Plan [Member]" } } }, "localname": "TwoThousandEighteenEquityIncentivePlanMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_TwoThousandFifteenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Fifteen Equity Incentive Plan [Member]", "label": "Two Thousand Fifteen Equity Incentive Plan [Member]", "terseLabel": "2015 Equity Incentive Plan [Member]" } } }, "localname": "TwoThousandFifteenEquityIncentivePlanMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_TwoThousandSevenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Seven Equity Incentive Plan [Member]", "label": "Two Thousand Seven Equity Incentive Plan [Member]", "terseLabel": "2007 Equity Incentive Plan [Member]" } } }, "localname": "TwoThousandSevenEquityIncentivePlanMember", "nsuri": "http://astro-med.com/20230429", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "country_CA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CANADA", "terseLabel": "Canada [Member]" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryGeographicMarketsDetail" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States [Member]" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryGeographicMarketsDetail" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "verboseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r611" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r612" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "verboseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r609" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r609" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r609" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r613" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r609" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r609" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r609" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r609" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r608" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r610" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_AsiaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asia [Member]", "terseLabel": "Asia [Member]" } } }, "localname": "AsiaMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryGeographicMarketsDetail" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r208", "r245", "r257", "r258", "r259", "r260", "r261", "r263", "r267", "r314", "r315", "r316", "r317", "r319", "r320", "r322", "r324", "r325", "r647", "r648" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://astro-med.com/role/SegmentInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r208", "r245", "r257", "r258", "r259", "r260", "r261", "r263", "r267", "r314", "r315", "r316", "r317", "r319", "r320", "r322", "r324", "r325", "r647", "r648" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://astro-med.com/role/SegmentInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail" ], "xbrltype": "domainItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Europe [Member]", "terseLabel": "Europe [Member]" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryGeographicMarketsDetail" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r273", "r588", "r651", "r764" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://astro-med.com/role/RevenueRecognitionAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r310", "r311", "r312", "r313", "r386", "r523", "r542", "r570", "r571", "r585", "r598", "r607", "r649", "r756", "r757", "r758", "r759", "r760", "r761" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r310", "r311", "r312", "r313", "r386", "r523", "r542", "r570", "r571", "r585", "r598", "r607", "r649", "r756", "r757", "r758", "r759", "r760", "r761" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r273", "r588", "r651", "r764" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://astro-med.com/role/RevenueRecognitionAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r269", "r524", "r586", "r605", "r645", "r646", "r651", "r763" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryProductTypeDetail" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r269", "r524", "r586", "r605", "r645", "r646", "r651", "r763" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryProductTypeDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r310", "r311", "r312", "r313", "r379", "r386", "r413", "r414", "r415", "r522", "r523", "r542", "r570", "r571", "r585", "r598", "r607", "r644", "r649", "r757", "r758", "r759", "r760", "r761" ], "lang": { "en-us": { "role": { "label": "Range [Axis]", "terseLabel": "Range [Axis]", "verboseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r310", "r311", "r312", "r313", "r379", "r386", "r413", "r414", "r415", "r522", "r523", "r542", "r570", "r571", "r585", "r598", "r607", "r644", "r649", "r757", "r758", "r759", "r760", "r761" ], "lang": { "en-us": { "role": { "label": "Range [Domain]", "terseLabel": "Range [Domain]", "verboseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r224", "r387", "r615", "r634" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "verboseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/LeasesAdditionalInformationDetail", "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r270", "r271", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r587", "r606", "r651" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail", "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryGeographicMarketsDetail" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r270", "r271", "r556", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r587", "r606", "r651" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail", "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryGeographicMarketsDetail" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r224", "r387", "r615", "r616", "r634" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "verboseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/LeasesAdditionalInformationDetail", "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r639", "r753" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Relationship to Entity [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r15", "r604" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": 20.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts Payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r275", "r276" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, Net, Current", "verboseLabel": "Accounts Receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r3", "r144", "r153" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": 26.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Income Taxes Payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": 22.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Other Accrued Expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r81", "r173" ], "calculation": { "http://astro-med.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail": { "order": 6.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated Depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r28", "r29", "r30", "r181", "r537", "r550", "r554" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": 35.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated Other Comprehensive Loss, net of tax" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r27", "r30", "r124", "r517", "r545", "r546", "r624", "r625", "r626", "r631", "r632", "r633" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AccumulatedOtherComprehensiveLossChangesInBalanceOfAccumulatedOtherComprehensiveLossDetail", "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r26", "r30", "r124", "r192", "r193", "r488", "r489", "r490", "r491", "r493", "r624" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign Currency Translation Adjustments [Member]" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AccumulatedOtherComprehensiveLossChangesInBalanceOfAccumulatedOtherComprehensiveLossDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Acquired Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsSummaryOfAcquiredIdentifiableIntangibleAssetDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "verboseLabel": "Useful Life (Years)" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsSummaryOfFairValueOfTheAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "durationItemType" }, "us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Acquired Indefinite-Lived Intangible Assets [Line Items]", "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "AcquiredIndefiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsSummaryOfFairValueOfTheAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r7" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": 32.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional\u00a0Paid-in\u00a0Capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r421", "r422", "r423", "r631", "r632", "r633", "r744" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r162", "r163", "r164", "r165", "r166", "r212", "r213", "r214", "r215", "r224", "r277", "r278", "r280", "r281", "r282", "r283", "r284", "r285", "r421", "r422", "r423", "r432", "r433", "r434", "r435", "r445", "r446", "r447", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r495", "r496", "r500", "r501", "r502", "r503", "r512", "r513", "r514", "r515", "r516", "r517", "r526", "r527", "r528", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "verboseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition", "terseLabel": "Share-Based Compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to Reconcile Net Income to Net Cash Provided (Used) by Operating Activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r36", "r349", "r498", "r627" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of Debt Issuance Costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r53", "r72", "r77" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/IntangibleAssetsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Number of common equivalent shares" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/NetIncomePerCommonShareAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AreaOfLand": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of land held.", "label": "Area of Land", "terseLabel": "Area of Land" } } }, "localname": "AreaOfLand", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements and Non-arrangement Transactions [Domain]", "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]", "verboseLabel": "Arrangements and Non-arrangement Transactions [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/IntangibleAssetsAdditionalInformationDetail", "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail", "http://astro-med.com/role/RoyaltyObligationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r142", "r152", "r176", "r205", "r253", "r259", "r265", "r279", "r314", "r315", "r317", "r318", "r319", "r321", "r323", "r325", "r326", "r450", "r454", "r473", "r604", "r647", "r648", "r754" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r169", "r183", "r205", "r279", "r314", "r315", "r317", "r318", "r319", "r321", "r323", "r325", "r326", "r450", "r454", "r473", "r604", "r647", "r648", "r754" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "CURRENT ASSETS" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/NetIncomePerCommonShareReconciliationOfSharesUsedInCalculatingBasicAndDilutedDetail", "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingRsuAndRsaActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail", "http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r125", "r126" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail", "http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies Update" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesUpdate" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingsAndImprovementsGross": { "auth_ref": [ "r80" ], "calculation": { "http://astro-med.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail": { "order": 3.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Buildings and Improvements, Gross", "terseLabel": "Buildings and Leasehold Improvements" } } }, "localname": "BuildingsAndImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r443", "r596", "r597" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail", "http://astro-med.com/role/AcquisitionsSummaryOfFairValueOfTheAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail", "http://astro-med.com/role/AcquisitionsSummaryOfPurchasePriceOfAcquisitionAllocatedOnBasisOfFairValueDetail", "http://astro-med.com/role/AcquisitionsSummaryOfRevenueAndEarningsBeforeTaxesDetail", "http://astro-med.com/role/IntangibleAssetsAdditionalInformationDetail", "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r111", "r112", "r443", "r596", "r597" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail", "http://astro-med.com/role/AcquisitionsSummaryOfFairValueOfTheAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail", "http://astro-med.com/role/AcquisitionsSummaryOfPurchasePriceOfAcquisitionAllocatedOnBasisOfFairValueDetail", "http://astro-med.com/role/AcquisitionsSummaryOfRevenueAndEarningsBeforeTaxesDetail", "http://astro-med.com/role/IntangibleAssetsAdditionalInformationDetail", "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail", "http://astro-med.com/role/AcquisitionsSummaryOfPurchasePriceOfAcquisitionAllocatedOnBasisOfFairValueDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Payments to Acquire Businesses, Gross" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r740", "r741" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "terseLabel": "Summary of Revenue and Earnings Before Taxes" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r108" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "verboseLabel": "Business Combination, Acquisition Related Costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r119", "r120", "r121" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Business Combination, Consideration Transferred" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r122", "r444" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Acquisitions" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/Acquisitions" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": { "auth_ref": [ "r110" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.", "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual", "terseLabel": "Earnings before Taxes" } } }, "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsSummaryOfRevenueAndEarningsBeforeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": { "auth_ref": [ "r110" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.", "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual", "terseLabel": "Revenue" } } }, "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsSummaryOfRevenueAndEarningsBeforeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r114" ], "calculation": { "http://astro-med.com/role/AcquisitionsSummaryOfPurchasePriceOfAcquisitionAllocatedOnBasisOfFairValueDetail": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsSummaryOfPurchasePriceOfAcquisitionAllocatedOnBasisOfFairValueDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r114" ], "calculation": { "http://astro-med.com/role/AcquisitionsSummaryOfPurchasePriceOfAcquisitionAllocatedOnBasisOfFairValueDetail": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Accounts Receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsSummaryOfPurchasePriceOfAcquisitionAllocatedOnBasisOfFairValueDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": { "auth_ref": [ "r114" ], "calculation": { "http://astro-med.com/role/AcquisitionsSummaryOfPurchasePriceOfAcquisitionAllocatedOnBasisOfFairValueDetail": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities", "negatedLabel": "Accounts Payable and Other Current Liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsSummaryOfPurchasePriceOfAcquisitionAllocatedOnBasisOfFairValueDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r114" ], "calculation": { "http://astro-med.com/role/AcquisitionsSummaryOfPurchasePriceOfAcquisitionAllocatedOnBasisOfFairValueDetail": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "verboseLabel": "Identifiable Intangible Assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsSummaryOfPurchasePriceOfAcquisitionAllocatedOnBasisOfFairValueDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r113", "r114" ], "calculation": { "http://astro-med.com/role/AcquisitionsSummaryOfPurchasePriceOfAcquisitionAllocatedOnBasisOfFairValueDetail": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventory" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsSummaryOfPurchasePriceOfAcquisitionAllocatedOnBasisOfFairValueDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r113", "r114" ], "calculation": { "http://astro-med.com/role/AcquisitionsSummaryOfPurchasePriceOfAcquisitionAllocatedOnBasisOfFairValueDetail": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsSummaryOfPurchasePriceOfAcquisitionAllocatedOnBasisOfFairValueDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r114" ], "calculation": { "http://astro-med.com/role/AcquisitionsSummaryOfPurchasePriceOfAcquisitionAllocatedOnBasisOfFairValueDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Total Purchase Price" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsSummaryOfPurchasePriceOfAcquisitionAllocatedOnBasisOfFairValueDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r0", "r58", "r64" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "verboseLabel": "Business and Basis of Presentation" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/BusinessAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalizedComputerSoftwareGross": { "auth_ref": [ "r765" ], "calculation": { "http://astro-med.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail": { "order": 5.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.", "label": "Capitalized Computer Software, Gross", "terseLabel": "Computer Equipment and Software" } } }, "localname": "CapitalizedComputerSoftwareGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostAmortization": { "auth_ref": [ "r288" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.", "label": "Capitalized Contract Cost, Amortization", "terseLabel": "Amortization of incremental direct costs" } } }, "localname": "CapitalizedContractCostAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/RevenueRecognitionAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostNetCurrent": { "auth_ref": [ "r287" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as current.", "label": "Capitalized Contract Cost, Net, Current", "terseLabel": "Deferred incremental direct contract costs reported in other current assets" } } }, "localname": "CapitalizedContractCostNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/RevenueRecognitionAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r132", "r133" ], "lang": { "en-us": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "verboseLabel": "Carrying Value [Member]" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/FairValueScheduleOfCompanysLongTermDebtIncludingTheCurrentPortionNotReflectedInFinancialStatementsAtFairValueDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r55", "r171", "r573" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r50", "r55", "r57" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and Cash Equivalents, End of Period", "periodStartLabel": "Cash and Cash Equivalents, Beginning of Period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r50", "r136" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net Increase in Cash and Cash Equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangeInAccountingEstimateByTypeAxis": { "auth_ref": [ "r61", "r219" ], "lang": { "en-us": { "role": { "documentation": "Information by type of change in accounting estimate.", "label": "Change in Accounting Estimate by Type [Axis]" } } }, "localname": "ChangeInAccountingEstimateByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/IntangibleAssetsAdditionalInformationDetail", "http://astro-med.com/role/RevenueRecognitionAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ChangeInAccountingEstimateTypeDomain": { "auth_ref": [ "r61", "r219" ], "lang": { "en-us": { "role": { "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities.", "label": "Change in Accounting Estimate, Type [Domain]" } } }, "localname": "ChangeInAccountingEstimateTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/IntangibleAssetsAdditionalInformationDetail", "http://astro-med.com/role/RevenueRecognitionAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r178", "r179", "r180", "r205", "r227", "r228", "r230", "r232", "r239", "r240", "r279", "r314", "r317", "r318", "r319", "r325", "r326", "r357", "r358", "r359", "r360", "r361", "r473", "r572", "r614", "r628", "r635" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "verboseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/LeasesLeaseCostInformationDetail", "http://astro-med.com/role/NetIncomePerCommonShareReconciliationOfSharesUsedInCalculatingBasicAndDilutedDetail", "http://astro-med.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail", "http://astro-med.com/role/RevenueRecognitionAdditionalInformationDetail", "http://astro-med.com/role/RoyaltyObligationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r631", "r632", "r744" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common Stock, Par Value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common Stock, Shares Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r6", "r604" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": 31.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common Stock" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r31", "r188", "r190", "r196", "r533", "r539" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive Income (Loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r44", "r195", "r532", "r538" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AccumulatedOtherComprehensiveLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r62", "r63", "r134", "r135", "r273", "r557" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "verboseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r62", "r63", "r134", "r135", "r273", "r555", "r557" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "verboseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r123", "r575" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesUpdatePolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r363", "r365", "r376" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, Net", "terseLabel": "Contract assets balance" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/RevenueRecognitionAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r363", "r364", "r376" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Contract liabilities and extended warranties" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/RevenueRecognitionAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r68", "r258", "r259", "r260", "r261", "r267", "r638" ], "lang": { "en-us": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "verboseLabel": "Corporate Expenses [Member]" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/SegmentInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r38", "r205", "r279", "r314", "r315", "r317", "r318", "r319", "r321", "r323", "r325", "r326", "r473", "r647" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 6.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Cost of Revenue" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsDetail", "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfRequiredPrincipalPaymentsRemainingOnLongTermDebtOutstandingDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsDetail", "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfRequiredPrincipalPaymentsRemainingOnLongTermDebtOutstandingDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerContractsMember": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Entity's established relationships with its customers through contracts.", "label": "Customer Contracts [Member]", "terseLabel": "Customer Contract Relationships [Member]" } } }, "localname": "CustomerContractsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelatedIntangibleAssetsMember": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "Customer-related asset, including, but not limited to, customer lists, and noncontractual customer relationships.", "label": "Customer-Related Intangible Assets [Member]", "terseLabel": "Customer Contract Relationships [Member]" } } }, "localname": "CustomerRelatedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsSummaryOfAcquiredIdentifiableIntangibleAssetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsSummaryOfFairValueOfTheAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r85", "r204", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r343", "r350", "r351", "r353" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Credit Agreement and Long-Term Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r2", "r3", "r4", "r143", "r145", "r151", "r208", "r327", "r328", "r329", "r330", "r331", "r333", "r339", "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r499", "r580", "r581", "r582", "r583", "r584", "r629" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "definitionGuidance": "Interest rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r4", "r145", "r151", "r354" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "USD Term Loan" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r138", "r140", "r327", "r499", "r581", "r582" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Principal amount of debt" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate": { "auth_ref": [ "r21", "r138" ], "lang": { "en-us": { "role": { "documentation": "Description of any adjustments made to the stated rate to determine the effective rate.", "label": "Debt Instrument, Interest Rate, Basis for Effective Rate", "verboseLabel": "Variable interest rate" } } }, "localname": "DebtInstrumentInterestRateBasisForEffectiveRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsDetail", "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfRequiredPrincipalPaymentsRemainingOnLongTermDebtOutstandingDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r22", "r208", "r327", "r328", "r329", "r330", "r331", "r333", "r339", "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r499", "r580", "r581", "r582", "r583", "r584", "r629" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "auth_ref": [ "r22" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments applied to principal.", "label": "Debt Instrument, Periodic Payment, Principal", "verboseLabel": "Debt Instrument, principal Periodic payment" } } }, "localname": "DebtInstrumentPeriodicPaymentPrincipal", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r22", "r87", "r88", "r89", "r90", "r137", "r138", "r140", "r150", "r208", "r327", "r328", "r329", "r330", "r331", "r333", "r339", "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r352", "r499", "r580", "r581", "r582", "r583", "r584", "r629" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsDetail", "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfRequiredPrincipalPaymentsRemainingOnLongTermDebtOutstandingDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtLongtermAndShorttermCombinedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt.", "label": "Debt, Long-term and Short-term, Combined Amount", "terseLabel": "Long-Term debt and related current maturities" } } }, "localname": "DebtLongtermAndShorttermCombinedAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/FairValueScheduleOfCompanysLongTermDebtIncludingTheCurrentPortionNotReflectedInFinancialStatementsAtFairValueDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r139", "r650" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedLabel": "Debt Issuance Costs, net of accumulated amortization" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r425", "r426" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred Tax Assets, net" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r425", "r426" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "verboseLabel": "Deferred Tax Liabilities" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r619" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred Revenue", "terseLabel": "Deferred Revenue" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/RevenueRecognitionAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r618" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": 27.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Revenue, Current", "terseLabel": "Deferred Revenue" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueNoncurrent": { "auth_ref": [ "r619" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": 18.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Deferred Revenue, Noncurrent", "terseLabel": "Deferred Revenue" } } }, "localname": "DeferredRevenueNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r53", "r79" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense on property, plant and equipment" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r53", "r248" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and Amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Abstract]" } } }, "localname": "DisaggregationOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryGeographicMarketsDetail", "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryProductTypeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r375", "r586", "r587", "r588", "r589", "r590", "r591", "r592" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryGeographicMarketsDetail", "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryProductTypeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r651" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Summary of Revenues Disaggregated by Primary Geographic Markets and Major Product Type" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/RevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r390", "r417", "r418", "r420", "r424", "r599" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r197", "r216", "r217", "r218", "r219", "r220", "r225", "r227", "r230", "r231", "r232", "r236", "r465", "r466", "r534", "r540", "r576" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net Income per Common Share\u2014Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r197", "r216", "r217", "r218", "r219", "r220", "r227", "r230", "r231", "r232", "r236", "r465", "r466", "r534", "r540", "r576" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net Income per Common Share\u2014Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r233", "r234", "r235", "r237" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "Net Income Per Common Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/NetIncomePerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r486" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 21.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of Exchange Rate Changes on Cash and Cash Equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "verboseLabel": "Effective tax rates for income from continuing operations" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/IncomeTaxesProjectedEffectiveTaxRatesDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": 21.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued Compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized compensation expense to be recognized, Weighted average period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r739" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options", "terseLabel": "Unrecognized compensation expense related to RSUs and RSAs" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r739" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options", "terseLabel": "Unrecognized compensation expense related to options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Stock Options [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r86", "r164", "r191", "r192", "r193", "r209", "r210", "r211", "r213", "r221", "r223", "r238", "r283", "r362", "r421", "r422", "r423", "r434", "r435", "r464", "r487", "r488", "r489", "r490", "r491", "r493", "r517", "r545", "r546", "r547" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AccumulatedOtherComprehensiveLossChangesInBalanceOfAccumulatedOtherComprehensiveLossDetail", "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r341", "r472", "r581", "r582" ], "lang": { "en-us": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "verboseLabel": "Fair Value [Member]" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/FairValueScheduleOfCompanysLongTermDebtIncludingTheCurrentPortionNotReflectedInFinancialStatementsAtFairValueDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/FairValueScheduleOfCompanysLongTermDebtIncludingTheCurrentPortionNotReflectedInFinancialStatementsAtFairValueDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r128", "r132", "r133" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/FairValueScheduleOfCompanysLongTermDebtIncludingTheCurrentPortionNotReflectedInFinancialStatementsAtFairValueDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r341", "r380", "r381", "r382", "r383", "r384", "r385", "r468", "r519", "r520", "r521", "r581", "r582", "r593", "r594", "r595" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/FairValueScheduleOfCompanysLongTermDebtIncludingTheCurrentPortionNotReflectedInFinancialStatementsAtFairValueDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r128", "r131", "r341", "r581", "r582" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/FairValueScheduleOfCompanysLongTermDebtIncludingTheCurrentPortionNotReflectedInFinancialStatementsAtFairValueDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r470" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/FairValue" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r341", "r380", "r381", "r382", "r383", "r384", "r385", "r468", "r521", "r581", "r582", "r593", "r594", "r595" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/FairValueScheduleOfCompanysLongTermDebtIncludingTheCurrentPortionNotReflectedInFinancialStatementsAtFairValueDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r129", "r130" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Summary of Changes in Fair value of Level 3 Financial Liability" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r341", "r380", "r381", "r382", "r383", "r384", "r385", "r519", "r520", "r521", "r581", "r582", "r593", "r594", "r595" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/FairValueScheduleOfCompanysLongTermDebtIncludingTheCurrentPortionNotReflectedInFinancialStatementsAtFairValueDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FederalFundsEffectiveSwapRateMember": { "auth_ref": [ "r743" ], "lang": { "en-us": { "role": { "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.", "label": "Federal Funds Effective Swap Rate [Member]", "verboseLabel": "Federal Funds Effective Swap Rate [Member]" } } }, "localname": "FederalFundsEffectiveSwapRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Useful Life (Years)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsSummaryOfAcquiredIdentifiableIntangibleAssetDetail" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r175", "r302" ], "calculation": { "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable": { "auth_ref": [ "r73" ], "lang": { "en-us": { "role": { "documentation": "A table containing detailed characteristics of finite-lived intangible assets acquired during a business combination. Finite-lived intangible assets are assets that have no physical form, but have expected future economic benefit, and are expected to be used over a defined period. Acquired finite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the Entity) and in total. Additionally, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period are also disclosed.", "label": "Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]", "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]" } } }, "localname": "FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsSummaryOfFairValueOfTheAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r78" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/IntangibleAssetsSummaryOfEstimatedAmortizationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r78" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five", "terseLabel": "2028" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/IntangibleAssetsSummaryOfEstimatedAmortizationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r78" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "2027" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/IntangibleAssetsSummaryOfEstimatedAmortizationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r78" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/IntangibleAssetsSummaryOfEstimatedAmortizationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r78" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/IntangibleAssetsSummaryOfEstimatedAmortizationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r299", "r301", "r302", "r303", "r525", "r529" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail", "http://astro-med.com/role/AcquisitionsSummaryOfAcquiredIdentifiableIntangibleAssetDetail", "http://astro-med.com/role/AcquisitionsSummaryOfFairValueOfTheAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail", "http://astro-med.com/role/IntangibleAssetsAdditionalInformationDetail", "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure": { "auth_ref": [ "r745" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of assets, excluding financial assets, that lack physical substance, having a limited useful life.", "label": "Finite-lived Intangible Assets, Fair Value Disclosure", "terseLabel": "Fair Value" } } }, "localname": "FiniteLivedIntangibleAssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsSummaryOfAcquiredIdentifiableIntangibleAssetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]" } } }, "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r76", "r529" ], "calculation": { "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r73", "r75" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail", "http://astro-med.com/role/AcquisitionsSummaryOfAcquiredIdentifiableIntangibleAssetDetail", "http://astro-med.com/role/AcquisitionsSummaryOfFairValueOfTheAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail", "http://astro-med.com/role/IntangibleAssetsAdditionalInformationDetail", "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r76", "r525" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Net Carrying Amount", "verboseLabel": "Identifiable Intangibles, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets", "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r300" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Finite-Lived Intangible Assets Acquired", "terseLabel": "Fair Value" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsSummaryOfFairValueOfTheAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r482", "r483", "r484", "r485" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 13.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "verboseLabel": "Gain (Loss) on Foreign Currency Transaction" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r40" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 10.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 }, "http://astro-med.com/role/SegmentInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "Corporate Expenses", "verboseLabel": "General and Administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome", "http://astro-med.com/role/SegmentInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "verboseLabel": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail", "http://astro-med.com/role/LeasesLeaseCostInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r174", "r289", "r531", "r579", "r604", "r641", "r642" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail", "http://astro-med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r37", "r205", "r253", "r258", "r264", "r267", "r279", "r314", "r315", "r317", "r318", "r319", "r321", "r323", "r325", "r326", "r473", "r578", "r647" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross Profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Impairment of Intangible Assets (Excluding Goodwill) [Abstract]" } } }, "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r627", "r643" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment of Intangible Assets, Finite-lived", "terseLabel": "Impairments of intangible assets" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/IntangibleAssetsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r33", "r141", "r147", "r160", "r253", "r258", "r264", "r267", "r535", "r578" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://astro-med.com/role/SegmentInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income Before Income Taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome", "http://astro-med.com/role/SegmentInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r305", "r307" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "verboseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail", "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/LeasesLeaseCostInformationDetail", "http://astro-med.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "verboseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail", "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/LeasesLeaseCostInformationDetail", "http://astro-med.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r107" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r206", "r429", "r430", "r431", "r436", "r438", "r440", "r441", "r442" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r207", "r222", "r223", "r251", "r427", "r437", "r439", "r541" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://astro-med.com/role/SegmentInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail": { "order": 6.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "definitionGuidance": "Income Tax Provision", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "presentationGuidance": "Income Tax Provision", "verboseLabel": "Income tax expense (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome", "http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail", "http://astro-med.com/role/SegmentInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r56" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Cash Paid (Received) During the Period for Income Taxes, Net of Refunds" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r52" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts Payable and Accrued Expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r52" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts Receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r52" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "verboseLabel": "Income Taxes" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r52" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in Assets and Liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r52" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedLabel": "Other" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r139", "r149", "r194", "r247", "r497" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 14.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest Expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r42", "r347", "r356", "r583", "r584" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "verboseLabel": "Interest Expense, Debt" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r199", "r202", "r203" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash Paid During the Period for Interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r620" ], "calculation": { "http://astro-med.com/role/InventoriesComponentsOfInventoriesDetail": { "order": 4.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished Goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/InventoriesComponentsOfInventoriesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryGross": { "auth_ref": [ "r622" ], "calculation": { "http://astro-med.com/role/InventoriesComponentsOfInventoriesDetail": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Inventory, Gross", "totalLabel": "Inventory, Gross" } } }, "localname": "InventoryGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/InventoriesComponentsOfInventoriesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r182", "r574", "r604" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://astro-med.com/role/InventoriesComponentsOfInventoriesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "definitionGuidance": "Inventories, net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets", "http://astro-med.com/role/InventoriesComponentsOfInventoriesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsAndSupplies": { "auth_ref": [ "r622" ], "calculation": { "http://astro-med.com/role/InventoriesComponentsOfInventoriesDetail": { "order": 2.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.", "label": "Inventory, Raw Materials and Supplies, Gross", "terseLabel": "Materials and Supplies" } } }, "localname": "InventoryRawMaterialsAndSupplies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/InventoriesComponentsOfInventoriesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r70", "r622" ], "calculation": { "http://astro-med.com/role/InventoriesComponentsOfInventoriesDetail": { "order": 5.0, "parentTag": "us-gaap_InventoryNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "negatedLabel": "Inventory Reserve" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/InventoriesComponentsOfInventoriesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r621" ], "calculation": { "http://astro-med.com/role/InventoriesComponentsOfInventoriesDetail": { "order": 3.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work-In-Progress" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/InventoriesComponentsOfInventoriesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandAndLandImprovements": { "auth_ref": [ "r617" ], "calculation": { "http://astro-med.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation and depletion of real estate held for productive use and additions or improvements to real estate held for productive use, examples include, but are not limited to, walkways, driveways, fences, and parking lots. Excludes land held for sale.", "label": "Land and Land Improvements", "terseLabel": "Land and Land Improvements" } } }, "localname": "LandAndLandImprovements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r751" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "verboseLabel": "Schedule Lease Cost Information" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "verboseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r752" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "verboseLabel": "Schedule of Maturities Of Lease Liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r510" ], "calculation": { "http://astro-med.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total Lease Payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r510" ], "calculation": { "http://astro-med.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r510" ], "calculation": { "http://astro-med.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2028" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r510" ], "calculation": { "http://astro-med.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r510" ], "calculation": { "http://astro-med.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r752" ], "calculation": { "http://astro-med.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2024, remaining" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r510" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Imputed Interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r511" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "verboseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r18", "r205", "r279", "r314", "r315", "r317", "r318", "r319", "r321", "r323", "r325", "r326", "r451", "r454", "r455", "r473", "r577", "r647", "r754", "r755" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r11", "r146", "r157", "r604", "r630", "r640", "r747" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r20", "r170", "r205", "r279", "r314", "r315", "r317", "r318", "r319", "r321", "r323", "r325", "r326", "r451", "r454", "r455", "r473", "r604", "r647", "r754", "r755" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": 19.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "NON-CURRENT\u00a0LIABILITIES" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r4", "r145", "r151" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Revolving loan outstanding" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r16", "r629" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]", "terseLabel": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeeAmount": { "auth_ref": [ "r16" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the fee for available but unused credit capacity under the credit facility.", "label": "Line of Credit Facility, Commitment Fee Amount", "terseLabel": "Line of Credit Facility, Commitment Fee Amount" } } }, "localname": "LineOfCreditFacilityCommitmentFeeAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line of Credit Facility, Commitment Fee Percentage", "verboseLabel": "Commitment fee rate" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r16", "r629" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]", "terseLabel": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r16" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "presentationGuidance": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r16" ], "crdr": "credit", "lang": { "en-us": { "role": { "definitionGuidance": "Line of Credit Facility, Remaining Borrowing Capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line of Credit Facility, Remaining Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LinesOfCreditCurrent": { "auth_ref": [ "r2", "r143" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": 24.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Line of Credit, Current", "presentationGuidance": "Revolving Line of Credit" } } }, "localname": "LinesOfCreditCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "LIBOR [Member]" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r4", "r145", "r155", "r340", "r355", "r581", "r582" ], "calculation": { "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfRequiredPrincipalPaymentsRemainingOnLongTermDebtOutstandingDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-term Debt", "totalLabel": "Long-term Debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfRequiredPrincipalPaymentsRemainingOnLongTermDebtOutstandingDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r17" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": 28.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "negatedLabel": "Current Portion of Term Loan", "terseLabel": "Current Portion of Long-Term Debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets", "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r84", "r208", "r345" ], "calculation": { "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfRequiredPrincipalPaymentsRemainingOnLongTermDebtOutstandingDetail": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months", "verboseLabel": "Fiscal 2024, remainder" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfRequiredPrincipalPaymentsRemainingOnLongTermDebtOutstandingDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r84", "r208", "r345" ], "calculation": { "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfRequiredPrincipalPaymentsRemainingOnLongTermDebtOutstandingDetail": { "order": 5.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Five", "verboseLabel": "Fiscal 2028" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfRequiredPrincipalPaymentsRemainingOnLongTermDebtOutstandingDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r84", "r208", "r345" ], "calculation": { "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfRequiredPrincipalPaymentsRemainingOnLongTermDebtOutstandingDetail": { "order": 4.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Four", "verboseLabel": "Fiscal 2027" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfRequiredPrincipalPaymentsRemainingOnLongTermDebtOutstandingDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r84", "r208", "r345" ], "calculation": { "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfRequiredPrincipalPaymentsRemainingOnLongTermDebtOutstandingDetail": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Three", "verboseLabel": "Fiscal 2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfRequiredPrincipalPaymentsRemainingOnLongTermDebtOutstandingDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r84", "r208", "r345" ], "calculation": { "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfRequiredPrincipalPaymentsRemainingOnLongTermDebtOutstandingDetail": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Two", "verboseLabel": "Fiscal 2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfRequiredPrincipalPaymentsRemainingOnLongTermDebtOutstandingDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r177" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-Term Debt", "verboseLabel": "Long-Term Debt, net of current portion" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets", "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtWeightedAverageInterestRateOverTime": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average interest rate of long-term debt outstanding calculated over time.", "label": "Long-Term Debt, Weighted Average Interest Rate, over Time", "terseLabel": "Long term debt weighted average interest rate over a period of time" } } }, "localname": "LongTermDebtWeightedAverageInterestRateOverTime", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_MachineryAndEquipmentGross": { "auth_ref": [ "r80" ], "calculation": { "http://astro-med.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail": { "order": 4.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment, Gross", "terseLabel": "Machinery and Equipment" } } }, "localname": "MachineryAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r746" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r469" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r201" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash Provided (Used) by Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flows from Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r201" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net Cash Used for Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flows from Investing Activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r50", "r51", "r54" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net Cash Provided (Used) by Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash Flows from Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r34", "r54", "r148", "r159", "r168", "r186", "r189", "r193", "r205", "r212", "r216", "r217", "r218", "r219", "r222", "r223", "r229", "r253", "r258", "r264", "r267", "r279", "r314", "r315", "r317", "r318", "r319", "r321", "r323", "r325", "r326", "r466", "r473", "r578", "r647" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://astro-med.com/role/SegmentInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net Income", "totalLabel": "Net Income", "verboseLabel": "Net Income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss", "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome", "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity", "http://astro-med.com/role/SegmentInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesUpdatePolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r41" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 11.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 }, "http://astro-med.com/role/SegmentInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedLabel": "Other Expense, Net", "totalLabel": "Other Expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome", "http://astro-med.com/role/SegmentInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other Income (Expense)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r637" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingCostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Costs and Expenses [Abstract]", "terseLabel": "Operating Expenses:" } } }, "localname": "OperatingCostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 7.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Operating Expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r253", "r258", "r264", "r267", "r578" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 }, "http://astro-med.com/role/SegmentInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating Income", "verboseLabel": "Operating Income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome", "http://astro-med.com/role/SegmentInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r750" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "verboseLabel": "Operating Lease Costs" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/LeasesLeaseCostInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r505" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "verboseLabel": "Total Lease Liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r505" ], "crdr": "credit", "lang": { "en-us": { "role": { "definitionGuidance": "Other Liabilities and Accrued Expenses", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/LeasesScheduleOfBalanceSheetAndOtherInformationRelatedToOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r505" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Lease Liabilities", "verboseLabel": "Lease Liabilities, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets", "http://astro-med.com/role/LeasesScheduleOfBalanceSheetAndOtherInformationRelatedToOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r506", "r507" ], "crdr": "credit", "lang": { "en-us": { "role": { "definitionGuidance": "Operating cash flows for operating leases", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/LeasesSupplementalCashFlowInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r504" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right of Use Assets", "verboseLabel": "Right of Use Asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets", "http://astro-med.com/role/LeasesScheduleOfBalanceSheetAndOtherInformationRelatedToOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r509", "r603" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "verboseLabel": "Operating Lease, Weighted Average Discount Rate, Percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r508", "r603" ], "lang": { "en-us": { "role": { "definitionGuidance": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r257", "r258", "r259", "r260", "r261", "r267" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/SegmentInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsMiscellaneousNoncurrent": { "auth_ref": [], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.", "label": "Other Assets, Miscellaneous, Noncurrent", "verboseLabel": "Other Assets" } } }, "localname": "OtherAssetsMiscellaneousNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r30", "r32", "r192", "r487", "r489", "r493", "r624" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "terseLabel": "Other Comprehensive Income before reclassification" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AccumulatedOtherComprehensiveLossChangesInBalanceOfAccumulatedOtherComprehensiveLossDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "auth_ref": [ "r184", "r185" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 4.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "negatedLabel": "Loss from Cash Flow Hedges Reclassified to Income Statement" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r25" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign Currency Translation Adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r32", "r86", "r187", "r190", "r195", "r487", "r492", "r493", "r532", "r538", "r624", "r625" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "definitionGuidance": "Other Comprehensive Income (Loss)", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Other Comprehensive Income (Loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss", "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "verboseLabel": "Other Comprehensive Income (Loss), Net of Taxes:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherExpenseMember": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other expense.", "label": "Other Expense [Member]" } } }, "localname": "OtherExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r43" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 12.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "verboseLabel": "Other, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r198" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedLabel": "Net Cash Used for Payment of Taxes Related to Vested Restricted Stock" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r45", "r448" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Purchase price of acquisition" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireLand": { "auth_ref": [ "r46" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow from the acquisition of real estate intended to generate income for the owner; excludes land acquired for use by the owner.", "label": "Payments to Acquire Land", "terseLabel": "Payments to Acquire Additional Interest in Subsidiaries" } } }, "localname": "PaymentsToAcquireLand", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r46" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Additions to Property, Plant and Equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance Based RSUs [Member]" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/FairValueScheduleOfCompanysLongTermDebtIncludingTheCurrentPortionNotReflectedInFinancialStatementsAtFairValueDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r5", "r357" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred Stock, Par Value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred Stock, Shares Authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r5", "r357" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred Stock, Shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r5", "r604" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": 30.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred Stock" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r623" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r47", "r105" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options", "terseLabel": "Net Cash Proceeds from Employee Stock Option Plans" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "auth_ref": [ "r48" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Proceeds from Long-Term Lines of Credit", "terseLabel": "Proceeds from long term line of credit" } } }, "localname": "ProceedsFromLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": { "auth_ref": [], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).", "label": "Proceeds from (Repayments of) Lines of Credit", "verboseLabel": "Net Borrowings under Revolving Credit Facility" } } }, "localname": "ProceedsFromRepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockPlans": { "auth_ref": [ "r47" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "label": "Proceeds from Stock Plans", "terseLabel": "Net Cash Proceeds from Share Purchases under Employee Stock Purchase Plan" } } }, "localname": "ProceedsFromStockPlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r168", "r186", "r189", "r200", "r205", "r212", "r222", "r223", "r253", "r258", "r264", "r267", "r279", "r314", "r315", "r317", "r318", "r319", "r321", "r323", "r325", "r326", "r449", "r452", "r453", "r466", "r473", "r535", "r578", "r601", "r602", "r626", "r647" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net Income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r83", "r558", "r559", "r560" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/PropertyPlantAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r80", "r172" ], "calculation": { "http://astro-med.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "totalLabel": "Gross Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r82", "r158", "r536", "r604" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://astro-med.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, Plant and Equipment, net", "totalLabel": "Net Property Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets", "http://astro-med.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Summary of Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/PropertyPlantAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RegulatedOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Regulated Operations [Abstract]" } } }, "localname": "RegulatedOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfMediumTermNotes": { "auth_ref": [ "r49" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to pay off borrowing used to receive debt funding on a regular basis with maturities ranging from 5-10 years.", "label": "Repayments of Medium-term Notes", "negatedLabel": "Principal Payments on Long-Term Debt" } } }, "localname": "RepaymentsOfMediumTermNotes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r106", "r161", "r762" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 9.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockExpense": { "auth_ref": [ "r53" ], "calculation": { "http://astro-med.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetail": { "order": 2.0, "parentTag": "us-gaap_ShareBasedCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.", "label": "Restricted Stock or Unit Expense", "terseLabel": "Restricted Stock Awards and Restricted Stock Units" } } }, "localname": "RestrictedStockExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://astro-med.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r59" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "RSA [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r8", "r91", "r156", "r549", "r554", "r604" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": 33.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r164", "r209", "r210", "r211", "r213", "r221", "r223", "r283", "r421", "r422", "r423", "r434", "r435", "r464", "r545", "r547" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTaxStatusAxis": { "auth_ref": [ "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712" ], "lang": { "en-us": { "role": { "documentation": "Information by tax status of plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Tax Status [Axis]", "terseLabel": "Retirement Plan Tax Status [Axis]" } } }, "localname": "RetirementPlanTaxStatusAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTaxStatusDomain": { "auth_ref": [ "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712" ], "lang": { "en-us": { "role": { "documentation": "Tax status of plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Tax Status [Domain]", "terseLabel": "Retirement Plan Tax Status [Domain]" } } }, "localname": "RetirementPlanTaxStatusDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r244", "r245", "r257", "r262", "r263", "r269", "r270", "r273", "r374", "r375", "r524" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 5.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 }, "http://astro-med.com/role/SegmentInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue", "verboseLabel": "Total Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome", "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryGeographicMarketsDetail", "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryProductTypeDetail", "http://astro-med.com/role/SegmentInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r377", "r378" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/RevenueRecognition" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility [Member]" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r39" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Royalty Expense", "terseLabel": "Royalty expense" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyGuaranteesCommitmentsAmount": { "auth_ref": [ "r530" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount the entity has committed to make for future royalty guarantees.", "label": "Royalty Guarantees, Commitments, Amount", "verboseLabel": "Royalty guarantee commitement amount" } } }, "localname": "RoyaltyGuaranteesCommitmentsAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r30", "r748", "r749" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Changes in Balance of Accumulated Other Comprehensive Loss" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AccumulatedOtherComprehensiveLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": { "auth_ref": [ "r73" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsSummaryOfAcquiredIdentifiableIntangibleAssetDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": { "auth_ref": [ "r73" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]", "terseLabel": "Summary of Acquired Identifiable Intangible Asset" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r111", "r112", "r443" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsAdditionalInformationDetail", "http://astro-med.com/role/AcquisitionsSummaryOfPurchasePriceOfAcquisitionAllocatedOnBasisOfFairValueDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCapitalizationEquityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Capitalization, Equity [Line Items]", "terseLabel": "Schedule of Capitalization, Equity [Line Items]" } } }, "localname": "ScheduleOfCapitalizationEquityLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AccumulatedOtherComprehensiveLossChangesInBalanceOfAccumulatedOtherComprehensiveLossDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCapitalizationEquityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning the equity component of the capitalization of the entity. The table may be detailed by subsidiary (legal entity) (if applicable) and include information by component of equity as may be included in the Statement of Changes in Shareholders' Equity.", "label": "Schedule of Capitalization, Equity [Table]", "terseLabel": "Schedule of Capitalization, Equity [Table]" } } }, "localname": "ScheduleOfCapitalizationEquityTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AccumulatedOtherComprehensiveLossChangesInBalanceOfAccumulatedOtherComprehensiveLossDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "verboseLabel": "Supplemental Cash Flow Information Related To Leases" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]", "terseLabel": "Share-Based Compensation Expense" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of Long Term Debt in the Accompanying Condensed Consolidated Balance Sheets" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock": { "auth_ref": [ "r73" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of finite-lived intangible assets acquired as part of a business combination or through an asset purchase, by major class and in total, including the value of the asset acquired, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period.", "label": "Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]", "terseLabel": "Summary of Fair Value of the Acquired Identifiable Intangible Assets and Related Estimated Useful Lives" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r73", "r75", "r525" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r73", "r75" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Fair Value of Acquired Identifiable Intangible Assets and Related Estimated Useful Lives" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r1", "r12", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Components of Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Schedule of Required Principal Payments Remaining on Long Term Debt Outstanding" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Summary of Purchase Price of Acquisition Allocated on Basis of Fair Value" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r65", "r66", "r67", "r71" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "verboseLabel": "Net Sales and Segment Operating Profit (Loss) for Each Reporting Segment" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r388", "r389", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingRsuAndRsaActivityDetail", "http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]", "terseLabel": "Summary of Options Outstanding" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r94", "r98", "r99" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]", "terseLabel": "Aggregated Information Regarding Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Aggregated Information Regarding RSU and RSA Activity" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "auth_ref": [ "r60" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "verboseLabel": "Summary of Basic and Diluted Net Income Per Share" } } }, "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/NetIncomePerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Summary of Estimated Amortization Expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r241", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r267", "r273", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r308", "r309", "r579", "r763" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/SegmentInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r241", "r242", "r243", "r253", "r256", "r261", "r265", "r266", "r267", "r268", "r269", "r272", "r273", "r274" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "verboseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/SegmentInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome": { "order": 8.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "terseLabel": "Selling and Marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r52" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://astro-med.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Compensation", "terseLabel": "Share-Based Compensation", "totalLabel": "Total" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://astro-med.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation [Abstract]" } } }, "localname": "ShareBasedCompensationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "Discount rate from fair value on purchase date that participants pay for shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date", "terseLabel": "Employee Stock Purchase Plan discount rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited, Restricted Stock Units and Restricted Stock Awards" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingRsuAndRsaActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingRsuAndRsaActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted, Restricted Stock Units and Restricted Stock Awards" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingRsuAndRsaActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingRsuAndRsaActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r402", "r403" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Ending balance, Outstanding Restricted Stock Units and Restricted Stock Awards", "periodStartLabel": "Beginning balance, Outstanding Restricted Stock Units and Restricted Stock Awards", "terseLabel": "Number of unvested shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingRsuAndRsaActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r402", "r403" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Ending balance, Weighted Average Grant Date Fair Value", "periodStartLabel": "Beginning balance, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingRsuAndRsaActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested, Restricted Stock Units and Restricted Stock Awards" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingRsuAndRsaActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingRsuAndRsaActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingRsuAndRsaActivityDetail", "http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r600" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Shares authorized for grant under the Plan" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for grant under the Plan" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r396" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Number of shares exercisable, total" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedLabel": "Canceled, Number of Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeited, Number of Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted, Number of Options", "verboseLabel": "Number of options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r394", "r395" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Ending balance, Number of Options", "periodStartLabel": "Beginning balance, Number of Options", "terseLabel": "Number of shares outstanding", "verboseLabel": "Number of shares outstanding, total" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingStockOptionActivityDetail", "http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r394", "r395" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending balance, Weighted-Average Exercise Price", "periodStartLabel": "Beginning balance, Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Equity Award [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/NetIncomePerCommonShareReconciliationOfSharesUsedInCalculatingBasicAndDilutedDetail", "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingRsuAndRsaActivityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "verboseLabel": "Exercised, Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "verboseLabel": "Cancelled, Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "verboseLabel": "Forfeited, Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Granted, Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r101" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]", "terseLabel": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r102" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]", "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "auth_ref": [ "r102" ], "lang": { "en-us": { "role": { "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit", "terseLabel": "Outstanding Range of Exercise prices, Lower Limit" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "auth_ref": [ "r97" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.", "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options", "terseLabel": "Exercisable, Number of shares" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "auth_ref": [ "r95" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.", "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options", "terseLabel": "Outstanding, Number of shares" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "auth_ref": [ "r102" ], "lang": { "en-us": { "role": { "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit", "terseLabel": "Outstanding Range of Exercise prices, Upper Limit" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable Remaining Contractual Life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": { "auth_ref": [ "r96" ], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.", "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price", "terseLabel": "Exercisable, Weighted Average Exercise Price" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "auth_ref": [ "r95" ], "lang": { "en-us": { "role": { "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.", "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price", "terseLabel": "Outstanding, Weighted Average Exercise Price" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding Remaining Contractual Life" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending Balance, Shares", "periodStartLabel": "Beginning Balance, Shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r167", "r241", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r267", "r273", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r306", "r308", "r309", "r579", "r763" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/SegmentInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r178", "r179", "r180", "r205", "r227", "r228", "r230", "r232", "r239", "r240", "r279", "r314", "r317", "r318", "r319", "r325", "r326", "r357", "r358", "r359", "r360", "r361", "r473", "r572", "r614", "r628", "r635" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "verboseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/LeasesLeaseCostInformationDetail", "http://astro-med.com/role/NetIncomePerCommonShareReconciliationOfSharesUsedInCalculatingBasicAndDilutedDetail", "http://astro-med.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail", "http://astro-med.com/role/RevenueRecognitionAdditionalInformationDetail", "http://astro-med.com/role/RoyaltyObligationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r24", "r86", "r164", "r191", "r192", "r193", "r209", "r210", "r211", "r213", "r221", "r223", "r238", "r283", "r362", "r421", "r422", "r423", "r434", "r435", "r464", "r487", "r488", "r489", "r490", "r491", "r493", "r517", "r545", "r546", "r547" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AccumulatedOtherComprehensiveLossChangesInBalanceOfAccumulatedOtherComprehensiveLossDetail", "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]", "verboseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail", "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity", "http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail", "http://astro-med.com/role/LeasesAdditionalInformationDetail", "http://astro-med.com/role/LeasesLeaseCostInformationDetail", "http://astro-med.com/role/LeasesSupplementalCashFlowInformationDetail", "http://astro-med.com/role/NetIncomePerCommonShareAdditionalInformationDetail", "http://astro-med.com/role/NetIncomePerCommonShareReconciliationOfSharesUsedInCalculatingBasicAndDilutedDetail", "http://astro-med.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail", "http://astro-med.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail", "http://astro-med.com/role/RevenueRecognitionAdditionalInformationDetail", "http://astro-med.com/role/RoyaltyObligationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "verboseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r209", "r210", "r211", "r238", "r524" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]", "verboseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/BusinessAndBasisOfPresentationAdditionalInformationDetail", "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity", "http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail", "http://astro-med.com/role/LeasesAdditionalInformationDetail", "http://astro-med.com/role/LeasesLeaseCostInformationDetail", "http://astro-med.com/role/LeasesSupplementalCashFlowInformationDetail", "http://astro-med.com/role/NetIncomePerCommonShareAdditionalInformationDetail", "http://astro-med.com/role/NetIncomePerCommonShareReconciliationOfSharesUsedInCalculatingBasicAndDilutedDetail", "http://astro-med.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail", "http://astro-med.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail", "http://astro-med.com/role/RevenueRecognitionAdditionalInformationDetail", "http://astro-med.com/role/RoyaltyObligationAdditionalInformationDetail", "http://astro-med.com/role/SegmentInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r5", "r6", "r86", "r91" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Shares purchase under Employee Stock Purchase Plan" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r86", "r91" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Restricted Stock Awards, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r5", "r6", "r86", "r91", "r399" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised, Number of Options", "terseLabel": "Employee Option Exercises, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity", "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r5", "r6", "r86", "r91" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "Restricted Stock Awards" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r24", "r86", "r91" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Employee Option Exercises" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionPlanExpense": { "auth_ref": [ "r53" ], "calculation": { "http://astro-med.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetail": { "order": 1.0, "parentTag": "us-gaap_ShareBasedCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for option under share-based payment arrangement.", "label": "Stock or Unit Option Plan Expense", "terseLabel": "Stock Options" } } }, "localname": "StockOptionPlanExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r6", "r9", "r10", "r69", "r604", "r630", "r640", "r747" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": 29.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "TOTAL SHAREHOLDERS' EQUITY" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AccumulatedOtherComprehensiveLossChangesInBalanceOfAccumulatedOtherComprehensiveLossDetail", "http://astro-med.com/role/CondensedConsolidatedBalanceSheets", "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "SHAREHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r494", "r518" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r494", "r518" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental Disclosures of Cash Flow Information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxesPayableCurrentAndNoncurrent": { "auth_ref": [ "r3", "r144", "r154" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.", "label": "Taxes Payable", "terseLabel": "Income Taxes Payable" } } }, "localname": "TaxesPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TrademarksAndTradeNamesMember": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trademarks and Trade Names [Member]" } } }, "localname": "TrademarksAndTradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/AcquisitionsSummaryOfFairValueOfTheAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TrademarksMember": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.", "label": "Trademarks [Member]", "terseLabel": "Trademarks [Member]" } } }, "localname": "TrademarksMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r23", "r92" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r23", "r92" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury Stock, Shares" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r23", "r92", "r93" ], "calculation": { "http://astro-med.com/role/CondensedConsolidatedBalanceSheets": { "order": 34.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury Stock, at Cost" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r162", "r163", "r164", "r165", "r166", "r212", "r213", "r214", "r215", "r224", "r277", "r278", "r280", "r281", "r282", "r283", "r284", "r285", "r421", "r422", "r423", "r432", "r433", "r434", "r435", "r445", "r446", "r447", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r495", "r496", "r500", "r501", "r502", "r503", "r512", "r513", "r514", "r515", "r516", "r517", "r526", "r527", "r528", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Type of Adoption [Domain]", "verboseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r742" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Type of Arrangement and Non-arrangement Transactions [Axis]", "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]", "verboseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/IntangibleAssetsAdditionalInformationDetail", "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail", "http://astro-med.com/role/RoyaltyObligationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r636" ], "calculation": { "http://astro-med.com/role/NetIncomePerCommonShareReconciliationOfSharesUsedInCalculatingBasicAndDilutedDetail": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "verboseLabel": "Effect of Dilutive Options, Restricted Stock Awards and Restricted Stock Units" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/NetIncomePerCommonShareReconciliationOfSharesUsedInCalculatingBasicAndDilutedDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r226", "r232" ], "calculation": { "http://astro-med.com/role/NetIncomePerCommonShareReconciliationOfSharesUsedInCalculatingBasicAndDilutedDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted Average Number of Common Shares Outstanding\u2014Diluted", "totalLabel": "Weighted Average Number of Common Shares Outstanding\u2014Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome", "http://astro-med.com/role/NetIncomePerCommonShareReconciliationOfSharesUsedInCalculatingBasicAndDilutedDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r225", "r232" ], "calculation": { "http://astro-med.com/role/NetIncomePerCommonShareReconciliationOfSharesUsedInCalculatingBasicAndDilutedDetail": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted Average Number of Common Shares Outstanding\u2014Basic", "verboseLabel": "Weighted Average Common Shares Outstanding \u2013 Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://astro-med.com/role/CondensedConsolidatedStatementsOfIncome", "http://astro-med.com/role/NetIncomePerCommonShareReconciliationOfSharesUsedInCalculatingBasicAndDilutedDetail" ], "xbrltype": "sharesItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org/topic&trid=2303972", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144471", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "https://asc.fasb.org/topic&trid=2134417", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473578&loc=d3e63223-108013", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r58": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r608": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r609": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e777-108305", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r611": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r612": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r613": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r64": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 92 0001193125-23-163282-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-163282-xbrl.zip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end